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Coronary heart disease is the primary global cause of morbidity and mortality, accounting for 
about 33% of global deaths in 2013. Atherosclerosis is the principal cause of coronary heart 
disease and is caused by inflammation of the arterial wall. This begins with the accumulation 
of foam cells in the subendothelial space of an inflamed segment of the endothelium to create 
the fatty streak. The accumulation of these cells, and their apoptosis creates a 
proinflammatory necrotic core. This triggers smooth muscle cells migration into the 
subendothelial space, where these cells form a fibrous cap that mechanically strengthens the 
plaque.  The ongoing inflammatory condition infit smooth muscle cell apoptosis which leads 
to cap thinning and eventual rupture of the plaque, triggering thrombus formation. 
Recreating this complex multi-step pathogenesis has principally relied on animal studies. 
However, key differences have been observed between the human and animal plaques. This 
has triggered attempts to develop a humanised in vitro models, however none of these have 
been demonstrated to reach later stages of plaque development, where plaque rupture 
trigger atherothrombosis. Previously our lab has used a layer-by-layer fabrication method to 
create a healthy tissue-engineered arterial construct. In this project, the aim was to develop 
and validate a simple 3D cell cultured neointimal model that can be inserted into this arterial 
construct to provide a novel tissue-engineered atherosclerotic plaque model.  A protocol was 
developed to generate a 3D neointimal culture model in which the THP-1 monocytic cell line 
can be differentiated into THP-1-derived foam cells within a compressed collagen hydrogel. 
The cells were demonstrated to remain viable and secrete greater quantities of pro-




The neointimal construct was found to possess significant tissue factor activity and could be 
observed to induce a slow platelet aggregation. These prothrombotic effects were reduced 
when the 3D neointimal model was treated with atorvastatin during the ox LDL loading period 
of the culture.  These results provided the first demonstration that a tissue-engineered 
atherosclerotic plaque model could replicate the prothrombotic properties of the native 
neointima. A co-culturing method was successfully developed that allowed reversible 
attachment of the neointimal model to the previously developed tissue-engineered medial 
layer using a fibrin hydrogel. Through treatment with plasmin containing solutions, the 
different layers of the co-culture could be shown to detach from one another, providing a 
basis for creating the first plaque rupture model in an in vitro atherosclerosis model. 
Additionally, it was possible to observe the migration of human coronary artery smooth 
muscle cells from the medial layer into the neointima. This provides the first evidence that 
tissue-engineered atherosclerosis models can elicit this key event in the development of the 
advanced stage of fibroatheroma. Overall, this thesis demonstrates the power of using a 
layer-by-layer fabrication method to develop a 3D human neointimal model that can replicate 
the early events in fibroatheroma. This ability to replicate both early and more advanced 
stage events highlight the potential for this construct to be further developed into an effective 
model of atherosclerotic plaque rupture to allow us to study human atherothrombosis more 








Chapter 1: Introduction 
 
1.1 The clinical importance of atherosclerotic plaques formation and rupture 
In 2013, Coronary artery disease (CAD) caused 17.3 million deaths globally, accounting for 
31.5% of the general mortality rate (Timmis et al., 2018). It is the principal cause of all 
mortality in developed countries (Islam et al., 2016). In the UK, and despite a significant 
decrease in the mortality and morbidity rates of CAD during the previous decade, it is still a 
significant health problem. As till April 2021, there were 7.6 million patients who have CAD 
with an average of 100,000 new hospital admissions because of CAD each year (BHF, 2021). 
Atherosclerosis is the main cause of CAD. It is a chronic inflammation of the blood vessel, 
characterized by progressive, focal, or diffuse thickening of the tunica intima (the interior 
layer of the blood vessel; Otsuka et al., 2016). The natural history of this disease involves 
stages of formation, progression, and rupture of the atherosclerotic plaque. However, the 
acceleration or regression of atherosclerosis also depends on the presence or absence of 
other risk factors, such as hypertension diabetes mellitus, hypercholesterolemia and genetic 
susceptibility (Bentzon et al., 2014). There are two groups of risk factors for atherosclerosis, 
modifiable and non-modifiable risk factors.  Modifiable risk factors include high blood 
pressure, high plasma levels of LDL, hypertriglyceridemia, homocysteinemia, high C-reactive 
protein, smoking, obesity, sedentary lifestyles, impaired glucose tolerance, psychological 
stress, and diabetes mellitus. Non-modifiable risk factors include genetic susceptibility, male 





1.2 The pathological consequences of atherosclerosis in the coronary circulation 
The signs, symptoms and outcomes of atherosclerotic plaque rupture are dependent on 
which artery becomes affected by displaced plaque or resulting thrombus. The coronary 
circulation is a network of arteries that supply heart muscles with blood. As the heart is a vital 
organ, any ischaemic damage caused by loss of blood supply may lead to a fatal heart attack. 
Thromboembolic phenomena related to disruption of atherosclerotic plaques may also affect 
other blood vessels, such as cerebral blood vessels, leading to a transient ischaemic attack 
(TIA) or ischaemic stroke (Timmis et al., 2018). In this project, we will be modelling a coronary 
artery to focus on the consequence of atherosclerosis in the coronary circulation. As 
atherosclerosis is a chronic progressive disease, it will gradually cause narrowing to the cross-
sectional area of the coronary artery as the atherosclerotic plaque extends into the lumen of 
the affected artery, even though the patient may remain asymptomatic for an extended 
period owing to the neovascularization and collateral circulation that can be created at the 
site of arterial narrowing. Once the narrowing of the lumen approaches 50% and above of the 
arterial lumen, the patient will start to suffer from symptoms of cardiac ischaemia such as 
exertional chest pain and shortness of breath, as the oxygen demand of the myocardium will 
exceed the rate of oxygen supply. These symptoms and signs are usually short-term and mild 
in severity and usually disappear after the patient rest or after the disappearance of the other 
provocative factors. This clinical syndrome is called stable angina pectoris (Valgimigli and 
Biscaglia, 2014). If the atherosclerotic inflammation progresses in severity, there will be more 
narrowing of the arterial lumen. The retrosternal chest pain will become more severe, and 
the attack may happen suddenly, even during rest. This clinical syndrome is called unstable 




fatal heart attack caused by UA reported that the atherosclerotic lesions were diffuse, and 
the arterial narrowing exceeded  75% of the total cross-sectional area of the coronary artery 
(Khandkar et al., 2021). Furthermore, arterial thrombosis may also be seen in UA. However, 
these are called mural thrombi, as they do not obstruct the arterial lumen. Other scientists 
reported that coronary thrombi in UA might wax and wane in size, so they might only 
temporarily occlude the arterial lumen. This might explain the rhythm of the ECG records seen 
during the attack, as there will be a temporary ST-segment elevation, which will return to 
normal after a period, even without any additional medical intervention (Braunwald et al., 
2002). The advanced atherosclerotic plaque is characterized by the thin fibrous cap, a necrotic 
core filled with collagen, tissue factor, calcification and multiple spots of haemorrhage or 
neovascularization (Virmani et al., 2003). This structure can be structurally unsound and, 
therefore, can fissure or rupture.  This can lead to the highly thrombogenic contents of the 
plaque (such as collagen and tissue factor) being released into direct contact with the blood. 
This can trigger uncontrolled platelet aggregation and blood coagulation around the 
dislodged plaque (Asada et al., 2020; Davis et al., 2014). This abnormal thrombus can be 
carried in the blood to downstream vessels. If it is a small micro embolus, the clot may not 
block any of the coronary arteries and create clinical symptoms, being filtered out in the 
pulmonary circulation. However, if it is large enough to block these vessels without sufficient 
collateral circulation at the site of obstruction, this will cause myocardial infarction (MI). The 
myocardium downstream of thrombotic obstruction will become ischemic and undergo 
necrosis – leading to a loss of cardiac function. If the coronary obstruction is complete, there 
will be severe infarction, and the necrotic area will extend across the whole thickness of the 
myocardium (from the endocardium to epicardium); this situation is called a full-thickness MI. 




shortness of breath, hypotension, or hypertension. If the arterial occlusion is not complete 
(for example, >90% occlusion), this is known as a partial thickness MI. The clinical features of 
this disease will be like the full thickness MI although it will be moderate in severity (Van de 
Werf et al., 2003; Cavallari et al., 2018). 
 
1.3 The biological basis for the development of atherosclerotic plaques 
1.3.1 Normal arterial structure and function 
The normal structure of the artery consists of three primary layers - the tunica intima, the 
tunica media, and the tunica adventitia (Figure 1.1). The tunica intima covers the interior 
surface of the blood vessels. This layer comprises a monolayer of endothelial cells (ECs) (Islam 
et al., 2016). Under normal physiological conditions, the endothelium plays an essential role 
as a barrier that prevents particles from passing from the plasma to the tunica media. The 
endothelial barrier is selective, such that water and small molecules in plasma can pass freely 
between ECs via spaces in intercellular junctions to the subendothelial area. Three types of 
endothelial cell junctions have been recognized, tight, adherence, and gap junctions. 
Occludin, a transmembrane protein, is the main constituent of the tight junction. The primary 
function of tight junctions is to prevent the diffusion of small particles across the endothelial 
cells. On the other hand, the transmembrane proteins vascular endothelial (VE-cadherin) are 
the main constituent of the adhesion junctions, which mainly regulate the movement of red 
blood cells across the endothelial cells. However, larger proteins and cells are prevented from 
passing. Low-Density Lipoproteins (LDL) carrying cholesterol and albumin particles are usually 
prevented from leaving the bloodstream by the EC barrier under normal physiological 




VE-cadherin. Inhibiting the function of VE-cadherin may lead to an increase in endothelial 
membrane permeability (Dejana, Orsenigo and Lampugnani, 2008). On the other hand, the 
integral membrane protein connexins (Cx) is the main constituent of gap junction which 
mainly work to regulate ions and small molecules movement across endothelial membrane 
(Goodenough &Paul,2009). In addition to their barrier function, ECs play an essential role in 
maintaining the normal haemostatic state of blood by preventing blood clotting in 
undamaged blood vessels. This is achieved by producing endogenous inhibitors of platelet 
activation such as nitric oxide (NO), prostacyclin, and inhibitors of the coagulation cascade 
such as anti-thrombin III, tissue factor pathway inhibitor and endothelial protein C receptors.  
However, upon vascular injury, ECs assist in recruiting platelets to the site of damage and 
formation of a blood clot to block the wound and prevent more bleeding by producing von 
Willebrand factor (vWF) and plasminogen activator inhibitor 1 (PAI-1). A thin layer called the 
internal elastic lamina (IEL) separates the tunica intima from the tunica media, containing 
elastin and basement membrane proteins (Aird, 2005). The middle layer of the blood vessel 
is the tunica media. This layer consists of smooth muscle cells (SMCs) and extracellular matrix 
(ECM). In contrast, the tunica media of veins do not contain smooth muscle cells. Collagen I 
and elastin provide the arteries with their mechanical strength. These extracellular matrix 
proteins are found in large arteries where these vessels need more supportive strength to 
adapt to the high pressure of the blood (Truskey, 2011). SMCs play an active role in controlling 
the mechanical properties of arterial walls, with contraction allowing dynamic regulation of 
vascular resistance and thus blood flow to the downstream tissues (Aird, 2007). The tunica 
adventitia is the outer layer of the blood vessel. It mainly consists of loose connective tissue, 
collagen and fibroblasts, and the nerves and blood vessels that supply the main blood vessel. 












Figure 1.1. Cross-sectional view of a normal artery. The normal structure of the artery 
consists of three main layers: the tunica intima which is composed from a monolayer of 
endothelial cells. Tunica interna is separated from the tunica media by internal elastic 
membrane. Tunica media is the second layer which is composed mainly from VSMCs. Tunica 
adventitia is the most outer layer of the blood vessel that contains connective tissues, 








1.3.2 Mechanisms of atherosclerotic plaque formation 
Atherosclerosis is chronic vascular inflammation that can started early in childhood as fatty 
streaks. The development of these initial lesions continues for decades, creating an advanced 
and highly thrombogenic plaque.  In some circumstances, these might rupture, leading to fatal 
heart attacks. 
 
1.3.3 Endothelial cell dysfunction 
Endothelial cell dysfunction is an early precursor of atherosclerosis. This is thought to occur 
due to hypercholesterolemia and abnormal blood flow at specific vulnerable areas of the 
arterial system (Braunwald et al., 2002). For instance, a blood vessel in which there are low 
shear stress, or are exposed to turbulent blood flow in branched or curved segments of the 
vessel are known to be vulnerable to plaque formation (Robert et al., 2013). This endothelial 
dysfunction can also be worsened by other cardiovascular risk factors such as high blood 
cholesterol, smoking, diabetes mellitus and hypertension (Yang et al., 2020). Each of these 
trigger structural changes that cause a disruption in the permeability of the intercellular 
junctions that lay between ECs. The function of the transmembrane proteins occludins and 
cadherin to seal the paracellular junctions between endothelial cells are affected by the 
inflammatory mediators released during atherosclerosis. Initially, during the early stage of 
atherosclerosis, there will be a localized loss for the selective barrier function of these 




cholesterol particles into the subendothelial matrix (Gallo et al., 2018). These particles are 
trapped and eventually modified and oxidized. Accumulation of oxidized LDL particles in the 
subendothelial area will enhance the endothelial dysfunction. The loss of normal endothelial 
cell function leads to a reduction in the production of NO (nitric oxide) and Prostacyclin (PGI2) 
removing the normal inhibitory influence of the endothelial cells on platelet aggregation 
favouring platelet activation in these regions (Cyr et al.,2020; Zuchi et al., 2020). Additionally, 
through increasing expression of the VCAM1 (vascular cell adhesion molecule 1) and ICAM1 
(intercellular adhesion molecule 1) cell surface markers it promotes increasing the 
recruitment of circulating monocytes and T- lymphocytes to the affected segment. In later 
stages of atherosclerosis, the endothelial cell dysfunction will also promote the migration and 
proliferation of vascular smooth muscle cells within the subendothelial space (Xue et al., 
2020). 
 
 1.3.4 Foam cell formation 
Endothelial dysfunction will promote the recruitment of circulating monocytes towards the 
injured area through increased endothelial permeability and monocyte adhesion. Several 
studies have reported that a considerable monocytes migration will happen across the 
endothelium without a significant disruption in the endothelial barrier (Navab et al., 1988). 
Moreover, this monocyte movement across the endothelial membrane will also accelerate 
albumin flux into the subendothelial space (Territo et al., 1984). Once recruited to the 
subendothelial area, the monocytes will differentiate into macrophages. As a result of the 
inflammatory process, the LDL particles moved from the circulation to the sub-endothelial 




products, an inflammatory enzyme secreted by the macrophage. As an anti-inflammatory 
response, the macrophages will start to engulf the oxidized LDL particles. At this point, the 
macrophages become enriched with intracellular lipid droplets and are known as foam cells 
because of their appearance. The accumulation of foam cells in the subendothelial space 
creating an early stage of atherosclerosis referred to as fatty streaks (Anastasia V. Poznyak et 
al., 2020)( Figure 1.2).  This new layer formed in the subendothelial space is known as the 
neointima. 
 
1.3.5 The role of platelets in the development of the atherosclerotic plaque 
Although platelets are principally known to play a role in thrombus formation, recent studies 
have demonstrated a vital role for platelets in the initiation and progression of the 
atherosclerotic lesion. This appears to occur through a mechanism independent of that used 
for thrombus formation. According to Huo and colleagues, platelets will adhere to the 
dysfunctional endothelial membrane even before the adherence and migration of monocytes 
into the subendothelial matrix (Huo et al., 2003). Although the mechanism by which platelets 
adhere to the inflamed endothelium is not fully understood, studies have reported that this 
occurs via integrin αIIbβ3 and the platelet vWF receptor, glycoprotein Iα (GPΙbα). This binding 
triggers platelet activation at the dysfunctional endothelial segments (Massberg et al., 2002; 
Gawaz et al., 2005). At healthy segments of the endothelium, platelets cannot be adhered or 
activated because of the inhibitory effects of endothelial PGI2 and NO. In areas of 
dysfunctional endothelium, these cells produce lower levels of PGI2 and NO, which facilitate 
platelet adhesion and activation. The adherent activated platelets will express P-selectin and 




endothelial adhesion and platelet-platelet aggregation (Gąsecka et al., 2021). Gawaz and 
colleagues demonstrated in mice that chronic blockade of GPIbα decreased subendothelial 
leukocyte recruitment and consequently slowed atherosclerosis progression in mice (Gawaz 
et al., 2005). After platelets became activated, they release monocyte attracting protein 
(MAP-1). This stimulates monocyte adhesion, invasion, macrophage differentiation and 
conversion to foam cells (Massberg et al., 2002). These macrophages propagate the 
inflammatory process by secreting Interleukin-1 (IL-1), Tumour necrosis factor-α (TNF-α) and 
monocyte chemotactic protein 1 (MCP-1), which elicits further leukocyte recruitment.  
 
 
Figure 1.2 Foam cell formation. Monocytes and LDL emigrate through the dysfunctional 
endothelium toward the subendothelial space where the monocytes will differentiate to 





1.3.6 T-lymphocyte recruitment 
Previous studies have demonstrated that T-lymphocytes play an essential role in the initiation 
and progression of atherosclerosis (Jonasson et al., 1985). T helper lymphocytes will move 
toward the subendothelial space after being activated by the human leukocyte antigen-DR-
positive (HLA-DR-positive) endothelium. In the subendothelial matrix, T helper 1 (Th1) 
lymphocytes will contribute to the inflammatory process by secretion of cytokines such as 
interferon-gamma (IFN-γ) and tumour necrosis factors (TNF), whose receptors have been 
detected on the surface of foam cells of mouse models. TNF-α and IFN-γ can enhance the rate 
of atherosclerosis progression by further increasing the permeability of the endothelial 
barrier leading to an acceleration of the influx of monocytes and LDL-cholesterol into the 
subendothelial space (Pober and Sessa, 2007).  T helper 2 (Th2) lymphocytes also have a role 
in plaque formation by secreting another group of cytokines that contribute to foam cells 
formation and smooth muscle proliferation through secretion of IL-4 and IL-13 (Folick et al., 
1997). These findings demonstrate a role for cellular immunity in promoting atherosclerosis. 
On the other hand,  there was no detected significant role for humoral immunity in 
atherosclerosis, as previous work had seen little contribution of the  B lymphocytes in this 
inflammatory process  (Hansson and Jonasson, 2009). However, Galigiuri and colleagues 
reported that splenectomy in mice would accelerate the atherosclerotic plaque formation 
compared to control animals, demonstrating the vital role of humoral immunity in the 







1.3.7 Infiltration and proliferation of smooth muscle cells 
As a result of the pro-inflammatory condition that the early stages of atherosclerosis have 
created, SMCs originating from the tunica media will be modified from their normal 
contractile phenotype to proliferative phenotype, and migrate to the intima, where they can 
assist in the thickening of the neointimal layer. This occurs both through the loss of inhibitory 
signals from the dysfunctional endothelium and due to the localized release of cytokines such 
as IL-1β and platelet-derived growth factor (PDGF) from endothelial cells and macrophages 
(Sheikine and Hansson, 2006). Besides, platelets have also been seen to invade through the 
endothelial barrier and accumulate in the subendothelial matrix. Here they become activated 
by collagen and other agonists in the subendothelial matrix and start to secrete PDGF and 
lysophosphatidic acid (LPA) which stimulates SMC migration and proliferation at the 
subendothelial space (Schafer and Bauersachs, 2008). Once SMCs invade the neointimal 
space, they will begin to produce and release a range of extracellular matrix molecules such 
as collagen and proteoglycans, leading to the formation of a fibrous cap that lies between the 
endothelium and the accumulated foam cells (Figure 1.3). The SMCs also take up lipids 
similarly to macrophages (Cadsuda et al., 1992). with recent studies demonstrating that 50% 
of all foam cells in human atherosclerotic plaques are of smooth muscle origin (Wang et al., 
2019). Additionally, they have reported that Smooth Muscle Cell-derived foam cells 
(SMCDFCs) express less ABCA1 than macrophage-derived foam cells. ABCA1 (ATP-binding 
cassette transporter 1) is a transporter that facilitates the expulsion of LDL particles from 
foam cells, and so facilitates regression of atherosclerosis. The downregulation of ABCA1 in 
SMCDFCs makes them more resistant to regression than macrophages-derived foam cells (Q 




proteins. For example, CEMIP (cell migration-inducing and hyaluronan-binding protein) plays 
an essential role in enhancing VSMCs proliferation and migration  through activation of the 
Wnt-Beta-Catenin signalling pathway (Chong et al., 2020). This group has reported that CEMIP 
level is upregulated in plasma of patients with atherosclerosis, compared to that observed in 
a matched group of healthy people. Similarly, overexpression of C-X-C motif chemokine 12 
(CXCL12) was associated with a high rate of VSMCs proliferation and their transformation to 
foam cells (Li et al., 2020).  Any intervention that decreases the expression of CEMIP or CXCL12 
may help prevent VSMCs proliferation and maturation within the plaque (Xue et al., 2020; Q 
et al., 2020; Li et al., 2020) pointing to a potential new therapeutic strategy in atherosclerosis. 
On the other hand, Ursodeoxycholic acid (UDCA), a natural bile acid that is used for the 
treatment of cholestatic hepatic pathologies, has been reported to prevent intimal 
hyperplasia and SMC migration, principally through inducing apoptosis. So, UDCA may be a 






Figure 1.3 Fibrous cap formation. The fibrous cap results from the migration of SMCs 
between the endothelial cells and macrophage-derived foam cells. Here they proliferate and 
lay down fibrin, collagen and proteoglycans that will form the fibrous cap of the 
atherosclerotic plaque. Figure reproduced from Glass and Witztum (2001). 
 
1.3.8 Formation of the necrotic core 
The size of the neointima is controlled in early atherosclerotic lesions by apoptosis of foam 
cells (Liu et al., 2005). This apoptotic response is driven by several different chemical 
messengers such as TNF-α and oxLDL. Additionally, induction of endoplasmic reticulum stress 
is a crucial mediator of foam cell death (Seimon and Tabas, 2009). Whilst this cell death 
initially acts to limit the size of the plaque, in more advanced lesions, there is a reduced ability 
of phagocytic cells to clear apoptotic foam cells (called defective efferocytosis). Due to the 
reduced clearance rate, these apoptotic cells start to become necrotic – with the cells become 




lipid contents to leak into the extracellular space alongside cytokines and other cytotoxic 
compounds. For instance, IL-1β, TNF-α and IFN-γ all work to propagate the growth of the 
plaque by increasing the size of the necrotic core (Andres et al., 2012). This creates a necrotic 
lipid-filled core of the plaque flanked on either side by a shoulder region, containing T-
lymphocytes, macrophages, and SMCs, underneath the fibrous cap (Figure 1.4). At this stage, 
the entire structure is referred to as a fibroatheroma, and if unperturbed, will often lead to 
no observable clinical symptoms (Bentzon et al., 2014). Further growth of the fibroatheroma 
causes progressive narrowing of the arterial lumen, which can cause angina by limiting blood 
supply to the cardiac muscle. However, plaque size does not correlate with the likelihood of 
its ability to trigger acute cardiovascular events (Jaberi et al., 2018). 
 
Figure 1.4 Formation of the necrotic core. Macrophage-derived foam cells and SMC-derived 
foam cells, and other ECM contents will accumulate and form the necrotic core. Figure 






1.3.9 Mechanisms of atherosclerotic plaque disruption 
An atherosclerotic plaque is often clinically silent and often will cause no notable symptoms 
for the affected individual throughout their entire life. However, some plaques may become 
disrupted decades after their formation, leading to exposure of the blood to the highly-
thrombogenic material contained within. There are three types of plaque disruption that can 
lead to the onset of clinical symptoms: Plaque rupture (PR), plaque erosion (PE), and plaque 
fissuring (PF). Although, some investigators consider PE and PF as subtypes of PR (Asada et 
al., 2020). 
1.3.9.1 Plaque Rupture 
Plaque rupture (PR) is the most common cause of acute coronary syndrome (Khandkar et al., 
2021). In plaque rupture, the fibrous cap of the atherosclerotic plaque will thin and 
progressively weakened till it breaks, leading to an opening that is large enough to release 
most of the highly atherogenic contents of the plaque into the circulation (Okuyama et al., 
2015). The exact mechanism that triggers atherosclerotic PR is unclear, with several suggested 
hypotheses (Fuster et al., 1988).  Badimon and Vilahur have reported that the current 
consensus is that PR is a multifactorial process that involves biomechanical, hemodynamic 
and physical factors (Badimon and Vilahur, 2014). In support of this evidence has suggested 
that mechanical disruption of the plaque caused by vasospasm and increased blood shear 
stress can contribute to rupture. Abela et al have also reported that cholesterol crystals 
penetrating the thin cap of the atherosclerotic plaque might be responsible for the PR (Abela 
et al., 2016).  However, the principal player in this event seems to be continuation of the 




Collagen is an essential source of atherosclerotic plaque cap strength. Type I, II and III collagen 
are found in the atherosclerotic matrix in unequal concentrations, with type I collagen being 
the most abundant (Wolf and Ley, 2019).  Over time, the macrophages inside the stabilized 
plaque will start to secrete matrix metalloproteinases (MMP), which will digest the collagen 
in the fibroatheroma (Gough et al., 2006). This will lead to thinning of the plaque wall, 
especially at the shoulder region. This type of fibroatheroma is called a thin cap 
fibroatheroma, or unstable plaque (Figure 1.5; Davies, 2000). However, it is still unclear how 
long it takes the stabilized fibroatheroma to convert into a thin cap fibroatheroma (Cao et al, 
2020). Other researchers have also raised several questions about the relationship between 
PR and thrombo-embolic phenomenon, as several post-mortem studies in cases of deaths 
due to non-cardiac causes have reported observing signs of PR without thrombosis. This might 
mean that the thrombosis could happen without the need for direct exposure of the luminal 
blood with the constituents of the plaque. It also suggests that the causative relationship 
between PR-induced thrombosis with ACS and sudden cardiac death could be overestimated, 
and might actually be incidental (Virmani et al., 2000).  According to several post-mortem 
studies conducted on patients who died as a result of acute coronary syndrome, ruptured 
atherosclerotic plaques also contain less smooth muscle cells in comparison to intact plaques, 
making the wall of the plaque thinner, weaker and more vulnerable to rupture, especially at 
the shoulder area (Lee et al., 1991). At this stage, the SMCs will be the most abundant 
constituents of the atherosclerotic fibroatheroma (Islam et al., 2016). They will start to engulf 
the oxidized LDL particles akin to macrophages, creating smooth muscle-derived foam cells  
(Bentzon et al., 2014). The immune system will begin to target both of these distinct foam cell 
populations, which engulf the modified lipid particles using several enzymes such as 




and leading to the formation of a large necrotic core (Clarke and Bennett, 2009). Additionally, 
these enzymes will also work to weaken the plaque by degrading collagen. Interestingly, the 
apoptosis rate among these SMCs is significantly higher than that of the local macrophages, 
which are especially pronounced in advanced and late atherosclerotic lesions. Although some 
researchers have suggested that the apoptotic rate might be the same for both cells, but the 
macrophages that undergo apoptosis are rapidly replaced by new macrophage cells from 
circulation giving the appearance of a slower turnover rate (Clarke and Bennett, 2009). 
Macrophage apoptosis may ameliorate or decrease the atherosclerosis progression, mainly 
by reducing the size of the plaque. However, SMC apoptosis will adversely affect the strength 
and stability of the atherosclerotic plaque architecture. It will lead to thinning of the fibrous 
cap of the plaque, making it more vulnerable to rupture (Figure 1.5). IFN-γ, which is mainly 
secreted from macrophages and T-lymphocytes, has been shown to increase SMC apoptosis 
and reduce their collagen synthesis, which would also contribute to the weakening of the 
fibrous cap.  So, inflammation is likely to play an essential role in triggering this loss of SMC, 






Figure 1.5 Thin-cap atherosclerotic plaque. Immunohistochemical staining of a segment of 
artery taken post-mortem.  Co: contrast medium, (Fc) thin fibrous cap, NC: necrotic core. The 
vulnerable thin fibrous cap is about to rupture. In such case, the highly thrombogenic content 
of the necrotic core (NC) will be released to circulation leading to the thrombo-embolic 
phenomenon, most of the cells inside the NC were positive for CD68 antibody. Figure 
reproduced from Bentzon et al., (2014) 
 
1.3.9.2 Plaque erosion 
In plaque erosion (PE), the endothelial membrane is disrupted; however, the contents of the 
necrotic core are still not in contact with the circulation (Jia et al., 2013). Plaque erosion (PE) 
is caused by a different mechanism from that of plaque rupture. Some studies have reported 
that the endothelium beneath the thrombus on an eroded plaque is either severely damaged 
or absent. However, both the internal and external elastic lamina are intact, and the medial 
layer is normal, with SMCs showing a contractile phenotype. In contrast, the internal elastic 




(Hao et al., 2006). Additionally, whilst smooth muscle cell number was reported to be lower 
in both lesions, the number in areas of PR was significantly lower than that found in areas 
undergoing PE (Van Der Wal et al., 1994). Also, the necrotic core in PE is smaller than that of 
PR, and the density of inflammatory cells is lower than that in PR. Furthermore, some studies 
have reported that several PE lesions have no necrotic core (White et al.,2016). In addition,    
Although several studies have reported that patients who have PE are less likely to develop 
acute coronary syndrome (ACS) in comparison with those patients with PR, other studies have 
suggested that the causative relationship between PE and ACS were underestimated owing 
to the difficulties in using common diagnostic tools such as standard coronary angiography 
and intravascular ultrasonography in which this superficial lesion that is easily missed (Shahar 
et al., 2003; Virmani et al., 2000). Furthermore, several post-mortem studies have reported 
that PE is responsible for about 40% of all sudden cardiac deaths (SCDs; Bentzon et al., 2014). 
Other studies have suggested considering PE as a cause for SCD when thorough microscopic 
examination fails to detect PR (Virmani et al., 2000). In addition, they have reported that 
young women have a significantly higher rate of PE lesions than other samples of patients 
(Shahar, 2003). The mechanism that is responsible for thrombus formation in PE is currently 
the subject of debate. How can there be a thrombus on top of the plaque in PE when a thick 
and intact fibrous cap prevents contact with the blood? This indicates that the highly-
thrombogenic constituents of the atherosclerotic plaque matrix may not always be the 
primary trigger for thrombosis in atherosclerotic disease (Arbustini et al.,1991). However, 
other investigators have documented that the constituents of thrombi caused by PE differ 
significantly from those triggered by PR. Although thrombi caused by  PE and PR are both 




whilst fibrin was seen to be the major constituent of PR thrombi (Sato et al., 2005). These 
data indicate that the mechanisms of PR thrombosis differ from those triggered by PE. 
Some studies have suggested that the inflammatory process that accompanies PE or PR differs 
from that found in the intact plaque. As stated previously, it is rare to detect neutrophil cells 
among the inflammatory cells during the formation of the intact plaque formation (Hansson 
and Jonasson, 2009). However, in the case of PE and PR, there are abundant neutrophil cells 
observed at the site of the lesion. As the neutrophil cells can secrete certain lytic enzymes, 
they may have a role in initiating plaque wall erosion or ulceration (Weiss et al., 1989). Some 
researchers have reported that collagenase Ι is mainly secreted from neutrophil cells. 
Activation of neutrophil will cause the secretion of this enzyme, which will degrade type I 
collagen leading to weakening and thinning of the fibrous cap. High expression of collagenase 
Ι is also known to be a risk factor for atherosclerotic plaque rupture, potentially further 
suggesting a role for neutrophils in this process (Herman et al., 2001). This localized 
neutrophilia also has been observed following coronary angioplasty-induced laceration (Van 
Der Wal et al., 1994). However, other studies have suggested that neutrophils play no role in 
plaque erosion or rupture, as they only accumulate at the lesion site after these events have 
occurred (De Servi et al., 1990) . In addition to the above local risk factors for PR and PE, there 
are other systemic factors, for instance, procoagulant conditions, recurrent infections, and 
systemic inflammation. 
 
1.3.9.3 Plaque fissuring  
Sometimes the thin plaque cap can tear, break, or crack, especially at the weaker shoulder 




to be associated with thrombosis, and in some cases, with fatal heart attacks (Davies and 
Thomas, 1981). Usually, PF is associated with intraplaque haemorrhage into the necrotic core 
(Virmani et al., 2000). Some researchers have suggested that the source of this haemorrhage 
is from the flow of the luminal blood through the tears or the cracks that are associated with 
PF (Davies & Thomas, 1985). However, other studies have hypothesized that the intraplaque 
haemorrhage is mainly caused by neovascularisation of the medial layer (Paterson, 1938). 
Plaque fissuring has also been considered a precursor for PR or an incidental lesion (Arbustini 
et al., 1991). 
 
1.4 The mechanisms of atherothrombosis 
Atherothrombosis is the term applied to the haematological process that leads to thrombosis 
in the setting of atherosclerosis. In the intact blood vessel, antithrombotic factors significantly 
outweigh any procoagulant thrombotic factors. However, after rupturing of atherosclerotic 
plaque, this balance will be disrupted, and the procoagulant effects will exceed the 
anticoagulant effects, ending with the formation of a thrombotic clot (Junt et al., 2007). 
 
1.4.1 Formation of a platelet aggregate 
After rupture of the atherosclerotic plaque, platelets start to accumulate and adhere to the 
exposed collagen at the site of the ruptured plaque. The adhesion of the platelets is mainly 
triggered by collagen in the subendothelial matrix, either directly or indirectly, via bound vWF 
(Kaplan and Jackson, 2011). The binding of platelets to these adhesive ligands activates them, 




thromboxane A2, and adenosine diphosphate (ADP) produced or released at the site of injury. 
After activation of the platelets, the inactive form of integrin αIIbβ3 will convert to its active 
form, enabling the activated platelets to bind with fibrinogen and vWF. Activated platelets 
begin to cohere to one another via the bound fibrinogen, leading to the formation of a platelet 
aggregate. (Kaplan and Jackson, 2020). 
 
 
Figure 1.6 Platelet activation in atherosclerosis. After rupture of the atherosclerotic plaque, 
platelets start to accumulate and adhere to the exposed collagen at the site of the ruptured 
plaque. (1) The adhesion of the platelets is mainly triggered by collagen in the subendothelial 
matrix, either directly or indirectly, via bound vWF. (2) Adherent platelets become activated 
through intracellular signalling pathways caused by binding to vWF or collagen.  This 
activation triggers platelet production of thromboxane A2, secretion of ADP and 5-HT, and 
production of a catalytic surface for thrombin production. These platelet agonists can then 
activate other circulating cells to recruit them to the growing thrombus.  (3) Activation also 
triggers the activation of integrin αIIbβ3 on the platelet surface.  This allows these cells to bind 
fibrinogen.  Cohesion of platelet through fibrinogen bridges helps trigger aggregation of 
platelets.  (4) This aggregation then can then contract and create a plug covering the surface 





1.4.2 Activation of the blood coagulation cascade 
Blood coagulation is a highly regulated and complex process. It plays a crucial role in keeping 
the blood in a highly hemodynamic balanced situation. Under normal physiological 
conditions, when vascular wall injury happens, the endothelial lining is interrupted, and sub-
endothelial collagen and tissue factor will expose to blood at the injury site. Collagen will 
stimulate aggregation and activation of the platelets at the site of vascular injury resulting in 
the formation of a platelet aggregate. Exposed tissue factor in the subendothelial matrix will 
stimulate a cascade triggering activation of plasma-derived coagulation factors. The final 
product for the activated coagulation cascade is the formation of Thrombin from 
prothrombin, which can cleave soluble plasma-derived fibrinogen into insoluble fibrin mesh. 
This, in turn, will enmesh the unstable platelet aggregate forming a stable thrombus (Asada 
et al., 2020). Classically, the coagulation cascade was divided into three pathways - the 
extrinsic, intrinsic, and common pathway (Figure 1.7).  This classical model of blood 
coagulation can interpret the results of in vitro coagulation screening tests (the prothrombin 
time and the activated partial thromboplastin time).  However, it does not require a role for 
cell surfaces in the coagulation process, and it fails to provide appropriate explanations for 
several bleeding disorders. For example, it is unable to explain why people with FIX and FVIII 
deficiency (haemophilia A and B) suffer from significant bleeding episodes, despite the 
extrinsic and common pathway being unaffected. This lead to the development of the cell-








                                                                                                        
Figure 1.7 The classic interpretation of the coagulation cascade. Classically, the coagulation 
cascade consists of three pathways - the extrinsic, intrinsic, and common pathways.  
According to this cascade, FXII is the main initiator of the intrinsic pathway, activating XI to 
XIa. Activation of FXIa will lead to activating FIX to IXa. In corporation with FIIIa, FIXa will 
activate FX to FXa. FXa with FVa will activate prothrombin (FII) to thrombin (FIIa). Thrombin 
will transform the soluble fibrinogen to more stable and insoluble fibrin. 
 
1.4.2.1 The cell-based model of haemostasis 
More recently, there has been a move away from the traditional conception of the extrinsic, 
intrinsic, and common coagulation pathways as three independently regulated parts of the 
coagulation cascade. Instead, the cell-based model of haemostasis proposes that these 
pathways work together to create three temporally overlapping stages that illustrate the 




certain bleeding disorders (Zaidi and Green, 2019). The three stages are known as the 
initiation, amplification, and propagation stages. 
1.4.2.2 Initiation phase 
Under normal physiological conditions, specific cells outside of the blood vessel, such as 
fibroblasts, macrophages, smooth muscle cells, and mononuclear cells express tissue factor 
(TF). This is why this step was traditionally referred to as the extrinsic pathway. Normally TF 
is not present on the surface of endothelial cells, but this can be triggered when cells are 
exposed to specific inflammatory mediators (e.g., TNF-α). TF is also expressed by endothelial 
cells in response to vascular wall injury.  
Immediately after vascular wall injury, inactive FVII in the plasma will be in direct contact with 
subendothelial TF at the site of vascular injury (Figure 1.8). Here, TF plays an essential role in 
initiating the coagulation cascade to activate FVII to FVIIa. This TF-FVIIa complex will activate 
FX to FIXa, which can then trigger the formation of thrombin from prothrombin. Moreover, it 
has been reported that TF-bearing cells secrete a small amount of thrombin even under 
normal physiological conditions, which may further contribute to the initiation phase of the 
coagulation cascade (Hoffman, 2003). 
 
1.4.2.3 Amplification phase 
During the amplification phase, the initial spark of thrombin formation that occurred in the 
initiation phase can be used to trigger a significant amplification of thrombin production. This 






Figure 1.8 The initiation phase of the cell-based model of haemostasis.  After vascular wall 
injury, inactive FVII in the plasma will be in direct contact with subendothelial TF at the site of 
vascular injury. TF plays a vital role in initiating the coagulation cascade as it works to activate 
FVII to FVIIa. This TF-FVIIa complex will activate FX to FXa, which can then trigger the 
formation of thrombin from prothrombin. Moreover, It has been reported that TF- bearing 
cells secreted a small amount of thrombin (FIIa) even under normal physiological conditions, 
which may further contribute to the initiation phase of the coagulation cascade by converting 
FV to FVa. 
 
the exposed subendothelial collagen at the site of vascular injury.  This aggregate formation 
is further reinforced by the ability of the initial thrombin spark to trigger further local platelet 
activation through cleavage of the proteas -activated receptor 1 (PAR1) and protease 
activated receptors 4 (PAR4) on the surface of human platelets, as well as their indirect 
binding to GPIb (Lordan et al., 2021). This high-level platelet activation allows platelets to 
expressed phosphatidylserine on its external face of its plasma membrane.  These 
procoagulant lipids can bind clotting factors bringing them together at a catalytic surface 




Simultaneously, thrombin produced in the initiation phase can cleave and activate Factor V, 
VIII and XI upon the surface of the activated platelets.  These helps increase local thrombin 
production as Factor XI activates Factor IX. This FIXa works together with Factor VIIIa from a 
second tenase complex that can cleave and activate Factor X on the surface of the activated 
platelets. 
1.4.2.4 Propagation phase  
On the surface of the activated platelets, activated FVIIIa will combine with activated FIXa. 
The FVIIIa-FIXa complex will be a cofactor for the activation of FXa, which will later bind to 
FVa (Figure 1.9).  After that, the FXa-FVa complex will play an essential role in activating 
prothrombin to thrombin, converting fibrinogen to more stable and insoluble fibrin. The 
amount of thrombin formed during the propagation phase is much more than that during the 
initiation phase. Consequently, Thrombin will activate more FVa and platelets, form more 







Figure 1.9 Propagation phase of the cell-based model of haemostasis. On the surface of the 
activated platelets, activated FVIIIa will combine with activated FIXa. The FVIIIa-FIXa complex 
will be a cofactor for the activation of FXa, which will later combine with FVa. After that, the 
FXa-FVa complex will activate prothrombin to Thrombin, converting fibrinogen to more stable 











1.4.2.5 Fibrinolysis  
This system acts to remove fibrin allowing the clot to be resolved once the vascular injury is 
patched. As mentioned above, there is a fine balance between the coagulation pathway and 
the fibrinolysis system. Once fibrin is formed, this will act as a physiological signal for 
fibrinolysis to begin. Initially, tissue plasminogen activator (tPA) and plasminogen accumulate 
over the surface of the fibrin clot. Thereafter, tPA will react with plasminogen activating it to 
plasmin which will act to lyse fibrin, creating fibrin degradation products such as D-dimer 
(Mybin and Critchley, 2016). 
 
1.5 Animal studies of atherosclerosis initiation and progression  
1.5.1 Clinical monitoring of the progression of atherosclerosis in humans is difficult 
Atherosclerosis is a chronic, longstanding disease. The natural history of atherosclerosis is a 
process that may extend over decades, therefore monitoring this disease may need to extend 
over similar timescales (Charo et al., 2011). Several studies have monitored a significant 
correlation between the intimal-medial thickness of the carotid artery (IMTC) and the 
progression of atherosclerosis (Urbina et al., 2006). The most common method to measure 
IMTC is by using Doppler ultrasonography. It is a non-invasive and cost-effective method but 
requires a specialist team to perform. This technique works by identifying areas of high-
velocity blood flow, indicating arterial stenosis or obstruction (Stein et al., 2008). Magnetic 
resonance imaging (MRI) studies can also measure IMTC but with higher sensitivity and 
specificity than Doppler ultrasonography (Grant et al., 2003). MRI also allows us to accurately 




(Sam et al., 2005; De Groot et al., 2008). Monitoring of atherosclerosis progression can also 
be done via monitoring of several plasma biomarkers such as C-reactive protein (CRP), cardiac 
troponin, tumour necrosis factor-α (TNF-α), IL-6, IL-8, MMPs 1,3,8, and 9, myeloperoxidase 
(MPO). Several studies have reported a proportional relationship between the level of these 
biomarkers and the severity of atherosclerosis. In addition, there was a significant correlation 
between the severity and number of cardiovascular attacks and the levels of the inflammatory 
biomarkers (Brown and Bittner, 2009). However, the specificity of some of these biomarkers 
is low. For example, CR-protein is an acute phase reactant, so, any inflammation whether 
vascular or non-vascular can increase its level. IL-6, IL-8 is nearly similar to CR-protein, 
however, MMPs and MPO are more specific for atherosclerotic inflammation as they are 
contributing to plaque thinning and rupture(Wang et al., 2017). Beyond this, it is difficult to 
study atherosclerotic plaques in live humans, with much of the research performed on post-
mortem examination of arterial specimens. Through documenting the histochemical and 
histopathological features of atherosclerosis at people who have died at different ages, it has 
been possible to study the natural history of this disease, which has helped investigators to 
monitor atherosclerosis among live people  (Zhdanov and Sternby, 2004).  However, this does 
not allow us to study the molecular and cellular events that lead to plaque formation, 
progression, and rupture directly in humans. 
Therefore, most of our knowledge about the pathology and pathogenesis of atherosclerosis 
has been obtained from in vivo animal studies. The animals that have been most used to study 
atherosclerosis are mouse, rabbits, and pigs.  These animal models allow researchers to study 
the mechanism of atherosclerosis within the complex cellular, chemical, and physical 




However, each of these different animals offers distinct advantages and disadvantages when 
modelling human atherosclerosis. 
 
1.5.2 Rabbit models 
Rabbits were the first animal models used to explore the biological, molecular, and 
immunological mechanisms of atherosclerosis. Rabbits are an attractive model as they are 
relatively small, easily handle, available, and cheap to maintain (apart from mice models). The 
first study in rabbits was conducted in 1908 by Ignatowski to assess the influence of a protein-
rich diet on atherosclerosis (Ignatowski, 1908), followed by a similar study which was 
conducted in 1913 to study the effects of hyperlipidaemia on changes in the structure of 
rabbits' blood vessels (Antischkow, 1913). Both demonstrated foam cell formation in the 
intima, demonstrating that rabbits can be susceptible to some degree of diet-induced 
atherosclerosis like humans. Kolodgie and his colleagues reported that to initiate an early 
atherosclerotic lesion with monocyte infiltration and foam cells forming in the subendothelial 
similar to that found in humans, investigators needed to feed rabbits for a long time a low 
cholesterol diet (Kolodgie et al., 1996). However, to elicit more advanced atherosclerotic 
lesions in rabbits, high cholesterol diets need to be used for long periods (6 months - years) 
alongside the induction of an artificial endothelial lesion (Aikawa et al., 1998).In addition to 
the need for mechanical intervention, the diets needed to induce abnormally high plasma 
cholesterol levels leading to the accumulation of dietary lipid in multiple additional organs 
which make this disease appear different from that seen in humans (Fan et al., 2001).Besides, 
the low levels of hepatic lipase in rabbits lead to significant mortality due to hepatotoxicity 




1997). Therefore, whilst rabbits have some similarities in plasma lipoproteins to humans, they 
are not identical, and they can struggle to fully recreate the human phenotype with dietary 
interventions alone fully. The development of genetically modified rabbits resulted in better 
models of human like atherosclerosis models. In 1980, Watanabe succeeded in creating a line 
of rabbits with a hereditary hyperlipidaemic disorder by breeding rabbits with a natural 
mutation in the LDL receptor. Most of these rabbits developed spontaneous atherosclerotic 
lesions across the aortic intima, similar in structure to those found in human patients with 
familial hypercholesterolemia. These mutant transgenic models demonstrated the power of 
transgenic models for in vivo studies of the genetic factors involved in the development of 
the in vivo atherosclerotic studies (Watanabe, 1980). Despite rabbits not being as easy to 
genetically modify as mice, there have been a number of transgenic models of altered lipid 
metabolism produced to try to model human cardiovascular disease (as reviewed in 
Watanabe, 1980); however, they are still unrelevant for more lifestyle-induced image (Tylor, 
1997).  Additionally, due to their larger size, they are more accessible to medical imaging 
techniques to track atherosclerotic lesion formation and development.  For example, previous 
studies in rabbits have demonstrated the possibility of using MRI over six months to monitor 
atherosclerosis formation.  This group concluded that an MRI scan is a non-invasive technique 
that might be possible to use to monitor and follow the human atherosclerotic plaque 
formation and progression (Worthley et al., 2000). Rabbit models have supplied the 
investigators with huge and valuable information regarding atherosclerosis. However, some 
authors have reported some limitations of this model (Kolodgie et al., 1996) These include 
differences in the anatomical distribution of atherosclerotic lesions in rabbits (aortic arch and 
descending thoracic aorta) compared to those seen in humans coronary arteries and 





1.5.3 Murine models 
Whilst rabbit models were the first animal models used; mice models have become the 
principal model used in this field. This because of the ease in which it is possible to genetically 
modify this species, which coupled with its rapid breeding rate, small size and low cost of 
maintenance – makes this a powerful model system in which to work (Veseli et al., 2017). 
However, haemodynamic factors have significantly differed between mice and humans, 
which may alter mechanical aspects of plaque development and rupture between these 
species (Feintuch et al., 2007). Initial studies examined the impact of feeding wild-type mice 
with lipid-rich diets. These discovered that mice are relatively resistant to atherosclerosis 
because of differences in their lipid profile compared to humans. In humans, most of the 
plasma cholesterol is carried in LDLs, which are pro-atherogenic particles. However, in mice, 
most of the plasma cholesterol is naturally maintained in the bloodstream by high-density 
lipoproteins (HDLs), whilst LDLs carries only a small percentage of the total plasma cholesterol 
(Getz and Reardon, 2012). Thus, the study of transgenic mice has played a crucial role in 
exploring the influence of atherosclerosis's genetic and environmental factors. This includes 
transgenic mice with LDL receptor (LDLR) deficiency, creating a Watanabe hereditary 
hypercholesterolemic rabbit model. These transgenetic mice have a significantly higher 
plasma LDL cholesterol than normal mice and are more prone than wild-type mice to 
developing atherosclerotic lesions(Ishibashi et al., 1993) .The main advantages are the plasma 
lipid profile of these mice are like human plasma lipid profile with the preservation of the 
apolipoprotein E (ApoE) protein. However, the main disadvantage of this model is that it is 




atherosclerotic lesion. Crucially these atherosclerotic lesions do not rupture spontaneously, 
erode or fissure, meaning that they cannot naturally replicate the crucial pathological event 
involved in triggering acute cardiovascular events in humans. Another widely used mouse 
model is the ApoE knockout mouse. ApoE is an essential protein within lipoprotein particles 
which allows them to be cleared from the plasma by the liver through binding bound to the 
LDLR. Plump and his colleagues reported that ApoE-deficient mice have significantly higher 
plasma cholesterol (mainly in the form of VLDL and IDL) than normal mice. After twenty weeks 
of normal diet feeding, these ApoE-deficient mice developed atherosclerotic lesions across 
the aorta and pulmonary artery – providing a model that does not require lipid-over-enriched 
diets to generate atherosclerosis. Unfortunately, these atherosclerotic lesions also do not 
rupture spontaneously or get thrombosis even with a longer feeding period (Plump et al., 
1992). 
Further attempts to create a transgenic mouse with a vulnerable atherosclerotic plaque led 
to developing a transgenic mouse deficient in both LDLR and ApoE. This double knockout 
mouse model presents severe hyperlipidaemia and spontaneous development of 
atherosclerotic lesions even with normal diet feeding. However, like the respective single 
knockout mouse models, the atherosclerotic lesions do not rupture spontaneously (Bontu et 
al., 1997). 
The only transgenic mice models that have been shown to develop spontaneous plaque 
rupture are the ApoE/Fibrillin-1 double knockout mouse (Van Der Donckt et al., 2015). 
Fibrillin-1 is a key glycoprotein that helps stabilize elastic microfilaments in the arteries, such 
that loss of this protein leads to filament destabilization and increased arterial stiffness. These 




thrombotic complications such as myocardial infarction and stroke. This appeared due to 
mechanical induction of increased plaque progression caused by the increased pulse pressure 
found in the stiffened arterial wall (figure 1.10; Van Herck et al., 2009); Van der Donckt et al., 
2015). Although fibrillin-1 mutations have been shown to increase atherosclerotic plaque 
development and cardiovascular risk in humans (Medley et al., 2002), this may not represent 
a normal causative event. Further studies will be required to see if this model fully replicates 





Figure 1.10 Mechanisms of Fibrillin-1/ApoE knockout plaque rupture. Rupture of the 
atherosclerotic plaque in Apo E/Fibrillin1 mice will release highly thrombogenic contents to 
the circulation leading to either myocardial infarction or stroke. Reproduced from van der 





1.5.4 Porcine models 
Pigs have an anatomy and physiology that are more like humans than mice and rabbits. More 
than two-thirds of the total body energy requirement of the pig is derived from the 
metabolism of non-esterified fatty acids, which is like that of a human. Furthermore, the size 
of the heart and other great vessels are similar to those of humans (Kaplan et al., 1982). The 
heart's electrical circuitry, the coronary circulation, and the morphology and structure of 
mitral, tricuspid, and aortic valves are like those found in humans. The heart rate of human 
(60-100 beat per minutes) and pigs (91-167 beat per minutes) are also mimic to that of human 
(Lelovas et al., 2014). The predominant plasma lipoprotein are LDLs, while high-density 
Lipoproteins (HDL) comprise about one-quarter of the total plasma lipoprotein, which is 
similar to that found in humans. This has perhaps made the natural history of atherosclerosis 
in pigs and humans appear to be similar (Getz and Reardon, 2012).  Bloor and White (1992) 
reported that ageing pigs might develop atherosclerosis spontaneously. For these reasons, 
many scientists have recommended pigs as the most appropriate animal for studying 
atherosclerosis. Under a normal diet, swine do not develop atherosclerosis; however, using a 
high lipid diet they will develop hypercholesterolemia and atherosclerosis. The speed of the 
atherosclerotic progression depends on dietary cholesterol intake, a period of feeding, and 
other coexistence risk factors (for example, diabetes mellitus). Usually, the atherosclerotic 
lesions that are seen in the hypercholesterolaemic model are simple, like those seen in fatty 
streaks of humans as they are distributed focally and over unpredictable locations. Advanced 
atherosclerotic lesions in these hypercholesterolaemic models are uncommon, and they 
require a prolonged period of high dose cholesterol intake (6-9 months) for this to occur 




shorten the time required to induce plaque formation. However, after about 2-3 months, 
most of the lesions were only early stages of plaque development, with only foam cell 
accumulation observed. After one year, they reported some advanced atherosclerotic lesions 
in the form of fibroatheroma, with necrotic core and intraplaque haemorrhage. Although 
intravascular trauma could help develop advanced atherosclerotic lesions, this did not 
decrease the time of the experiment (Mihaylov et al.,2000). The large size of pigs makes them 
easier to image atherosclerotic plaques. Therefore, they have played an important role in 
assessing and evaluating some novel imaging techniques, such as CT and MRI angiography 
(Granada et al., 2009). Unlike mice, the genetic modification of pigs is not as easy to achieve. 
However, a knockout of models of the LDLR has been developed. This resulted in pigs with a 
metabolic disease that is similar to human familial hypercholesterolemia. Pigs with this 
mutation developed atherosclerosis while they were fed their normal diet. After one year 
from the onset of the experiment, there were early atherosclerotic lesions in the form of fatty 
streaks. After two years, there were more advanced human-like atherosclerotic lesions in 
form of fibroatheroma with a necrotic core. Moreover, there was a thin cap membrane and 
multiple spots of haemorrhages distributed within the fibroatheroma. The coronary arteries 
were the most affected vessels, especially at low shear segments. After three years of follow 
up, thin cap membrane rupture could be observed to happen in some pigs. Therefore, these 
pigs provide an excellent tool for modelling human disease. The most important 
disadvantages of this model are the long period of observation required to see these changes, 
which means experiments take time and are expensive to perform. In addition, these large 
and heavy animals are more challenging to handle than the smaller mouse or rabbit models 
(Davis et al., 2014).The large size of the pigs represents a considerable challenge for the 




practical issues facing this model. It has allowed the imaging studies to become more feasible 
with better resolution, as the thick fatty tissues of the normal pig were a barrier against 
ultrasound and other imaging studies. Researchers have now prepared several 
atherosclerotic models from this type of pig with good results and with low cost (Gal et al., 
1990). 
 
1.5.5 The limitations of using animal models to study human atherosclerotic plaque 
formation and development 
Animal models can develop an atherosclerotic plaque like those found in vivo in humans, with 
similar cellular components to human plaque. However, differences in gene expression were 
observed between the two types of plaques (Poznyak et al., 2020).  Navab and colleagues 
have stated considerable molecular and biological differences between the inflammatory 
processes found in human and animal atherosclerotic plaques (Navab et al., 1988). 
Furthermore, the plasma lipid profile in most animal models is known to differ from that of 
the human. Also, there are other important molecular differences between these species that 
may alter atherosclerotic plaque development. For example, it has been reported that 
macrophages of mice do not have ApoE. This protein plays an essential role in the 
development and propagation of atherosclerosis in humans. This could make mice an 
unsuitable place for drug experiments that will be used to treat human atherosclerosis 
(Lindmark et al., 2004). Therefore, an alternative to using animal studies is to examine the 
atherosclerotic process using tissue-engineered human cell models of atherosclerosis (Navab 
et al., 1988). Whilst many atherosclerosis drugs trials have reported successful results on pre-




volunteers in later clinical studies. For example, Torcetrapib is a drug designed to treat 
atherosclerosis by raising plasma HDL levels and lowering LDL levels. The results that have 
been collected from the animal studies were successful. However, after about one year of the 
human clinical trial, this medication was stopped abruptly because of its serious adverse side 
effects. These data suggested that biological, molecular, and physiological differences 
between animals and humans may impact the ability of animal models to be used to perform 
pre-clinical drug testing successfully. As such, it might be unsafe to translate the results of 
some animal drug experiments to humans (de Haan et al., 2008). 
 
1.6 Developing tissue-engineered models of human atherosclerosis 
1.6.1 The use of human in vitro models for the study of atherosclerosis  
Since Virchow made the first description of an atherosclerotic plaque in 1856, there has been 
an ambition to create realistic atherosclerotic models to increase our understanding for the 
pathological aspects of this disease. This must lead to many different in vivo and in vitro 
models having been created. Initial atherosclerotic in vitro models were limited to simplified 
2D models consisting of a monolayer cell culture. This included models incorporating 
monocyte-macrophage, endothelial cells, and SMCs using either primary or human cell lines 
(Gualtero et al., 2018). However, these models did not reflect the normal in vivo environment. 
For example, these models fail to replicate the physical conditions of blood flow which are 
known to play a key role in modulating endothelial cell function in vivo during the onset of 
atherosclerosis, as they lacked the pulsatile wall pressure changes present in the native 
tissues (Hosseini et al., 2021; Yurdagol et al.,2016).  Additionally, these 2D culture models are 




polystyrene. This stiff wall differs considerably from the mechanical properties of the natural 
in vivo environment. This type of model does not reflect the dynamic interactions between 
the endothelial cells with other cellular and molecular components of the subendothelial 
matrix. Furthermore, the phenotype, proliferation, and protein expression of these cells differ 
from that of the cells found in vivo (Timraz et al., 2015). Due to these limitations of 2D cell 
culture these models have been deemed unsuitable to replace the animal models as they 
either assess a single cell type or a monolayer of incorporating cells cultured in a non-dynamic 
environment (Robert et al., 2013). Therefore, researchers have developed 3D cell cultures 
that used components from the extracellular matrix as a scaffold. Most of these extracellular 
substances like collagen, gelatin, fibrin and proteoglycan derived either from animal sources 
or the human placenta. This allows investigators to co-culture multiple cells in the same 
construct to better replicate the normal blood vessel tissues. For example, Navab and 
colleagues created an in vitro human co-culture model to study monocytes migration in 
atherosclerosis. In this experiment, they used human aortic endothelial cells and smooth 
muscle cells isolated from the ascending aorta of a donor. They reported a considerable 
monocytes migration across the endothelium toward the subendothelial space, thus 
replicating the early stages of atherosclerotic plaque development and demonstrating the 
potential of human co-culture models. (Navab et al.,1988). Culturing within 3D models has 
been shown to prolong the viability of the cell (Gualtero et al., 2018). On the other hand, they 
have been reporting that the  expression of cytokines, chemokines, and the pro-inflammatory 







1.6.2 The use of human ex vivo models for the study of atherosclerosis  
In vitro human models have provided novel information about the formation of 
atherosclerotic plaque. However, most of this information is restricted to the initial stages of 
the disease, and not the advanced stages responsible for acute coronary syndrome and other 
acute cardiovascular events. This limits their ability to be used for pre-clinical studies of these 
pathologies. For instance, these models cannot assess the effects of specific molecules or 
enzymes on the development and stability of atherosclerotic plaque. This has led 
investigators to establish ex vivo models. The ex vivo and the in vitro atherosclerotic studies 
complement each other – with each having advantages and limitations over the other. Human 
ex vivo models have also been used to explore more detail about the pathology and 
pathogenesis of atherosclerosis. These models utilize samples from endarterectomy surgeries 
to collect atherosclerotic plaques from human donors. The main advantage of ex vivo models 
is that as primary tissue, they fully recreate the complex inflammatory milieu of the 
atherosclerotic plaque, which is not entirely played in current in vitro models (Erbel et al., 
2014). Several studies have used primary human tissue specimens from the carotid artery of 
patients who have undertaken carotid endarterectomy. In 1989, Goran and colleagues 
documented the presence of T-lymphocytes in the atherosclerotic plaque. They reported that 
activated T-lymphocytes play an essential role in the pathogenesis of atherosclerosis by 
secretion of cytokines such as IFN-γ transforming growth factor-β and tumour necrosis factor-
β. These cytokines affect the proliferation and differentiation of smooth muscle cells and 
macrophages in atherosclerotic plaque. IFN-γ was observed to be a potent activator for 




of smooth muscle cells(Hansson et al., 1989). Similarly, in 2007, Meissner and his colleagues 
reported that IFN-α could stimulate T-lymphocytes to be more effective in killing smooth 
muscle cells, leaving the atherosclerotic plaque weak and liable to rupture (Niessner et al., 
2007). Other studies have utilized human atherosclerotic tissue samples from carotid and 
femoral arteries of patients undergoing revascularization to create ex vivo models. For 
example, previous work used these samples to show that the activated form of the NF-κβ 
(nuclear factor kappa B)transcription factor is associated with unstable atherosclerotic plaque 
rupture (Monaco et al., 2004). However, there are also several limitations of ex vivo models. 
Whilst it is easy for us to grow and culture primary human cells in vitro in a reproducible 
manner, the performance and the functions of these cells can differ significantly from the 
same human cells found in situ (Yang et al., 2007). Investigators using ex vivo models have 
encountered difficulties in sustained culturing the tissue sections obtained from patients- 
with the optimal culture period of the primary human tissue often being restricted to one day 
(Nakashima et al., 1994)  .Attempts to culture these cells for longer have led to the disruption 
in the architecture of the obtained section of the human atherosclerotic artery, leading to 
difficulties in the interpretation of the results obtained. The short survival period and donor-
to-donor variability of the sectioned human tissue creates practical and experimental 
difficulties. It is also more challenging to recreate physiological blood flow conditions and 
other in vivo conditions in an ex vivo culture model than in vitro models. Lastly, as the 
endarterectomy samples are taken from patients at various stages of atherosclerosis, they 
represent a very heterogeneous array of tissue samples. This variance between 
endarterectomy samples will cause intrinsic variability in the results of these studies, and 
these can confound the results of cellular, protein and genetic analysis (Erbel et al., 2014). 




critical limiting factor in their widespread uptake by the scientific community and usefulness 
in drug testing (Lebedeva et al., 2017). Therefore, finding a more standardized human model 
of atherosclerosis could help us better understand the cellular and molecular basis and better 
predict the effect of prophylactic and therapeutic drugs to reduce the incidence and severity 
of acute cardiovascular events. 
1.6.3 The potential of vascular tissue-engineering techniques to create a novel in vitro 
model of human atherosclerosis 
Creating an in situ atherosclerotic plaque model requires the creation of a realistic replica of 
the arterial wall.  For a quarter of a century, regenerative medicine has been developing 
tissue-engineered arteries as alternatives to autologous donor grafts in revascularization 
surgery for conditions such as coronary artery bypass graft surgery, congenital heart 
anomalies corrective surgery and arterio-venous anastomosis of renal dialysis (Matsumura 
and Shin, 2005). The tools and techniques used for creating clinical grafts have also paved the 
way for creating realistic replication of human arteries that may be adapted to develop 
artificial human arterial tissues, which can replicate thrombosis and haemostasis under near-
physiological conditions found in the human body. Recent studies have reported that vascular 
tissue engineered (VTE) arterial constructs can be used as alternatives to the traditional in 
vivo models to assess and evaluate the effectiveness of anti-platelet and anti-thrombotic 
therapies. For example, pre-clinical trials have previously successfully used a VTE model 
instead of in vivo animal models to assess the efficacy of the hemodynamic properties of anti-
platelet therapy (Copes et al., 2019).  These methods can be adapted to develop a healthy 
arterial model into which can be incorporated a neointimal layer to create a full tissue-




Tissue engineering comprises 3 main pillars that will determine the effective replication of 
both the morphological and functional properties of the tissue.  These are the cell source, the 
scaffolds used to structure these cells, and the use of chemical and physical stimuli to direct 
the proliferation, differentiation, and maturation of the tissue.  Vascular tissue engineering 
studies have principally utilised primary human endothelial and smooth muscle cells to 
generate the key intimal and medial layers of the artery. However, the variability in 
proliferation and phenotypic properties between batches of these cells have caused 
investigators to consider other cell sources including the use of bone marrow cells, 
mesenchymal stem cells and induced pleuripotent stem cells with which to develop tissue-
engineered arteries (Bajpai and Andreadis, 2012; Mallone et al., 2021).  
Vascular tissue engineering has achieved the development of artificial arteries using a variety 
of scaffold-based and scaffold-free approaches. Scaffold-based tissue engineering uses a 
range of synthetic (e.g., expanded polytetrafluoroethylene, Dacron) or endogenous 
extracellular matrix (e.g., collagen, fibrin) materials to create a structure supporting growth 
and development of the component cells within a 3D cell culture environment. These 
scaffolds can be made in several different ways, including through electrospinning, hydrogel 
formation, 3D printing, or decellularisation of endogenous tissue (Gualtero et al., 2018). 
Alternatively, scaffold-free engineering using the creation of self-supporting cell sheets can 
also be used to create effective tissues. Each of these methodologies provides distinct 
advantages and disadvantages with regards to their ability to effectively replicate the 






1.6.3.A Scaffold-based VTE 
 
1.6.3.A.1 Hydrogels 
Collagen hydrogels scaffold are one of the most common applications for the scaffold -based 
tissue engineering. Collagen and fibrin are commonly used as an extracellular matrix to 
support the growth of the cells (Ovsianikov et al., 2018; Ovsianikov et al., 2020). These 
scaffolds provide great flexibility in modifying the size and morphology of the resulting tissue-
engineered blood vessel according to the requested grafting situation and the ability to direct 
cell colonization and proliferation through a pathway (Ovsianikov .,2020).However, specific 
challenges face this technique's the scaffold base technique progress, for example, the 
heterogeneous distribution and low concentration cells density, mainly when a large, porous 
3D construct is used. However, this disadvantage is less pronounced with hydrogel scaffolds, 
as the cells will be distributed more homogenously with somewhat higher density (Copes et 
al., 2019). The main disadvantage of hydrogel scaffold is its relatively weak consistency. Water 
represents more than 90% of the composition of a collagen hydrogel, so whilst these models 
are good at mimicking the local extracellular environment, from a mechanical point of view, 
they are weak and lack the stiffness of native tissues. This may cause the cell behaviour and 
inflammatory cytokines secretion to be different from that of the native human environment 
(Brown et al., 2005; Yang et al., 2009). To improve the biological realism of 3D hydrogel 
cultures, collagen hydrogels can be made more mechanical strong through a process of plastic 
compressed, where the aqueous component of the intercellular medium is squeezed from 
the gel through application of a mass atop of the gel, and the extruded liquid can then be 




collagen and cells contained within will be increased, making the collagen hydrogel stronger 
and denser, and improving its similarity to the native tissue (Cheema and Brown, 2013). The 
mechanical stiffness of the collagen hydrogels also influences cell behaviour, with vascular 
smooth muscle cells adopting proliferative phenotypes in stiffer gels and a contractile 
phenotype in more compliant hydrogels and can promote angiogenic behaviours in 
endothelial cells (Ryan and O’Brien, 2015; McDaniel et al., 2017; Mason et al., 2013).  Thus, 
modulating the stiffness of gels can significantly alter the effectiveness of 3D cell culture 
models. 
1.6.3.A.2 Decellularized vascular tissue engineering 
To create a biologically relevant scaffold in vascular tissue engineering, some researchers 
have utilised decellularized vascular tissue.  This involves treating segments of veins or 
arteries with detergents or other chemicals to remove the cellular content and leave the 
extracellular matrix proteins largely intact.  These can then be seeded with cells to create a 
healthy blood vessel that can be utilised for implantation.  This is particularly helpful for 
creating vascular grafts for patients using their own cells to seed the construct and thus 
decrease the recipient’s immunological reactions to the vascular implant. However, the 
availability of vascular tissue is limited, and so the most common source of material is from 
xenogenic sources (Chih-hsun Lin, 2018). Therefore, this is unlikely to provide a viable 







1.6.3.A.3 Electrospun scaffolds 
Electrospinning is a production process that utilised high voltage electrical forces to charge a 
droplet of polymer solutions.  Due to the electrostatic repulsion elicited by the applied 
voltage, this can trigger a stream of liquid to arise from this droplet, which as it dries can then 
be elongated to form nanofibers that can be collected onto frames.  Depending on the 
parameters used this can be set-up to produce meshes of randomly orientated or highly 
aligned fibres.  These meshes of nanofibers have been used to create 3D scaffolds that 
resemble the fibrous nature of the extracellular matrix, and thus provides an artificial 
replacement for decellularized vein scaffolds.  Through choice of the appropriate polymer for 
electrospinning, as well as choice of coating this can create strong scaffolds with a high 
capacity for cellular binding. Electrospinning is a promising tissue engineered technique that 
has been used to produced cellular scaffold with mechanical and biological properties that 
are nearly similar to that of natural in vivo blood vessel (Anwarul hasan et al., 2014; Karkan et 
al., 2019). 
1.6.3.A.4 3D bioprinting 
During the past decade, there have been great progress in the development of 3D bioprinting 
technology in tissue engineering. In this process specialised bioinks are produced in which 
cells and natural or synthetic scaffold molecules to create the basis for the bioink, then 
printing this drop-by-drop onto a substrate using either inkjet, extrusion, or laser-assisted 
printing techniques (Gungor-Ozkerim et al., 2018).  Due to the high spatial resolution possible 
through this deposition, this allows the tissue to be micropatterned to closely-resemble the 
structure of the native tissue.  A particular advantage is the ability to build up hollow 3D 




that closely resemble the native artery.  The limitations of this method revolve around the 
potential cell stress induced by the bioprinting process can lead to lower cell viability, 
however as the bioinks and printer technology have improved this has become less of an issue 
(Wang et al., 2021) 
 
1.6.3.4 Scaffold-free blood vessel models 
One of the disadvantages of scaffold-based tissue engineering is the difficulty in distributing 
cells at high density evenly through the construct. Cell sheet-based tissue engineering 
provides the ability to fabricate highly organised, functional, structurally complex tissues or 
organs without using scaffolds. This strategy of tissue engineering is based on the assembly 
of cell spheroids or cell sheets. Matrix materials are thermoresponsive surfaces that provide 
a base for the growth of the vascular cells into cell sheets. Once confluent, the cell can then 
be harvested through changing the temperature to reversibly detach the sheets in a non-
invasive manner (Figure 1.11). From here they can be assembled into more complex tissues, 
whilst maintaining their highly regular structures (Imashiro and Shimizo, 2021). This 
procedure allows researchers to build up complex tissues through stacking of cell sheets to 
create 3D models with comparable cell density and depth to the native tissues (Moschouris 
et al., 2016). 
 
1.6.3.5 Perfusion bioreactors and cellular stimuli 
Whilst vascular tissue engineering initially involved the development of tissues under static 




case of vascular tissue engineering, it is widely appreciated that the phenotypic properties of 
both endothelial and smooth muscle cells are heavily affected by the presence of shear 
stresses elicited by the flow of blood over the intimal surfaces, as well as the circumferential 
and longitudinal forces elicited by arterial blood pressure exerted on the wall of the blood 
vessel (Mironov et al., 2003). Therefore, perfusion bioreactors are utilised which allow  
 
Figure 1.11 An example of scaffold-free tissue engineering. Adhesion and detachment of the 
confluent cultured cells can be controlled by modifying the temperature. At 37°C, the surface 
of the matrix material (PolyN-isopropyl acrylamide) is hydrophobic and so adheres well to the 
cell sheet. By decreasing the temperature below 32°C, the properties of the matrix material 
changes and becomes hydrophilic, allowing easy detachment of the cell sheets. This allows 
their harvesting where they can be incorporated into tissue-engineered models. Figure 
reproduced from Sekine and Okano (2021). 
 
continuous flow of culture media over the construct during the culture period (Selden and 




exposed to during the culture period. To help this better they do this by delivering key 
biochemical signals for cell differentiation, maintaining oxygen and nutrient concentration 
within desired levels, as well as deliver the mechanical cues that cells are exposed to in the 
body (Paez-Mayorga, 2019).  In vascular tissue engineering, the ability to mimic fluid flow has 
been shown to prevent endothelial cells adopting a pro-inflammatory phenotype and helps 
maintain smooth muscle cells in a contractile phenotype (Chiu et al., 2004; Bennett et al., 
2016).  The major disadvantages of this approach are the costs and availability of perfusion 
bioreactors, as this requires specialist equipment, and a steady supply of specialist culture 
media which could make this approach inaccessible to some groups.  Recent studies have 
demonstrated that it may be possible to mimic the effect of flow on endothelial cells by 
artificially triggering the activation of mechanosensitive channels using chemical agonists.  
This has been shown to induce the same anti-inflammatory responses as the application of 
fluid flow (Davies et al., 2019) therefore may offer an alternative approach to continuous 
perfusion. 
1.6 Aims and Objectives 
Previous work by Musa and colleagues has succeeded in developing a three-dimensional 
tissue-engineered human arterial construct using a layer-by-layer methodology (Musa et al., 
2016). The arterial construct was made by culturing separate intimal and medial layers, which 
were then subsequently co-cultured together. The intimal layer was made through culturing  
human umbilical vein endothelial cells (HUVECs) on top of an aligned mesh of fibronectin-
coated PLA nanofibres, whilst the medial layer was produced through culturing human 
coronary artery smooth muscle cells (HCASMCs) in a type I collagen hydrogel. Upon combining 




adhesive, this single arterial construct was able to replicate the pro- and anti-aggregatory 
functions of native human intact and damaged artery. These data therefore demonstrated 
the potential for utilising tissue engineered human arterial models to study thrombosis and 
haemostasis in a healthy human artery under near-physiological conditions.  
The layer-by-layer methodology used to produce this model makes it possible to modify each 
layer independently of each other, as well as develop and introduce additional layers to be 
included within the model systems. This opens the possibility of creating a 3D neointimal cell 
culture construct to introduce within the tissue engineered arterial construct to represent 
various stages of atherosclerosis. Through adapting and developing the techniques previously 
used by Musa et al., (2016), it should be possible to assess the impact of these constructs on 
the activation of primary and secondary haemostatic systems. This would form the basis of a 
humanised testing platform for anti-atherosclerotic and anti-thrombotic therapies used to 
treat patients at risk of acute cardiovascular events.  
Previous studies have shown that it is possible to use tissue-engineered arteries to study the 
first stages of plaque formation through assessing migration of monocytes and development 
of foam cells (Robert et al., 2013; Zhang et al., 2020). Additionally a hanging drop cell culture 
has been used to generate a fibroatheroma model, however this exists outside of the 
structure of a blood vessel (Mallone et al., 2018). Furthermore, there has been no previous 
attempt to use tissue engineered blood vessels to create a more advanced stage model of 
atherosclerosis.   
In this project, we aim to develop and validate a simple 3D cell cultured neointimal model 
that can be inserted into the previously developed tissue-engineered arterial construct to 




The objectives of this project are: 
1)  Develop a 3D neointimal culture model that is compatible with the pre-existing tissue-
engineered arterial constructs 
2) Assess the ability of the 3D neointimal culture model to activate the primary and 
secondary haemostatic system 
3) Assess the ability of the 3D neointimal culture model to modulate the behaviour of 

















Chapter 2: Materials and Methods 
2.1 Materials 
Name of the material Name of the supplier 
Proliferating THP-1 cells European Collection of Authenticated cell 
cultures (Porton Down, UK). 
Phorbol 12–myristate 13-acetate (PMA), 
paraformaldehyde, trypan blue and copper 
sulfate pentahydrate, Nile-Red, and Hoechst 
33342, formaldehyde solution, Oil Red O 
powder, Lipopolysaccharide (LPS), Ascorbic 
acid, Acid citrate dextrose (ACD), 85 mM 
sodium citrate, Fibronectin from bovine 
plasma, N-N-dimethyl formamide (DMF),  
Isopropanol, Iron III chloride (FeCl3), 
Fibrinogen from human plasma, Bovine 
Thrombin 
Sigma Aldrich (Gillingham, UK) 
RPMI 1640 with L-glutamine, fetal bovine 
serum (FBS) , phosphate-buffered saline 
(PBS), Penicillin/Streptomycin (AA), Cell 
scrapers, Whatman filter paper, Scalpel 
blades, Polytetrafluoroethylene (PTFE), 
99.9% Ethanol, Trypan blue, CORNING 
Collagen type 1 Rat Tail (low concentration), 
Collagen type 1 Rat Tail High Concentration 
(high concentration), Copper sulphate 
(CuSO4.5H2o) 
Scientific Laboratory Supplies (Nottingham, 
UK). 
Phycoerythrin-conjugated CD68 mouse 
monoclonal antibody, FITC-conjugated CD86 
mouse monoclonal antibody, phycoerythrin-
conjugated CD163 mouse monoclonal 
antibody, ethylenediaminetetraacetic acid 
(EDTA), MEM-α Medium powder, Slide-lyzer 
dialysis cassetes (gamma-irradiated, 10K 
MWCO), and Corning high concentration rat 
tail collagen 




Monoclonal recombinant human full-length 
CD80 protein and polyclonal CD206 
Mannose Receptor Antibody 
Novus Biologicals (Abingdon, UK) 
The goat anti-mouse secondary antibody, 
the goat anti-rabbit secondary antibody, 
and the FITC-conjugated anti-CD36 
antibody, Human IL-1, PDGF-BB, IL-6 and 
TNF-α ELISA Kits, oxLDL assay kit, 
Recombinant Anti-ICAM1 antibody, Goat 
F(ab')2 Anti-Rabbit IgG - H&L (FITC), pre-
adsorbed, Anti-CD31 antibody, Anti-alpha 
smooth muscle Actin antibody 
Abcam (Cambridge, UK). 
Human IFN-γ and IL-4 cytokines Peprotech (London, UK). 
Sterile low-density lipoprotein 2B Scientific (Upper Heyford, UK). 
Live/Dead Staining Kit ‖ accutase PromoCell GmbH (Heidelberg, Germany), 
macrophage detachment solution  VWR international Ltd (Leicestershire, UK). 
Human Coronary Artery Smooth Muscle 
cells (HCASMCs), Human umbilical vein 
endothelial cells (HUVECs), Gibco medium 
231, Medium 200, Gibco smooth muscle 
growth supplement (SMGS), Low serum 
growth supplement (LSGS), α-MEM 
medium powder and Corning TM, 5-(and-6) 
carboxyfluorescein diacetate, succinimidyl 
ester, mixed isomers (CFSE) 
Fisher Scientific (Loughborough, UK), 
SN-17a Cambridge Bioscience (Cambridge, UK). 
Human FVII and Human plasmin Enzyme Research Laboratories (Swansea, 
UK). 
Atorvastatin Calcium Trihydrate (5g) Active Pharma Supplies Ltd. (Leyland, UK) 
Acetate sheets Ryman's 





Nunc™ Cell Scrapers, CellTrace™ Violet Cell 
Proliferation Kit, for flow cytometry 
Thermo Fisher Scientific. (Paisley, UK) 
Eppendorf cell culture dishes, 35 mm Eppendorf UK Limited 
Silicon glue RS 
Watson-Marlow 505 series peristaltic pump Watson-Marlow 
Leica inverted fluorescence microscope 
(MSV269) 
Leica 
UV cabinet BioRad 
3D SLA printer Elego mars 
 
2.2 Methods  
2.2.1 2D Culture 
2.2.1.1 2D THP-1 cell culture  
1x105 THP cells were seeded in each well of 24-well plates in RPMI 1640W media 
supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin. To induce 
differentiation into M0 macrophages, THP-1 cells were treated with 50nM PMA (Phorbol 12- 
myristate 13- acetate) in a humidified incubator at 37°C, 5% CO2, for 48 hours. To further 
polarize the M0 cells into M1 and M2 macrophages, the media was then replaced with a PMA-
free media for 24 hours and cells were then treated with either 100 ng/mL lipopolysaccharide 
(LPS) and 20 ng/mL IFN-γ (for M1 macrophages) or 20 ng/mL IL-4 (for M2 macrophages) at 






2.2.1.1.1 Trypan Blue Cell Viability Assay 
Cell viability of M0, M1 and M2 macrophages was assessed by removing the cell culture 
medium and adding 400 µl of PBS containing 5% [v/v] trypan blue stain into each well. Cells 
assessed by light microscopy using a 20x objective. Three pictures were captured in the centre, 
left and right side of each well using Q-Capture/Pro7 software. Live, dead, and total cells were 
counted, and the percentage of live cells was used to quantify cell viability for each condition.  
 
2.2.1.1.2 Light microscopy 
The THP-1-derived cells were assessed and photographed under light microscopy using a 20x 
objective. Q-Capture/Pro7 software was used to photograph the cells using Olympus 
brightfield microscope (CKX41). 
2.2.1.1.3 Immunofluorescent staining of M0 macrophages 
Cells from M0 cultures were fixed with either a 4% [w/v] paraformaldehyde or 10% [w/v] 
formalin solution overnight at 4°C. The fixatives were then removed, and each well was 
blocked by the addition of HEPES-buffered saline (HBS; 10 mM HEPES, 145 mM NaCl, 5 mM 
KCl, 1 mM MgSO4, pH 7.4) supplemented with 1% [w/v] bovine serum albumin (BSA) for 1 h 
at room temperature. Afterwards, the blocking solution (1% [w/v] BSA in HBS) was removed 
and cells resuspended in the blocking solution to which a 1:100 dilution of either a 
phycoerythrin-conjugated anti-human CD68 antibody or the FITC-conjugated anti-human 
CD36 antibody was added. The plates were incubated with this staining solution at 4ºC 
overnight. The staining solution was removed, and the cells were washed with the blocking 




were resuspended in the blocking solution was added to each well, and then the cells were 
examined using the 20x objective on a Nikon ECLIPSE Ti fluorescent microscope.  The FITC 
filter set was used for cells stained with the CD36 antibody, whilst the TRITC filter set was used 
for cells stained with the CD68 antibody.  Immunofluorescence signals were also analyzed 
from the 24-well plates using a BioTek 2 synergy microplate reader using excitation 
wavelengths of 475-495 nm excitation for both antibodies and emission at either 518-538 nm 
for CD36 staining or 607-621 nm for CD68 staining. 
2.2.1.1.4 Immunofluorescent staining of M1 and M2 macrophages 
M1 and M2 polarized THP-1 cells were fixed with either 4% paraformaldehyde or 10% [w/v] 
formalin solution and incubated overnight at 4°C. The fixatives were then removed, and each 
well was blocked by the addition of blocking solution of 1% [w/v] BSA in HBS for 1 hour at 
room temperature. Afterwards, the blocking solution was removed, and cells resuspended in 
the blocking solution containing either 200 µg/mL CD80 or 1 µg/mL CD206 primary antibody. 
The plates were then incubated at 4ºC overnight. The staining solution was removed, and the 
cells were washed and incubated with the blocking solution for five minutes at room 
temperature.  This was repeated 3 times in total and then labelled by incubation with either 
a 1:5000 dilution of FITC-conjugated anti-mouse (CD80), or 1:7500 dilution of anti-rabbit 
(CD206) secondary antibodies in the blocking solution for 1 hour at room temperature.  The 
wells then washed three times with HBS with 1% [w/v] BSA three times for 5 minutes. After 
that, the sample was resuspended in HBS with 1% [w/v] BSA was analyzed using a Fluoview 
FV1200 laser scanning confocal microscope (Olympus, UK) using 473 nm excitation 





2.2.1.1.5 Preparation of oxidized low-density lipoproteins. 
A commercially available preparation of sterile low-density lipoprotein (LDL) isolated from 
human plasma was diluted to 5 mg/mL using sterile PBS. Half of this stock was aliquoted and 
stored at -80°C before its use in experiments as a non-oxidized LDL preparation. LDL oxidation 
was performed as previously described by Wraith et al., (2013). 10 µM copper sulphate was 
added to the remaining LDL solution and incubated for 24 hours at 37ºC to allow for its 
oxidation. Excess copper sulphate was then removed from the sample solution through 
dialyzing the sample against a PBS buffer containing 100 µM of EDTA for 24 hours at room 
temperature under sterile conditions. Dialysis was performed using a Slide-a-Lyzer dialysis 
cassette (gamma-irradiated 10K MWCO; Fisher Scientific) according to the manufacturer's 
instructions. Aliquots of this sample were then preserved at -80 ºC before its use in 
experiments. 
2.2.1.1.6 Validation of oxidation of low-density lipoprotein 
The oxidized Low-density lipoprotein samples were characterized through a comparison of 
the absorbance of the oxidized and native low-density lipoproteins at 300 nm, as well as 
through an oxidized LDL ELISA assay kit from Abcam.  Samples were run on the ELISA kit as 
per the manufacturer’s instructions. Oxidized LDL Assay ELISA Kit was designed to be used for 
the measurement of oxidized phospholipids associated with human LDL in plasma, serum, or 
other biological fluid samples. The kit has an OxLDL Standard and has a detection sensitivity 
limit of ~100 ng/mL. Each kit provides sufficient reagents to perform up to 96 assays including 
standard curve and unknown samples. For the absorbance readings, oxidized and native LDL 
samples were loaded into a 96-well plate and their absorbance was read at 300 nm on a BioTek 




2.2.1.1.7 THP-1-derived foam cell production  
To create macrophage-derived foam cells, M1 macrophage cell cultures were supplemented 
with 50 µg/ml oxidized LDL (see section 2.2.A.1.G below for further details) and they were 
incubated at 37°C, 5% CO2 for 72 hours. Control samples were also made at the same time by 
incubating cells with either non-oxidized LDL or an equivalent volume of PBS and incubated 
for the same time under the same conditions. 
2.2.1.1.8 Oil Red O staining of THP-1-derived foam cells 
After the culture period, cells were fixed by incubation with 4% paraformaldehyde solution 
for one hour at room temperature. The paraformaldehyde was removed, and the cells were 
washed with distilled water two times to remove any excess solution. A 60% isopropanol 
solution was then added to each well, and the cells were incubated for five minutes at room 
temperature. This was then removed, and then the cells were stained with 0.5% Oil Red O 
solution for 20 minutes at room temperature. The staining solution was removed, and cells 
were washed five times with distilled water. Cells were then photographed using Q-
Capture/Pro7 software using a 20x objective on an Olympus brightfield microscope (CKX41), 
or the EVOS brightfield microscope using the 10x objective. 
 
2.2.1.1.9 Detachment of THP-1-derived foam cells 
THP-1-derived foam cells were prepared inside a T25 flask (using 6-8x106 THP-1 cell 
concentration) using the same methodology stated in 2.2.1.1.7.  Cells were then attempted 
to be attached using either Macrophage detachment solution, accutase, trypsin/EDTA and 




2.2.1.2 2D Human coronary artery smooth muscle cell culture  
2.2.1.2.1 Preparation and proliferation of the HCASMCs 
HCASMCs were cultured in accordance with the supplier's instructions. 3x105 cells suspended 
in Medium 231 supplemented with SMGS were seeded in a T75 flask. The cells were grown in 
a humidified incubator at 37oC, and 5% CO2 and the media were changed every 48 hours until 
the HCASMCs were 80-90% confluent. HCASMCs used in experiments did not exceed passage 
5. 
2.2.1.2.2 Preparation and fluorescent imaging of HCASMCs-derived foam cells 
HCASMCs were seeded into 24-well plates with 5 x 10 5 /mL cell seeding density and incubated 
at 37ºC, 5% CO2 in a humidified incubator for 48 hours. The culture media was then 
supplemented with either 50 µg/mL of either oxidized or native LDL and incubated at 37°C 
and 5% CO2 in a humidified incubator for an additional three days. After culturing, HCASMCs-
derived foam cells were fixed with a 10% [w/v] formalin solution overnight at 4°C. The fixatives 
were then removed, and the cells were washed with PBS for 1 h at room temperature. The 
washing solution was then removed, and cells were resuspended in 400 µL PBS containing 100 
µg/mL Nile-Red and 5 µg/mL Hoechst 33342 stain solution. After 45 minutes of incubation at 
room temperature, the staining solution was removed and then the collagen hydrogels were 
washed with PBS. The cells were imaged using the Fluoview FV 1200 laser scanning confocal 
microscope (Olympus, UK) using 473 nm excitation wavelength and emission at 490-520 nm.  
 
2.2.1.3 2D Endothelial Cell Culture 




instructions in Medium 200 that was supplemented with low serum growth supplement 
(LSGS), penicillin and streptomycin. The cells were incubated in the 37°C, 5% CO2, humidified 
conditions. The media was changed every 48 hours.  HCASMCs used in experiments did not 
exceed passage 5. 
 
2.2.2 3D culture methods 
2.2.2.1 3D THP-1 cell culture 
2.2.2.1.1 Culture of THP-1 cells on top of non-compressed collagen hydrogels 
 Collagen hydrogel was prepared by mixing the following materials: type I rat tail collagen 
hydrogels, 10x DMEM, cell suspension, 1M Sodium Hydroxide, and 50 nM PMA using the 
following equations: 
Volume of Collagen (µL) = [(final solution volume x final [collagen] of hydrogel)] ÷ stock 
[collagen] 
Volume of 10x DMEM (µL) = final solution volume ÷ 10 
Volume of 1M NaOH (µL) = volume of collagen added x 0.023 
Volume of cell suspension (µL) = Final solution volume - (volume of 10x DMEM + Volume of 
collagen + volume of 1M NaOH)  
The final concentration of the collagen desired is 3 mg/mL. All materials were kept pre-chilled 
on ice to prevent early gelation. The solution was mixed carefully and slowly to avoid air 
bubble formation, until a homogenous solution was formed.  THP-1 cells were pelleted by 
centrifugation at 200 x g for 5 minutes, and then resuspended into completed RPMI media to 




105 cells/mL cell seeding density, and then each well supplemented with 200 µL of completed 
RPMI media. The collagen hydrogels were incubated at 37°C, 5% CO2, for 4 days. Media was 
changed every 48 hours. The cells were then assessed by light microscopy using Q-
Capture/Pro7 software and a 20x objective. 
 
2.2.2.1.2 Preparation of the 3D human neointimal cell culture construct 
To trigger M0 differentiation - THP-1 cells were mixed at a cell density of 3.6 x 106 cells/mL 
into a neutralized solution of 3 mg/mL type I collagen (Figure 2.1). 0.2 mL of the THP-
1/collagen mixture was then loaded under sterile conditions onto a 1 x 1 cm (6x 105 cells/mL 
cell seeding density, sterile filter paper frame prepared on a PTFE base inside a petri dish. The 
collagen-cell mixture was left to set for 30 minutes at 37°C, 5% CO2. The hydrogel was then 
transferred to 6-well plates and covered with RPMI medium containing 10% [v/v] FBS, 
Penicillin, Streptomycin, and 50 nM PMA, and then incubated for 48 h at 37C̊, 5% CO2 to trigger 
differentiation of the cells into M0 macrophages.   
To trigger M1 differentiation – The M0-containing hydrogels were then placed into PMA-free, 
supplemented RPMI media (containing 10% [v/v] FBS, Penicillin and Streptomycin), and 
incubated for 24h. The RPMI media was then changed to a fresh supplemented RPMI media 
containing 100 ng/mL LPS &20 ng/mL IFN-ɣ.  The gels were then incubated at 37°C, 5% CO2 
incubator for 3 days. 
To generate THP-1 derived foam cells.  The media was exchanged with a fresh, supplemented 
RPMI media that contained either 50 µg/mL oxLDL, 50 µg/mL LDL or an equivalent volume of 




further 3 days.  
  
Figure 2.1 – A summary of the culturing of the 3D neointimal cell culture model. A THP-1-
containing compressed hydrogen gel was cultured with 50 nM PMA for 48 h to induce THP-1 
differentiation to M0 macrophages.  Following this the media was changed for 24 h followed 
by incubation with Lipopolysaccharide and IFN- for 72 h to induce differentiation to M1 
macrophages.  Finally, the M1 macrophages were treated with oxLDL for 72 h.  The resultant 
hydrogels on day 10 of the culture were then used for experiments. Monocyte, macrophage, 
and foam cell icons were obtained from bioicons.com. 
 
2.2.2.1.3 Immunofluorescent staining of the M1-containing hydrogels 
To assess M1 differentiation within the collagen hydrogels, collagen hydrogels cultured to 
contain M0 and M1 macrophages were prepared as stated above in Section (2.2.2.1.2). The 
hydrogels were then fixed with a 10% [w/v] formalin solution overnight at 4°C. The fixatives 
were then removed, and each frame of the collagen hydrogels was blocked by the addition of 
HBS supplemented with 1% [w/v] bovine serum albumin (BSA) for 1 h at room temperature. 
Afterwards, the blocking solution was removed, and the frames of the collagen hydrogels 
were resuspended in a labelling solution made up of the blocking solution containing 0.2 
mg/mL CD80 primary antibody. The collagen hydrogels were incubated with this staining 




washed three times with the blocking solution for five minutes at room temperature. After 
the third wash, the collagen hydrogels were stained by the addition of blocking solution 
containing varying concentrations of FITC-conjugated anti-mouse secondary antibodies (using 
a dilution concentation of 1:5000 )   for 1 hour at room temperature. The collagen hydrogels 
were then washed 3 times with HBS containing 1% [w/v] BSA for five minutes at room 
temperature. The collagen hydrogels were then analyzed by confocal microscopy using the 
Fluoview FV 1200 laser scanning confocal microscope (Olympus, UK) using 473 nm excitation 
wavelength and emission at 490-520 nm. Fluorescent intensity was assessed using ImageJ.  
 
2.2.2.1.4 Fluorescent imaging of THP-1 derived foam cells in the 3D neointimal constructs  
After culture, the tissue-engineered neointimal layer was fixed with a 10% [w/v] formalin 
solution overnight at 4°C. The fixative was then removed, and the collagen hydrogels were 
washed with PBS for 1 h at room temperature. Afterwards, the PBS was removed, and the 
collagen hydrogels were resuspended in 400 µL of PBS containing 100 µg/mL Nile-Red and 
400 µg/mL Hoechst 33342.  After incubation for 20 minutes at room temperature, the staining 
solution was removed, and the collagen hydrogels were washed with PBS. The samples were 
then imaged with a Fluoview FV 1200 laser scanning confocal microscope (Olympus, UK) using 
473 nm excitation wavelength and emission at 490-520 nm.  
2.2.2.1.5 Plastic compression of tissue-engineered neointimal constructs 
The collagen hydrogel was prepared as described previously. Two 1x1 cm filter paper frames 
were placed inside either 2x1x1cm metallic or plastic moulds. Two mL of hydrogel were put in 
each mould, and then placed inside 9.6 cm2 petri dish. They were incubated in a humidified 




extracted onto a nylon sheet with tissue paper underneath. A 50g metal weight was applied 
atop of the hydrogel for 5 minutes. The compressed collagen hydrogels were then separated 
into two 1cm x 1cm frames (Brown et al., 2005, Yang et al., 2009). Each compressed collagen 
hydrogel has 5x105 cells. Thereafter, the compressed collagen hydrogels were transferred to 
24-well plates containing completed RPMI media. The culture media was exchanged for PMA-
free RPMI media, and the hydrogels were incubated for 24 hours at 37°C, 5% CO2.  RPMI media 
was then exchanged again for fresh RPMI media containing 100 ng/mL LPS and 20 ng/mL IFN-
ɣ was added, and then incubated for a further 3 days in an incubator at 37°C, 5% CO2.  The 
media was changed for fresh RPMI media containing either 50 µg/mL Ox LDL or 50 µg/mL 
non- oxidized LDL and placed in the incubator for a further 3 days prior to experimentation. In 
some experiments, 20 µg/mL of atorvastatin, or an equivalent volume of its vehicle, methanol, 
was added alongside the OxLDL.   
2.2.2.1.6 Assessing cell viability of 3D culture of THP-1-derived cells  
After culture, the collagen hydrogels were initially photographed by light microscopy using 
Q-Capture/Pro7 software and 20x objectives. The size and the morphology of the THP-1 cells 
were evaluated. The collagen hydrogels were then transferred to 24-well plates and the 
collagen hydrogels were stained using the Live-Dead Staining Kit II (Promocell) according to 
the manufacturer's instruction. Cells viability was assessed for fluorescent staining within 
the collagen hydrogels using a Fluoview FV 1200 laser scanning confocal microscope 
(Olympus UK) using a 10x objective and with excitation at 473 nm (Calcein staining of live 
cells) or 543 nm (EthDIII staining of dead cells) and emission at 490–520 or 590–620 nm 
respectively.   




0.5% [w/v] Oil Red O solution dissolved in isopropanol was filtered on the day ten of the 
experiment.  Each hydrogel was incubated with 500 µL Oil Red O solution for 30 minutes at 
room temperature on an orbital shaker (100 rpm). After this the gels were washed three times 
with PBS. After this the hydrogels were restrained by addition of 500 μL isopropanol to each 
gel and rocked on an orbital shaker for 30 minutes.  From this solution, 100 μL was placed into 
a 96-well plate and absorbance was read at 570 nm to quantify the amount of neutral lipids 
present in the sample. 
2.2.2.2 Preparation of the tissue engineered medial layer (TEML) construct 
This was performed as previously described by Musa et al., (2016). To prepare the tissue 
engineered medial layer, the collagen hydrogel was prepared according to the manufacturer’s 
instructions. To prevent early gelation of the collagen hydrogels, all constituents of the 
 
        
A                                                         B                                                    C 
Figure 2.2. Plastic compression of the collagen hydrogels of THP-1 derived foam cells. This 
technique was specifically initiated to be used in the atherosclerotic models to increase the 
cell density and mechanical stiffness of the collagen hydrogels and to make the culture 
environment more suitable with the inflammatory condition that is initiated by the pro-
inflammatory macrophages and foam cells. A. the collagen hydrogels before compression, B. 
During compression, and C after compression. 
 




were mixed into a neutralized solution of 3 mg/mL type I collagen. 200 µL of this solution was 
then pipetted into 1x1cm2 filter paper frames to create hydrogels containing 1x105 cells. The 
hydrogels were set by incubation for 40 minutes at 37°C, 5% CO2. The hydrogels were 
subsequently transferred into 24-well plates and cultured in completed Medium 231 
supplemented with 50 µg/ml ascorbic acid. The media was changed daily with fresh ascorbic 
acid supplemented media. After this the culture media was removed and exchanged with 
fresh completed Medium 231 that contained either 50 µg/mL OxLDL, 50 µg/mL of non-
oxidized LDL or an equivalent volume of PBS. The hydrogels were incubated for another 72 
hours at 37°C, 5% CO2 for a total culture period that did not exceed 6 days. 
2.2.2.3 Optimizing media to allow co-culture of the 3D neointimal mode with layers of the 
tissue engineered arterial construct 
Tissue-engineered neointimal constructs were made as stated above in Section 2.2.2.1.  After 
day 10 of culture, the cell culture media was switched to RPMI media, Medium 231 or Medium 
200. The cells were then incubated at 37°C, 5% CO2, for 48 h.  Cell viability was then assessed 
as stated in Section 2.2.2.1 
2.2.2.4 Fibrin polymerization assay 
Monitoring of thrombin-induced polymerization of fibrin gel was monitored in 96-well plates 
through measuring changes in sample turbidity using a modification of the method of 
Stabenfeldt et al., (2012). A 3 mg/mL human fibrinogen solution was pipetted into 100 µL 
samples in a 96-well plate, where it was mixed with various concentration of thrombin to 
give final concentrations of 0.01U/mL, 0.05 U/mL, 0.1 U/mL, 0.5 U/mL, 1 U/mL, and 5 U/mL. 




sample was read at 350 nm every minute for 1 hour using a BioTek 2 Synergy microplate 
reader. 
2.2.2.5 Neointimal-medial co-cultures 
The neointimal and TEML cultures were prepared as previously described in sections 2.2.2.1 
and 2.2.2.2.  Upon day 2 of the TEML culture and day 10 of the neointimal culture, the two 
constructs were attached via a fibrin gel. Immediately prior to use, a 3 mg/mL human 
fibrinogen solution was mixed with a 50 U/mL thrombin. This gelating solution was then 
distributed over the four corners (20 µL) of the non-compressed collagen hydrogel of the 
media layer, and then the neointima layer was placed on top of it for one hour at room 
temperature to ensure it had fully gelated. The hydrogels were subsequently transferred into 
24-well plates and cultured in completed Medium 231 for 4 days at 37°C, 5% CO2 prior to use 
in experiments.    
In the cell migration experiments, the HCASMCs were tracked through labelling with CFSE 
(Carboxyfluorescein succinimidyl ester) by incubation with 5 µM CFSE in fresh media for 30 
minutes at 37°C and then replaced with fresh media. In some experiments, foam cells were 
labelled with CellTrackerTM Violet by incubation with fresh RPMI containing 15 µM dye for 20 
minutes at room temperature under gentle agitation. 
 
2.2.2.6 Shear-induced separation of fibrin-coupled hydrogels 
A compressed collagen hydrogel and non-compressed collagen hydrogel were made using the 
method described above and set in 10 mm x 5 mm filter paper frames. These were then 
attached to one another using a fibrin gel created by mixing a 3 mg/mL human fibrinogen 




compressed acellular gel atop of the non-compressed collagen hydrogel of the media layer, 
and then the neointima layer was left on top of it for one hour at room temperature to ensure 
full gelation. After this, samples were either incubated with either a plasmin-free HBS (as a 
control sample) or HBS-containing (30nM) plasmin for one hour at room temperature.  
After the treatment, the construct was placed inside a custom-made 3D printed flow chamber 
to allow exposure to shear stress (Figure 2.3).  The flow chamber was prepared using an Elegoo 
Mars 3D SLA printer. After printing the printed chamber was treated twice with isopropyl 
alcohol for 5 minutes in an ultrasonic cleaner. These were then dried and cured in ultraviolet 
light (405 nm) for one hour under rotation.  
The combined hydrogel model was placed inside the 3D printing template and held in place 
using a coverslip and silicone grease to ensure the hydrogel was tightly held within the flow 
chamber (Figure 2.3). The flow chamber was connected to a Watson-Marlow 505 series 
peristaltic pump and perfused at maximum flow speed with distilled water ( 0.07 cm2/s; Figure 
2.4).  The quantification of the generated shear stress was calculated according to the 





                                                              
Where the 𝜏 is the shear stress, u is the viscosity of the fluid, Q is the flow rate, b is the width 
of the flow space, and h is the height of the space between the hydrogel model and the 
coverslip. While width of the chamber is 0.5 cm, its height is 0.5 cm and the value of water 
viscosity at room temperature is 0.7 CP (Centipoise), leading to a calculated shear stress on 




2.2.2.7 Intimal-neointimal co-cultures 
The neointimal model was prepared according to protocol detailed in Section 2.2.2.1.2. On 
day 10 of the culture, the collagen hydrogels were sprayed twice with a 10 ng/ml fibronectin 
solution and then left to air dry for 45 minutes at room temperature. The fibronectin-coated 
surface of the neointimal constructs were then seeded with 200 μL of a HUVEC seeding 
density suspension (3X105 cells/mL). The coculture samples were incubated at 37°C, 5% 
CO2for one hour to allow for HUVEC cell attachment. The samples were then placed into 
Medium 200 supplemented  
with low serum growth supplement, penicillin and streptomycin and incubated for 37°C, 5% 










Figure 2.3 3D printed flow chamber for shear-induced hydrogel construct disassembly 
experiment. These 3D printing templates were prepared using a 3D Elegoo mars printer. (A) 
A top-down view of the flow chamber. The flow chamber was designed to create a 10 mm x 5 
mm x 5 mm (L x w x d) space in which to insert the hydrogel model into the flow chamber.  
This is flanked either side a flow buffer zone, which provides a space to ensure laminar flow 
occurs across the construct. (B) A side on slice through the flow chamber. In the centre of the 
template, there is a chamber in which we put the collagen hydrogels of the co-culture 
construct held in place by a coverslip. (C) Silicone grease was used around the edge of the 
coverslip to hold the coverslip onto the surface of the 3D printed flow chamber. The hydrogel 
model is then placed in the centre of the coverslip to ensure that it aligns with the insertion 






Figure 2.4. The set-up of the shear stress-induced hydrogel disassembly experiment. A 
Watson-Marlow 505 series peristaltic pump machine (Fluid Technology, UK) was attached to 
the 3D printed flow chamber and set to pump from a water reservoir at maximum speed.  
 
 
2.2.2.8 FeCl3 injury of Neointima-HUVECs co-cultures 
Filter paper strips were soaked in a 10% FeCl3 solution. This was placed upon a PTFE board 
and the neointimal surface of the co-culture not coated with HUVEC cells was placed on top 
of this for 5 minutes at room temperature. The co-culture was then washed 3 times for 1 
minute, 2 minutes and 5 minutes in PBS prior to exposure to washed platelet suspensions (see 
figure 2.5 below).  Uninjured constructs were also washed with PBS for the same time prior 





Figure 2.5 FeCl3-induced neointimal injury. (A) Filter paper strips were soaked in 10% FeCl3 
solution for at least 1 hour prior to use. These were then removed, wiped of extraneous FeCl3 
solution, and placed on a sterile PTFE plate. (B) The collagen hydrogels of the neointima 
coculture were placed on the FeCl3-soaked filter paper on the neointimal surface of the co-
culture for 5 minutes. The samples were then washed 3 times in PBS and then photgraphed 
to demonstrate the permeation of FeCl3 through the complete construct. 
 
2.2.3 Conditioned Media ELISA experiments 
Conditioned media samples from atorvastatin-treated neointima-SMCs and neointima-
HUVEC co-cultures samples were collected at the end of their incubation period including 
three conditions, foam cells-SMCs, M1-SMCs, and SMCs alone, and the same was applied for 
HUVECs co-culture experiments. Four kits for four inflammatory cytokines have been assessed 
which were IL-1β, TNF-alpha, IL-6, and PDGF. The cell samples were processed according to 
the manufacturers’ instructions and read at 450 nm wavelength on a BioTek 2 Synergy 
microplate reader. 
2.2.4 Preparation of Cryosections  




3050 S). To prevent ice crystal, the hydrogels were infiltrated by 15% sucrose until the 
specimens sunk down in the container, then infiltrated by 30% sucrose until the specimens 
sunk down in the container embedded, then 50:50 30% sucrose and Optimal Cutting 
Temperature compound (OCT), then OCT before mounting for section. After sectioning, the 
cryosections were then affixed to Superfrost microscope slides.  Slides were stored at 4°C until 
staining. To enhance the adhesion of the sections to the slide, samples were then heated in a 
slide over for 60°C for 45 minutes. Samples were allowed to cool prior to use. 
 
2.2.4.1 Staining of Cryosections 
2.2.4.1.A Haematoxylin and Eosin Staining  
Samples were washed twice with PBS to dissolve the residual OCT from the cryosections.  
Samples were then stained in freshly filtered Harris Haematoxylin solution for 5 minutes, 
followed by washing under running tap water. Samples were then differentiated in 0.3% 
acid-alcohol solution for 45 seconds. After washing under running tap water, samples were 
then blued through addition of Scott’s tap water for 45 seconds. After washing with running 
tap water, samples were then incubated with Eosin solution for 3 minutes. After washing 
with running tap water, sample were then imaged using an EVOS brightfield microscope 
using a 10x and 20x objective. 
2.2.4.1.B Nile Red Staining 
Samples were washed twice with PBS to dissolve the residual OCT from the cryosections.  
Samples were then covered with 1 µg/mL Nile Red solution dissolved in a PBS solution 




minutes at room temperature on an orbital shaker set for 100 rpm. Samples were then washed 
3 times with PBS, and then were mounted with a coverslip in fluoroshield mounting medium 
containing DAPI (Abcam, UK).  Samples were then imaged using the 10x and 20x objectives on 
an Fluoview FV1200 laser scanning confocal microscope (Olympus, UK) using 405 nm and 473 
nm excitation wavelength and emission at 430-455 nm and 490-520 nm.  
 
2.2.4.4 Immunostaining 
Samples on the slide were separated by a hydrophobic barrier pen (Pap Pen, Scientific 
Laboratory Supplies), and then washed 3 times with PBS to remove residual OCT.  After 
washing, the samples were blocked by incubation in PBS containing 0.1% [v/v] Tween 20, 1% 
[w/v] Bovine serum Albumin, 0.3M glycine and 10% [v/v] Normal goat serum for 1 hour at 
room temperature.  The blocking solution was then removed, and the samples were then 
incubated overnight at 4°C in a humidified slide staining tray with either mouse anti-type I 
collagen (1:100 dilution), rabbit anti-tissue factor (1:100 dilution), mouse anti-α Smooth 
muscle actin (1:1000 dilution), or mouse anti-CD31 (1:1000 dilution). The antibody solution 
was then removed, and the samples were washed three times with PBS containing 0.1% [v/v] 
Tween 20 and 1% [w/v] Bovine serum albumin (PBST-BSA) for 10 minutes at room 
temperature. After washing, the samples were incubated with a PBS solution containing 1% 
[w/v] Bovine serum albumin and either 2 µg/mL of either goat anti-mouse-Alexa Fluor488 (α 
Smooth muscle actin), goat anti-mouse-Alexa Fluor 647 (CD31, collagen), or goat anti-rabbit 
anti Rabbit-Alexa Fluor488 (tissue factor). After incubation with the secondary antibodies, 
samples were washed 3 times with PBS-BSA for 10 minutes at room temperature.  After this 




DAPI (Abcam, UK).  The slides were then imaged using the 10x and 20x objectives on an 
Fluoview FV1200 laser scanning confocal microscope (Olympus, UK) using 405 nm, 473 nm 
and 635nm excitation wavelength and emission at 430-455 nm, 490-520 nm and 655-755nm 
respectively. 
.   
2.2.5    Assessment of the hemostatic effects of the 3D neointimal layer and derived co-
cultured constructs 
2.2.5.1 Preparation of human platelet-poor plasma (PPP) 
Blood donations were approved by the Keele University Research Ethics Committee. Blood 
was taken from healthy medication-free volunteers. Each one-part blood was mixed with 9 
parts 3.8 % [W/V] sodium citrate solution. Thereafter, the blood was centrifuged at 700 x g 
for 8 minutes to separate blood into its constituents. Platelet-rich plasma (PRP) was isolated 
and 100 µM aspirin, and 0.1 U/mL apyrase were added. Isolated PRP was centrifuged again 
at 350 x g for 20 minutes to pellet platelets. The coagulation experiments were done using 
the supernatant of the platelet poor plasma. 
2.2.5.2 Preparation of washed human platelet suspension  
Blood donations were approved by the Keele University Research Ethics Committee. Blood 
was donated by healthy medication-free volunteers who gave written informed consent. 
Whole blood was mixed in a 5:1 ratio with acid citrate dextrose anticoagulant (85 mM sodium 
citrate, 78 mM citric acid and 111 mM d-glucose). The PRP was obtained by centrifugation for 
700 x g for 8 minutes. After extraction this was treated with 100 μM aspirin and 0.1 U/mL 




platelets were re-suspended into supplemented HEPES –Buffered Saline (HBS) to a final cell 
density of to 2x108 cells/mL. To make supplemented HBS, HBS (pH 7.4, 145 mM NaCl, 10 mM 
HEPES, 10 mM d-glucose, 5 mM KCl, 1 mM MgSO4), was supplemented on the day of the 
experiments with 1 mg/mL BSA, 10 mM glucose, 0.1 U/mL apyrase and 200 μM CaCl2. 
Immediately prior to all experiments the CaCl2 concentration of the washed human platelet 
suspension was increased to 1 mM. 
 
2.2.5.3 Prothrombin time measurement 
Citrated PPP (0.5 mL) was aliquoted into cuvettes and recalcified by addition of 20 mM 
CaCl2.  The samples were then incubated for 10 minutes prior to the experiment in a water 
bath held at 37°C. The tissue-engineered neointimal constructs were washed with PBS, and 
then inserted into sodium acetate frames to allow the surface of the neointimal constructs 
to be placed in contact with PPP (Figure 2.6). Prothrombin time was measured as the time 
taken between construct contact with PPP and the observation of the formation of fibrin 







Figure 2.6 Experimental Set-up for assessing prothrombin time stimulated by 3D neointimal 
culture models.  (A) Diagram demonstrating the experimental set-up. Washed human 
platelets or platelet-poor plasma (PPP) was placed in contact with the luminal surface of the 
3D neointimal culture model held in position using a sodium acetate frame.  The cuvette was 
then held in a water bath held at 37°C under constant magnetic stirring. (B) Picture of the 
sodium acetate frame. (C) Photos of complete set-up with frame not fully inserted. Parafilm is 
placed around the outside of the cuvette to help hold it in a cuvette holder in the waterbath. 
Cuvette and Foam cell icons obtained from Bioicons.com. 
 
2.2.5.4 Tissue factor assay 
Tissue factor activity of the tissue-engineered neointimal constructs were assessed by 
measuring tissue factor-dependent activation of FVII. THP-1 cells were mixed at a cell density 
of 6 x 105 cells/mL into a neutralized solution of 3 mg/mL type I collagen, and then 200 µL of 
this sample was then set into 48-well plates.  These cells were then cultured in RPMI media 
over 10 days to foam cells as detailed in Section 2.2.2.1.2 through sequential addition of PMA, 
IFN-γ and LPS, and oxLDL or native LDL.  On day 10 of the culture, were treated with 100 µL of 




substrate - 6-amino-1-naphthalenesulfonamide-based , ANSN) . Cleavage of the SN-17a which 
is the fluorescent indicator of FVIIa activity) was then measured fluorometrically using a 
BioTek 2 synergy microplate reader using excitation wavelengths of 340-380 nm, and emission 
wavelengths of 518-538 nm. Readings were taken every 10 seconds for 10 minutes at 37°C.  
 
2.2.5.5 Platelet aggregometry  
Platelet aggregation was measured using a ChronoLog light transmission aggregometer. The 
baseline for 0% aggregation was set at the start of experiment against a tube filled with 450 
µL of unused washed human platelet suspension, and for 100% aggregation was set using a 
tube filled with 450 µL supplemented HBS. The neointimal constructs were placed into sodium 
acetate frames and placed into contact with 0.8 mL washed human platelet suspension.  These 
were incubated for 10 minutes at 37°C under constant magnetic stirring (Figure 2.7). Following 
this the construct was removed, and in some experiments was fixed in 4% paraformaldehyde.   
450 µL of the platelet suspension was transferred into glass aggregometry tubes containing 
magnetic stir bars. Stirring was set to 1200 rpm and temperature of the aggregometry tube 
holder was maintained at 37°C.  Changes in light transmission was recorded during constant 





Figure 2.7: Experimental Set-up for assessing aggregatory responses to 3D neointimal 
culture models.  Diagram demonstrating the experimental set-up. A cuvette containing 800 
µL washed human platelet suspension containing 1 mM CaCl2 was placed in contact with the 
luminal surface of the 3D neointimal culture model held in position using a sodium acetate 
frame.  The cuvette was then held in a water bath held at 37°C under constant magnetic 
stirring. Cuvette and Foam cell icons obtained from Bioicons.com. 
 
2.2.5.6 ATP secretion assay  
A Luciferin-luciferase assay was used to assess secretion of ATP from platelet dense granules. 
After incubation with the neointimal construct for 10 minutes at 37°C, the construct was 
removed, and samples of the washed platelet suspension were extracted for aggregometry 
analysis as stated above in 2.2.3.4.  The remaining washed platelet suspension was incubated 
without the construct for a further 10 minutes at 37C. 80 µL of the washed platelet suspension 
was then placed into a 96-well plate and mixed with 20 µL luciferin-luciferase assay mixture 
(Sigma Aldrich, UK) immediately prior to reading. A BioTek Synergy 2 microplate reader was 





2.3 Statistical Analysis 
Values stated are mean ± SEM of the number of observations (n) indicated. For experiments 
comparing two variables, a Student’s T-test was used. Statistical analysis of experiments in 
which multiple comparisons between variable were made simultaneously was assessed by 
using one-way analysis of variance (ANOVA) followed by a post hoc Tukey test. A P < 0.05 was 





















Chapter 3: Development of a neointimal layer for 3D human tissue-engineered arterial 
constructs 
3.1 Introduction 
The atherosclerotic artery is distinguished from the normal vessel by the presence of an 
abnormal thickening of the intimal layer of the blood vessel, leading to the formation of a 
neointima. This neointima is formed from the infiltration of monocytes and smooth muscle 
cells at sites of endothelial dysfunction (See Figure 1.1). Monocytes migrate to the site of the 
inflamed endothelial lining and migrate into the subendothelial space where they transform 
into macrophages (Gawaz et al., 2005). These macrophages start to engulf the oxidized low-
density lipoproteins (ox LDL) forming specialized macrophage-derived foam cells. These foam 
cells are then covered by a fibrous cap that is made up by smooth muscle cells migrating from 
the medial layer – leading to the fibroatheroma stage of plaque development (Virmani et al., 
2003).  Beneath this fibrous cap, there will be apoptotic death of some of the foam cells, leads 
to the formation of a necrotic core characterized by live and dying foam cells as well as an 
accumulation of extracellular lipids. This creates a proinflammatory environment which 
appears to propagate atherosclerosis plaque development and then to potential plaque 
rupture. Therefore, to create a realistic model system in which to study advanced 
developmental stages of atherosclerosis requires the production of tissue-engineered model 
with the potential to elicit a fibrous cap and a necrotic core (Seimon and Tabas, 2009).  
As development of atherosclerotic plaques occurs over decades and in a manner that is 
unpredictable in different individuals, it is infeasible and unethical to study much of the 
process of atherosclerotic plaque development and rupture at the cellular and molecular level 




of tissue samples collected post-mortem, as well as imaging studies conducted in patients 
who have or who died because of ischemic heart disease (Beausire et al., 2018: Precht et 
al.,2018: Gallo et al., 2018). Whilst these studies have advanced our understanding of large-
scale morphological changes in plaque structure, they do not provide an accessible model in 
which to study the cellular and molecular changes underlying plaque development (Yonetsu 
and Jang, 2018).  Furthermore, human ex vivo studies have also contributed to progressing 
the advantages of human studies. The main advantage of ex vivo studies is their ability to 
analyse the complex inflammatory milieu of the atherosclerotic plaque which is not fully 
recreated in current in vitro models (Erbel et al., 2014). On the other hand, the very short 
period that human tissue can be maintained in culture significantly limits the usefulness of 
these models, as well as the difficulty in researchers obtaining these samples, and 
standardising these tissues to allow for reproducible biological study.   
Therefore, most of our current knowledge about the pathology and pathogenesis of 
atherosclerosis has been obtained from in vivo animal studies. The animals that have been 
most using to study atherosclerosis in vivo are mouse, rabbits, pigs, as well as non-human 
primates. These animal models provide a method to study the mechanism of atherosclerosis 
within a complex cellular, chemical, and physical environment found within the animal body 
as well as non-human primates and allows investigators to study atherosclerosis throughout 
all stages of the disease progression. However, each of these models presents with different 
issues in fully recreating human atherosclerotic plaque development and treatment. These 
include differences in anatomical locations of plaques, the need for transgenic animals to 
mitigate for interspecies differences in lipid metabolism, failure for plaque rupture to occur 




model organisms into humans during clinical trials (Veseli et al., 2017).  These differences 
necessitate the use of multiple experimental models to create reliable findings.  
The limitations of animal models have led to some researchers examining the possibility of 
recreating human atherosclerosis in in vitro human cell models (De Haan et al., 2008). 
However, traditionally these models either replicate the early stages of atherosclerosis ahead 
of foam cell formation, in which monocyte and lipids are recruited to the subendothelial 
compartments or represent isolated atherosclerotic plaque models created outside the 
cellular context of the vasculature (Mallone et al., 2017). As later stages of plaque 
development are clinically relevant, there is a need for an in vitro human atherosclerosis 
blood vessel model which can be used to examine plaque development, rupture, and 
subsequent thrombosis. 
Initially, researchers used in vitro human models instead of animal models to study the 
pathogenesis and pathology of atherosclerosis. These have focussed heavily on the initial 
formation of the plaque with aims based around creating models to study monocyte 
infiltration and foam cell formation (Islam et al., 2016). Initial work focussed on the use of 2D 
culture methods using monolayers of endothelial cells, smooth muscle cells and 
macrophage/foam cells to simulate the initial stages of atherosclerosis. However, all these 
models did not reflect the normal in vivo environment due to limited realism of these 2D 
monolayer. More recently, Noonan et al., (2019) have reported the use of a triple-cell 2D 
atherosclerosis model in which human coronary artery endothelial cells and smooth muscle 
cells were culture on opposite sides of a transwell insert.  To finish the model, THP-1 cells 
were differentiated in 6-well plates to M0 macrophages by treatment for 72 h with phorbol 




phenotype between the 3 cell types can be assessed but does not provide a method for 
studying further development of the plaque (Noonan et al.,2019).  Another significant 
disadvantage of these 2D models is that they devoid of any relevant physical stimuli found in 
vivo, such as the shear forces that the blood vessel is exposed to by blood flow (Yurdagol et 
al.,2016).  
These limitations lead to the development of 3D cultures to more effectively model. These 
initial stages of atherosclerosis, for example, (Liu et al., 2017) developed a model in which 
human coronary artery smooth muscle cells (HCASMCs) were cultured within a collagen 
hydrogel, atop with human coronary artery endothelial cells were plated to create a simple 
tissue engineered coronary artery model. After activation of the model with oxidised low-
density lipoprotein, these cultures could be seen to trigger effective transmigration of THP-1 
cells into the subendothelial compartments. Similar experiments in these models have been 
improved using stretchable microfluidic channels (Gu et al., 2019), or through incorporation 
of tissue-engineered blood vessels into microfluidic chambers (Robert et al., 2013; Zhang et 
al., 2020) to allow for physical stimulation of the models. The primary endpoints of these 
projects have been to examine the effects of experimental conditions and pharmacological 
agents upon the accumulation of foam cells within the neointima. However due to the limited 
time of monocyte exposure, the degree of foam cell infiltration observed is limited in these 
models.   
Production of a more comprehensive fatty streak, as well as development of later stage 
models of atherosclerosis within these tissue-engineered blood vessels is difficult because it 
involves the effective maintenance of the viability of the surrounding blood vessel cells, whilst 




Recreating the full development and breakdown of an atherosclerotic plaque within an in 
vitro model would be extremely technical challenging, time-consuming and expensive. An 
alternative approach is to begin to create tissue-engineered blood vessels in which more 
developed atherosclerotic plaques are engineered directly into them. Previously Musa et al., 
(2016) created tissue-engineered blood vessel constructs using a layer-by-layer building 
methodology – with a medial layer being made through culturing HCASMCs within a type I rat 
collagen hydrogel, and an intimal layer developed through culturing human umbilical vein 
endothelial cells (HUVECs) atop of an aligned PLA nanofibers mesh through creating 
independently cultured constructs representing the intimal and medial layers which are able 
to effectively replicate the primary haemostatic properties of arteries.  The modularity of this 
design provides the potential to directly incorporate a pre-developed fatty streak, 
fibroatheroma or unstable plaque between the intimal and medial layers of the construct. 
This construct could allow the in vitro development of a range of different stages of the 
atherosclerotic plaque ranging from the fatty streak, to the fibroatheroma, to plaque rupture. 
As macrophage-derived foam cells play a principal role in the pathology of atherosclerosis, 
human monocytes have been used in in vitro experiments as a source to culture human 
macrophages and human foam cells for atherosclerosis studies. However, as monocytes 
comprise only 2-8% of all leukocytes, this separation requires a complex and expensive 
process to separate and isolate these cells from other types of leukocytes from fresh human 
blood (Huo et al., 2003). Therefore, previous studies have used human monocytic cell lines 
such as U937, HL-6p or THP-1 cells. THP-1 cells are human monocytic cells obtained from a 
patient with acute monocytic leukaemia and are the most used cell type as they share many 




(e.g., expression of CD14, and LDL receptors; Mallone et al., 2017). In addition, they share a 
similar cytokine production response upon polarization, especially IL-6, IL1-ß, TNF-ὰ, and 
PDGF. Furthermore, upon polarization of M1 cells, both types of cells exhibit a similar 
expression level of CD80. However, human primary monocytes exhibit a higher expression 
level of CD206 upon M2 polarisation in comparison with that of THP-1-cells. Additionally, 
human primary monocytes produce significantly higher levels of IL-2, IL-7, IL-8, and IL-9 upon 
polarization in comparison with that of THP-1 cells (Tedesco et al.,2018). Furthermore, it has 
been reported that the phagocytic activity of primary human monocytes derived 
macrophages is higher than that of THP-1-derived macrophages (Madhvi et al.,2019).Despite 
these differences in behaviour, THP-1 cells have been widely used as a viable alternative to 
human monocytes in the culture of macrophage-derived foam cells as they can be readily 
differentiated to macrophages when artificially stimulated upon treatment with phorbol 12-
myristate 13-acetate (PMA) and provide a more sustainable supply of foam cells possible than 
when using fresh peripheral blood monocytes (Daigneaul et al.,2010). 
Human macrophages are not a homogenous cell type in vivo as they can significantly change 
their phenotype depending on the local tissue environment. This has traditionally led to 
macrophages being divided into two main groups, M1 and M2 macrophages (Figure 2). M1 
cells are characterized by their pro-inflammatory activity, while M2 by their phagocytic, anti-
inflammatory activity. These different phenotypes can be artificially induced in culture using 
different combination of cytokines and other chemical signals. For example, polarisation of 
M1 macrophages can be achieved by culturing in the presence of lipopolysaccharide and IFN-
gamma, leading to these cells expressing certain pro-inflammatory cytokines, for instance, 




this will lead to a polarisation to an M2 macrophage phenotype leading to these macrophages 
secreting certain anti-inflammatory cytokines, for instance, IL-10 (Via et al., 1989). More 
recently it has become clear that the M1/M2 polarisation is a simplification with multiple 
distinct M2 subgroups having been demonstrated (Yuan et al., 2015).  Both M1 and M2 
macrophages are found in human atherosclerotic plaques, but with M1 macrophages 
predominating in more rupture prone plaques, whilst M2 macrophages are observed in more 
stable plaques (Genin et al., 2015). Therefore, being able to replicate mixed populations of 
M1 and M2 macrophage may be required to best replicate atherosclerotic plaques. 
Furthermore, although macrophage-derived foam cells have been traditionally considered to 
be the principal source of foam cells within the neointima, this has been challenged by data 
demonstrating that smooth muscle cell-derived foam cells contribute around about 50% of 
all the foam cells present in atherosclerotic plaques found in human arteries (Allahverdian et 
al., 2014). Interestingly, these cells show reduced expression of the cholesterol efflux 
transporter ABCA1 in later stage atherosclerotic lesions, whereas macrophage-derived foam 
cells show upregulated expression (Wang et al., 2019).  This loss of this lipid-exporting 
transporter prevents the regression of smooth muscle cell derived foam cells back to its 
original form, facilitating its accumulation within the plaque.   As previous 3D culture models 
of atherosclerosis have not investigated the incorporation of this cell type, experiments were 
also performed to investigate whether smooth muscle derived foam cells could be developed 
within a 3D culture. Due to the complexity of the cellular and biochemical environment 
contained within the atherosclerotic plaque, this chapter has focussed on developing a 3D 
culture model of a foam cell-rich neointimal layer containing either macrophage- or smooth 
muscle cell-derived foam cells that can be incorporated within our previously developed 




3.2 Aims and Objectives  
The aim of this chapter is to develop a novel 3D neointimal construct within a collagen 
hydrogel that can be incorporated into our previously developed tissue-engineered arterial 
model.  
Objective 1:  Establish a 2D culture of THP-1-derived foam cells, and assess whether these 
can be successfully detached from the culture plastic for introduction into a 3D hydrogel 
Objective 2:  Incorporate THP-1 cells into a 3D collagen hydrogel and assess the ability of 
using the 2D culture protocol to produce THP-1-derived foam cells within the scaffold.  
Evaluate whether 3D cultures of THP-1-derived foam cells through differentiation within the 
3D gel or following culture in a 2D environment.  
Objective 3: Assess the potential for utilising plastic compression of the 3D culture 
containing construct to increase the mechanical support from the 3D gel and to increase 
foam cell density within the gel 
Objective 4: Assess the potential for incorporating human coronary artery smooth muscle 











To create an in vitro 3-dimensional atherosclerotic plaque inside the tissue-engineered 
human blood vessel constructs, it was necessary to be able to develop a neointimal layer 
representing the accumulation of macrophage-derived foam cells into the fatty streak. This 
can then be transferred between the intimal and medial layers of our current construct to 
create a neointimal layer, which can be used to create a tissue-engineered model of 
atherosclerosis.  
Firstly, it was necessary to establish a reliable culture methodology to allow the scalable 
production of macrophage-derived foam cells within a 3D collagen hydrogel.  Whilst it is 
possible to culture foam cells from monocytes derived from human blood, this would require 
a significant supply of fresh human blood and the use of expensive cell isolation methods to 
allow for the extraction of sufficient human monocytes to make this a viable route. Therefore, 
instead, it was decided it was more sensible to establish the foam cell culture using THP-1 
cells, a human monocytic cell line derived initially from a leukemic patient. To develop a 
neointimal layer for a blood vessel construct it was necessary to create and characterise a 
reliable in vitro foam cell culture from THP1 cells. This was initially attempted in 2D culture to 
allow for the establishment of methods to assess cellular differentiation prior to beginning 
work on developing 3D culture techniques. 
3.3.1 Establishing a reliable methodology for creating a proliferating THP-1 cell suspension 
culture 
Initial work involved establishing a reliable methodology for culturing THP-1 cells. THP-1 cell 
cultures require high-seeding density to allow them to reach a proliferative stage of rapid 




experiment cell culture was established using a proliferating THP-1 cell culture received 
directly from the supplier. This culture could be seen to rapidly expand upon incubation and 
was used to establish the initial THP-1 cell culture, as well as provide aliquots of low passage 
cells that were placed into cryostorage (Figure 3.1A). The first attempt to revive a frozen 
cryovial of THP-1 cells led to a non-proliferating culture, despite cells being seeded at the 
recommended cell density and culture conditions, with the cell density in the culture 
remaining below 2.5 x105 THP-1 cells/mL (Figure 3.1B). This culture was established according 
to the supplier’s instruction in which the thawed cells should be rapidly diluted into a large 
volume of RPMI containing 10% [v/v] FBS to facilitate rapid removal of DMSO from the cells 
and prevent toxic effects of this solvent.  Therefore, a different strategy was used to attempt 
to establish a method of successfully reviving the cryovials of THP-1 cells. The thawing 
procedure was changed to reduce the possibility of osmotic swelling of the THP-1 cells and 
increasing the nutrients available for them by slowly adding RPMI media supplemented with 
20% [v/v] FBS.  This attempt proved successful, leading to cells achieving a rapid phase of 
proliferation after 10 days in culture (Figure 3.1C). This technique has been successfully 






Figure 3.1.  
Proliferation curves 
of differentially 
revived THP-1 cell 
cultures. (A) Upon 
arrival, the cells 
were incubated at 
37°C, 5% CO2 as per 
the supplier’s 
instructions. (B) 
Upon defrosting the 
cryoprotected THP-1 
cells were rapidly 
mixed with RPMI 
with 10% [v/v] FBS 
and incubated at 
37°C, 5% CO2 as per 
the manufacturer’s 
instructions. (C) 
Upon defrosting, the 
cryoprotected THP-1 
cells were slowly 
mixed with RPMI 
with 20% [v/v] FBS 
and incubated at 
37°C, 5% CO2 as per 
the supplier’s 
instructions. Viable 
cell density was then 
daily measured using 
trypan blue and a 
haemocytometer 
under a light 
microscope, n=49. * 
= P < 0.05 between 
indicated conditions 
using a one-way 
ANOVA with post 
hoc Tukey test).  
                                                                                                                                 Values are shown as 





3.3.2 Differentiation of THP-1 into M0 macrophage cells in 2D culture 
Having established a proliferating THP-1 cell suspension, experiments were performed to 
differentiate M0 macrophage cells from THP-1 cells in 2D culture. This has traditionally been 
achieved by treating the cells with phorbol 12-myristate 13-acetate (PMA). However, there is 
great variability in the differentiation protocols used between labs, with no consensus on a 
standardised protocol for this stage of cell culture. Different labs use a variety of PMA 
concentrations and incubation periods, with these variables ranging between 6 – 500 nM for 
the PMA concentration, and between 3-72 hours for the incubation period (Lund et al., 2016). 
Therefore, experiments were performed to assess the optimal conditions for M0 macrophage 
culture in the laboratory.  Previous studies have suggested that 48h incubation with PMA was 
the optimal period for THP-1 differentiation (Daigneault et al., 2010); Aldo et al., 2013), and 
so experiments investigated the effect of using different PMA concentrations incubated for 
48 h to induce an M0 phenotype in 2D cultures of THP-1 cells. THP-1 cells were cultured in 
24-well plates at a seeding density of 1x 105 cells/well. The cells were treated with either 
completed RPMI media alone or completed RMPI media containing either 25, 50 or 100 nM 
PMA, and then incubated for 48 h. Cells were imaged by light microscopy to look for 
morphological signs of differentiation. At the end of the incubation period, adherent cells in 
the culture were then labelled with a fluorescence antibody to CD68, a cell surface marker for 
macrophages and assessed by fluorescent microscopy  (Jensen et al., 2009). The fluorescent 
readings from each well were then measured using a microplate reader. PMA treatment 
induced morphological differentiation of the THP-1 cells during the incubation period. Most 




phenotype, with minimal, weak cell adhesion seen in cells not treated with PMA (Figure 3.2). 
Additionally, PMA-treated cells also showed a difference in their size as they differentiated 
from THP-1 monocytic cells to THP-1-derived macrophages (the mean cell diameter 
increasing from 8.5 µm to 21 µm). Furthermore, as THP-1 cells differentiate to macrophage, 
distinct morphological changes appear. The cells started to change from round to oval-shaped 
and could be seen to form some elongated, spindle-like cells (Figure 3.3). As THP-1 cells 
differentiated to macrophages, they become larger and either rounded or elongated to form 
spindle-like structures. 
 To assess macrophage differentiation, experiments were performed to examine the cell 
surface expression of CD68. CD68 is a member of the lysosomal-associated membrane 
proteins (LAMPs).  Previous studies have demonstrated that the cell surface expression of this 
marker can be seen to be increased in THP-1 cells derived macrophages(Genin et al., 2015) . 
This marker is also of interest due to previous studies that have demonstrated that CD68 may 
also play a role in the uptake of oxidised low-density lipoproteins (ox LDL), and as such, may 
be necessary for foam cell formation  (Biros, Reznik and Moran, 2021). PMA-treatment also 
increased the fluorescent labelling of CD68 Expression on the cell surface of THP-1 cells. 





Figure 3.2 THP-1 cells become adherent after PMA stimulation. THP-1 cells were treated 
with either completed RPMI media alone (Left) or completed RMPI media containing either 
25, 50 or 100 nM PMA, and then incubated for 48 h (Right, the PMA concentration for this 
image was 50nM). The cells were then fixed and imaged using light microscopy. Cells 
treated without PMA were found to attach in low-density. Most of the remaining cells were 
dislodged during the washing process and were therefore difficult to get into focus (Left).  
PMA-treated THP-1 cells became firmly adhere to the surface of the 24-well plate during the 












Figure 3.3.  PMA stimulation of THP-1 
cells induces an increase in size, and a 
transition of a population into more 
elongated, spindle-like forms. THP-1 
cells either before (Top panel) or after 
(Bottom panel) treated with PMA 
(25nM) for 48 h at 37°C, 5% CO2 (Right). 
The cells were found to become larger, 
and some were seen to take up rounded 
or elongated cellular morphologies, 





















Figure 3.4. PMA induces CD68 Expression in THP-1 cells. THP-1 cell suspensions were seeded 
at 1x105 cells/well in 24-well plates in RPMI media with varying concentrations of PMA.  Cells 
were then incubated at 37°C, 5% CO2 for 48 h. Adherent cells were then stained with a 
fluorescent CD68 antibody. The immunofluorescence signals were read by a microplate 




fluorescence image on fluorescence microscope of cells treated with 25 nm PMA. The 
brightness and contrast of the fluorescent image was amended to improve clarity of the 
image. (C) Fluorescence reading from the microplate reader. † = P < 0.05 compared to 0 nM 
PMA, * = P < 0.05 between indicated conditions using a one-way ANOVA with post hoc Tukey 
test). Values shown are Mean ± SEM of 10 experiments 
 
 
been treated with PMA. This could be explained by the lack of THP-1 cell adherence on the 
culture plastic when cultured in the absence of PMA (Figure 3.2). 
Interestingly stimulation with 25 and 50 nM appeared to create the optimal environment for 
macrophage differentiation, whilst stimulation with 100 nM appeared to create a weaker 
response (Figure 3.4). One possibility is that prolonged treatment of THP1 cells with high 
concentrations of PMA might adversely affect cell viability. Therefore, a trypan blue assay was 
done to assess if there was any effect on cell viability in these cultures. As shown in figure 3.5, 
none of the treatment condition adversely affected cell viability, with all conditions showing 
cell viability of around 99%. 
To further confirm this, additional studies examined the expression of the CD36 protein, 
which is known to be upregulated during the differentiation of monocytes to macrophages 
(Tontonos et al., 1998). CD36 is also an essential mediator of ox LDL uptake during foam cell 
formation, thus higher expression of this protein would help us increase the changes of 
forming THP-1-derived foam cells (Biros et al., 2021). Experiments were therefore performed 
to assess the PMA concentration that optimally upregulated expression of CD36 cell surface 
expression in THP-1 cells. These data demonstrated a similar pattern to CD68 expression, with 
expression highest in cells treated with 50 nM PMA (Figure 3.6).  Although this increase was 




25 nM PMA, it was decided that THP-1 cell differentiation into macrophages would be 
performed by treating with 50 nM PMA for 48 h in all future studies. 
 
 
Figure 3.5: Incubation with PMA does not affect cell viability significantly in THP-1 cell 
cultures. THP-1 cell suspensions were seeded at 1x105 cells/well in 24 well plates in RPMI 
media with varying concentrations.  Cells were then incubated at 5% CO2 at 37°C for 48 h. At 
the end of the culture trypan blue was added to the well and live and dead cells were counted 
across 5 different parts of the well to assess cell viability. Values shown are Mean ± SEM of 
12 experiments. (* = P < 0.05 between indicated conditions using a one-way ANOVA with post 
































Figure 3.6. PMA treatment increases cell surface expression of the oxLDL receptor, CD36 in 
THP-1 cells. THP-1 cell suspensions were seeded at 1x105 cells/well in 24-well plates in 
completed RPMI media with various concentrations of PMA.  Cells were then incubated at 
5% CO2 20% O2 at 37°C for 48 h.  Adherent cells were then stained with a fluorescent CD36 
antibody. Then the immunofluorescence signals were read by a microplate reader.  † = P < 
0.05 compared to 0 nM PMA.  Values shown are Mean ± SEM of 10 experiments. (* = P < 
0.05 between indicated conditions using a one-way ANOVA with post hoc Tukey test)  
 
 
3.3.3 Differentiation of M0 THP-1 derived macrophages into M1 macrophages in 2D cultures 
Macrophages can polarise further into multiple alternative phenotypes.  The most common 
of these different polarisations are the M1 and M2 macrophages – with M1 macrophages 
generally considered to be pro-inflammatory, whilst the alternatively-activated M2 
macrophages are often regarded as an anti-inflammatory (Murray et al., 2014). Both 
macrophage types have been previously observed to be present in human atherosclerotic 




rupture-prone lesions and able to form foam cells (Stoger et al., 2012). whilst M2 
macrophages are associated with more stable plaques,  are resistant to oxLDL uptake  and 
have been shown to be associated with atherosclerosis regression (Chinetti-Gbaguidi et al., 
2011). Therefore, it would be ideal to be able to create atherosclerotic plaques with differing 
compositions of M1 and M2 macrophages to assess their impact on the biological function of 
the tissue-engineered arteries.  To be able to do this, experiments were performed to assess 
the potential of our PMA-differentiated macrophage cells to be polarised using further 
treatment with commonly-used cytokine cocktails such as lipopolysaccharide (LPS) and 
Interferon-γ (IFN- γ) for M1 macrophages, and IL-4 for M2 macrophages (Yang et al., 2020). 
To assess effective polarisation of our M0 macrophages to M1 macrophages, experiments 
were performed to assess whether treatment of our macrophages with 100 ng/ml LPS and 20 
ng/ml IFN-γ could induce an increase in M1 macrophages in our cell population.  This was 
assessed by examining immunoflorescent staining of adherent cells with CD80, a widely used 
cell surface marker for M1 macrophages (Xu et al., 2019).  
An initial optimisation experiment was performed to select the best dilution for the FITC-
lablled secondary antibody. In this experiment we stained the cells directly with four different 
dilutions of the secondary antibody (1:2500, 1:5000, 1:7500 and 1:10000) without using the 
primary antibody. From this experiment, 1:5000 was observed to provide minimal observable 
background staining in the absence of the primary antibody (data not shown). This antibody 
concentration was then used to stain THP-1-derived M0 macrophages that had been treated 
with 100 ng/ml LPS and 20 ng/ml IFN-γ (or an equivalent volume of their vehicle, DMSO). As 




the surface of the THP-1-derived macrophages – demonstrating that it is possible to 
successfully differentiate the M0 macrophages to THP-derived M1 macrophages 
 
3.3.4 Differentiation of M0 THP-1 derived macrophages into M2 macrophages in 2D culture 
To assess effective polarisation of the M0 macrophages to M2 macrophages, experiments 
were performed to assess whether treatment of the M0 macrophages with 20 ng/mL IL-4 
could induce M2 macrophage differentiation.  This was initially assessed by examining the 
staining of adherent cells with an indirect labelling method using a primary antibody to CD206 
and a FITC-conjugated secondary antibody. Initial optimisation experiments assessed the 
optimal FITC-conjugated anti-rabbit secondary antibody concentration to provide the lowest 
non-specific secondary antibody binding by treating cells with different dilutions of the 
secondary antibody (1:2500, 1:5000, 1:7500 and 1:10000) without using the primary 
antibody. The lowest background staining was observed with the 1:10000 dilution, so this was 
used for the subsequent experiments. Treatment of THP-1-derived M0 macrophages with IL-
4 elicited an increased cell surface expression of the M2 macrophage cell surface marker, 
CD206 compared to M0 macrophages treated the vehicle control, PBS (Figure 3.7). Thus, the 
M0 macrophages can be differentiated into either M1 or M2 macrophages using appropriate 
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Figure 3.7 THP-1 derived M1 cells could be generated by treatment of M0 macrophages with 
LPS and IFN-γ. THP-1 cell suspensions were seeded at 1x105 cells/well in 24-well plates in 
completed RPMI media with various concentrations of PMA.  Cells were then incubated at 5% 
CO2 20% O2 at 37°C for 48 h. The RPMI media was then replaced with a PMA-free media for 
24 hours and cells were then treated with either 100 ng/mL lipopolysaccharide (LPS) and 20 
ng/mL IFN-γ (A-C), or an equivalent volume of their vehicle, DMSO (D-F), at 37°C, 5% CO2 for 
72 hours.   Cells were then fixed and labelled with a mouse anti-CD80 antibody, followed by 
a FITC labelled anti-mouse secondary antibody.  Samples were then imaged using a Fluoview 
laser confocal scanning microscope. (A, D) FITC fluorescence (B,E) Brightfield image of 






3.3.5 Generation of THP-1 derived foam cells from M1 macrophage in 2D cultures 
Finally, to establish the protocol for creating THP-derived foam cells, experiments were 
performed to assess the ability of the M1 macrophage cells to form foam cells in 2D culture.  
Previous studies have found that macrophage cells will transform to foam cells after taking 
up oxLDL from the culture medium  (Poznyak et al., 2020). Sterile oxLDL samples were created 
through a copper sulphate oxidation process (Section 2.2115).  The oxidation state of the LDL 
samples was first validated via reading of the absorbance spectrum.  As shown in Figure 3.8A, 
the oxidised samples were visibly cloudy compared to the non-oxidised aliquots taken from 
the same sample.   Previous studies have demonstrated that oxidised LDL has a different 
absorbance property to the non-oxidised LDL (Levitan et al., 2010). A notable difference in 
the absorbance spectra with differences could also be observed at every wavelength in our 
samples.  This indicated that oxidation state had been effectively changed. To definitively 
validate the oxidation of the LDL samples, these were via an oxLDL ELISA kit, which showed a 
significant increase in the presence of oxLDL within the samples compared to the non-
oxidised LDL, although a small basal oxidisation of this sample was unexpectedly observed 
(Figure 3.8C). These data therefore indicate that copper sulphate-mediated oxidation of the 
samples was effective and could be used to trigger foam cell formation in the THP-1-derived 
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Figure 3.8 IL-4 treatment of THP-1-derived M0 macrophages elicits increased expression of 
CD206. THP-1 cell suspensions were seeded at 1x105  cells/well in 24-well plates in completed 
RPMI media,  cells were then incubated at 5% CO2, 37°C for 48 h .Cells were then rested by 
incubation in a PMA-free media for 24 h, and then treated with either 20 ng/mL IL-4 (A-C) or 
an equivalent volume of PBS (D-F). Adherent cells were then stained with the primary CD206 
antibody and then with its secondary antibody. (A, D) Fluorescent imaging of CD206 (B, E) 





 the foam cells are they are found to predominate in rupture-prone plaques (Genin et al., 
2015).  
M1 macrophage cells were cultured in 24-well plates as previously described, but at the same 
time of IFN-γ and LPS addition for M1 polarization, the media was also supplemented with 
either 50 µg/ml LDL and 50 µg/ml oxLDL or an equivalent volume of their vehicle, PBS. 
Following the incubation for 72h, the samples were fixed and subject to Oil red O staining to 
assess whether M1 macrophages treated with oxLDL could be observed to have developed 
the intracellular accumulations of lipids observed in foam cells. As shown in Figure 3.9, Whilst 
most oxLDL-treated M1 macrophages could be seen to have developed intracellular lipid 
accumulations, neither those treated with LDL or PBS could be seen to have any significant 
Oil Red O staining indicating that intracellular neutral lipid deposits had developed specifically 
in the oxLDL-treated macrophages. These data demonstrate that we have developed the 
techniques to generate THP-1-derived foam cells in 2D culture, as well as the methods to 
assess each of the stages of THP-1 differentiation into these cells.   
3.3.6 Assessment of strategies to develop a 3D hydrogel culture of THP-1 cells 
Having established the methodology for culturing THP-1-derived foam cells in 2D culture, two 
distinct strategies were considered for developing a 3D hydrogel culture of THP-1-derived 
foam cells.  The first was to detach the cells generated through the 2D culture system and 
then seed these into 3D collagen hydrogels, whilst the second was to seed THP-1 cells directly 
into the 3D hydrogels and then use the culture conditions developed in 2D culture to elicit 













Figure 3.9. Validation of the 
oxidation of the LDL samples. 
Oxidised and non-oxidised LDL 
samples were assessed to 
validate effective oxidation of 
the LDL particles.  (A) Picture of 
the oxidised (ox) and non-
oxidised (n) samples when 
loaded in 96-well plate (B) 
Absorbance spectra of the 
oxidised (oxLDL) and non-
oxidised (nLDL) samples. Data 
are shown as mean ± SEM (n = 
2).  (C) Measurement of 
oxidative state using an oxLDL 
ELISA assay kit. n = 4. (* = P < 
0.05 relative to the nLDL control 
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Figure 3.10 Oil Red O staining of M1 macrophages treated with LDL and oxLDL. THP-1 cell 
suspensions we reseeded at 1x105 cells/well in 24-well plates in RPMI media with 50 nM  
PMA.  Cells were then incubated at 5% CO2, 37°C for 48 h. Cells were rested by incubation in 
a PMA-free media for 24 h, and then cells were treated with LPS and IFN-γ and either 50 
µg/mL LDL (B), 50 µg/mL oxLDL (C) or an equal volume of their diluent PBS (A) at 5% CO2,  
37°C for 72 h. After this period, cells were fixed and stained with Oil Red O to assess 
intracellular accumulations of neutral lipids, n=6. 
 
within T25 flasks to provide sufficient cells to make hydrogel culture viable, and then 
attempted to detach viable foam cells from 2D cultures using either a commercial 
Macrophage Detachment Solution (Promocell), accutase, EDTA/Trypsin or cell scrapers. After 
treatment, the cell suspension extracts were collected and number of viable and non-viable 
cells was assessed using trypan blue. The cells remaining in the flask were stained with Oil 
Red O and imaged.   These studies found that none of the treatments identified above were 
successful in detaching significant numbers of THP-1-derived foam cells from the flask, with 
the majority being found remaining on the surface of the flask.  Assessment of cells found in 




focussed on seeding THP-1 cells into collagen hydrogels and attempting to differentiate these 
into THP-1-derived foam cells. 
3.3.7 Establishing a 3D culture by seeding THP-1 cells on top of a collagen hydrogel  
Pilot experiments assessed whether THP-1 cells could successfully attach, proliferate, and 
differentiate in contact with a collagen hydrogel. This was assessed by assessing cell 
attachment and differentiation under PMA treatment when seeded onto the top of a 3D 
collagen hydrogel. This experiment is an intermediate stage between the 2D-THP-1 cells 
culture and the typical 3D-hydrogel culture of the THP-I cells. To do this, collagen hydrogels 
were set into 24-well plates, and THP-1 cells were then seeded in a small volume of RPMI 
media containing either 0, 25, 50 or 100 nM PMA. As can be seen in Figure 3.10, cells not 
stimulated with PMA stayed rounded and showed none of the morphological indicators of 
macrophage differentiation seen in our earlier experiments on cell culture plastic.  In contrast, 
cells treated with PMA showed considerable morphological changes ranging from more oval-
shaped and elongated cells with some showing spindle-like shapes, indicative of successful 
M0 differentiation (Figure 20B-D).   These studies, therefore, indicated that PMA-induced 
differentiation of THP-1 cells is possible when PMA cells are cultured within 3D collagen 
hydrogels. 
 
3.3.8 Establishing a method for THP-1 cell culture within a 3D collagen hydrogel 
Following these pilot experiments, further experiments assessed the potential of THP-1 cells 
to be differentiated into macrophages within a type I collagen hydrogel both in the presence 




the hydrogel solution prior to setting was 50 nM. Light microscopy experiments of PMA 
treated hydrogels showed the presence of cells with an elongated or stretched morphology 
within the 3D hydrogel which indicates the possibility of differentiation of the THP-1 cells into 
M0 macrophages (Figure 3.11). Following the end of the culture period, these collagen 
hydrogels were then subject to live/dead cell staining and found that almost all cells within 
the gel were live (91.1% ± 1.7 % and 96.1 ± 0.8 % viability for cells treated with and without 
PMA respectively), with no differentiation between the cells at different depths within the gel 
or between cells incubated with or without PMA.  These indicated that THP-1 cells could be 
successfully treated with PMA within the hydrogels, without altering cell viability. 
 
3.3.9 Differentiation of THP-1 derived M1 macrophages within the collagen hydrogels 
To assess if it was possible to generate M1 macrophages following PMA stimulation of THP-1 
cells in 3D cultures, collagen hydrogels were prepared using the same method which was used 
for THP-1 derived M0 macrophages. To be sure that PMA treatment did not affect Cells 
growing and viability, the collagen hydrogels were assessed using microscopic monitoring and 
live/dead cell staining respectively (Figure 3.12 and 3.13). After that we proceeded in the 
experiment using the same protocol that have been used for the 2D culture experiments. 
Following PMA treatment, the collagen hydrogels were rested by incubation in a PMA-free 
media for 24 h. The RPMI media was changed to a fresh RPMI media containing 100 ng/mL 
LPS and 20 ng/mL IFN-γ to induce differentiation to M1 macrophages, as previously 
demonstrated in the 2D culture experiments. 
 





   
 
Figure 3.11 PMA-induced differentiation of THP-1 cells cultured on top of a type I collagen 
hydrogel. Two groups of modified 3D-hydrogel were prepared, those which did not treat with 
PMA (A), and those which were treated with 25 nM B, 50 nM C, 100 nM of PMA D. THP-1 cells 
in first group (A) stay rounded in shape and small in size, however, the second group (B,C,D) 
as they differentiated to macrophage, they elongated or stretched and form spindle-like cells 






    
Figure 3.12. THP-1 cells undergo morphological change when stimulated with PMA when 
cultured in a 3D collagen hydrogel. THP-1 cells were mixed at a cell density of 3 x 106 
cells/mL into a neutralized solution of 3 mg/mL type I collagen. The THP-1/collagen mixture 
was then loaded under sterile conditions onto a 1 x 1 cm, sterile filter paper frame prepared 
on a PTFE base inside a petri dish. The collagen-cell mixture was left to set for 30 minutes at 
37°C, 5% CO2. The hydrogel was then covered with RPMI medium containing 10% [v/v] FBS, 
Pencillin, Streptomycin and 50 nM PMA, and then incubated for 48 h at 37˚C, 5% CO2.  Cell 
morphology was then observed using light microscopy, n=6. 






Figure 3.13 THP-1 cell viability was not affected by PMA treatment within the collagen 
hydrogels. THP-1 cells were mixed at a cell density of 3 x 106 cells/mL into a neutralized 
solution of 3 mg/mL type I collagen. The THP-1/collagen mixture was then loaded under 
sterile conditions onto a 1 x 1 cm, sterile filter paper frame prepared on a PTFE base inside a 
petri dish. The collagen-cell mixture was left to set for 30 minutes at 37°C, 5% CO2. The 
hydrogel was then covered with RPMI medium containing 10% [v/v] FBS, Penicillin, 
Streptomycin and either with 50 nM PMA (A) or an equivalent volume of DMSO (B), and then 
incubated for 48 h at 37˚C, 5% CO2.  Cell morphology was then observed using light 
microscopy. On the sixth day of the experiment, the cytokines completed media was changed 
by a live/dead stain solution, and then the collagen hydrogels were imaged by the confocal 







The hydrogels were then subject to immunolabelling with the unconjugated primary antibody 
to CD80 and a FITC-labelled secondary antibody previously used in the 2D culture 
experiments. Pilot studies retested the secondary antibody to find a concentration that did 
not induce significant non-specific staining in the absence of a primary antibody. Four 
different dilutions of the secondary antibody were used (1:2500, 1:5000, 1:75000 and 
1:10000). From this experiment, a 1:10000 dilution was found to produce the lowest 
background (data not shown). Using this and the CD80 primary antibody concentration 
previously utilised in the 2D cultures, it was possible to identify strong labelling of cells within 
the 3D construct indicating that M1 differentiation had successfully occurred (Figure 3.14).  
To ensure that the CD80 labelling was specific for M1 macrophages, experiments compared 
immunofluorescent labelling achieved in M1 and M0 macrophages cultured within the 3D 
hydrogels.   As shown in Figure 3.14A, B, whilst M1 macrophages showed strong 
immunofluorescent labelling, weaker staining was observed in the M0 macrophages not 
stimulated to differentiate with LPS and IFN-γ. The fluorescent labelling of CD80 within the 
hydrogel constructs was quantified using Image J and was found to be consistently and 
significantly greater in M1 macrophage-containing hydrogels compared to those containing 
M0 macrophages (Figure 3.15C). These data therefore demonstrate that the CD80 staining is 
specific for M1 macrophages, and that it is possible to generate M1 macrophages within the 







Figure 3.14 LPS and IFN-γ can induce M1 macrophage differentiation in 3D cultures. THP-1 
cell suspensions were seeded at 6x105 cells/hydrogel in RPMI media with 50 nM 
concentration PMA.  Cells were then incubated at 5% CO2, 37°C for 48 h. Cells were rested by 
incubation in a PMA-free media for 24 h, and then cells were transferred into fresh RPMI 
containing 100 ng/mL LPS and 20 ng/mL IFN-γ for a further 72 h. Collagen hydrogels were 
then fixed and then immunolabelled using an unconjugated CD80 antibody and a FITC-










Figure 3.15 CD80 antibodies stain M1-differentiated macrophages but not M0 macrophages 
within the 3D collagen hydrogels. (A-C) THP-1 cell suspensions were seeded at 6x105 
cells/hydrogel in RPMI media with 50 nM concentration PMA.  Cells were then incubated at 
5% CO2, 37°C for 48 h. Cells were rested by incubation in a PMA-free media for 24 h, and then 
cells were transferred into fresh RPMI containing either (A) 100 ng/mL LPS and 20 ng/mL IFN-
γ or their vehicle, DMSO (B) for a further 72 h. Collagen hydrogels were then fixed and then 
immunolabelled using an unconjugated CD80 antibody and a FITC-labelled secondary 





(Bottom) Image J analysis of the total FITC fluorescence observed through the entire hydrogel. 
* = P < 0.05 between indicated conditions using a student’s T-test. Values shown are Mean ± 




Figure 3.16. Live/dead staining of THP-1 derived foam cells. THP-1 cell suspensions were 
seeded at density of 6x105 cells/collagen hydrogel in completed RPMI media with 50nM 
PMA concentration RPMI media.  Collagen hydrogels were then incubated at 5% CO2 20% O2 
at 37C for 48 h. Cells were rested by incubation in a PMA-free media for 24 h, and then cells 
were treated with LPS and IFN-γ for 72 h. Lastly, collagen hydrogels were treated with 50 
µg/mL oxLDL at 5% CO2, at 37°C for 72 h. Cells were then stained using a live/dead cell 
staining kit. Samples were then subject to z-stack imaging using a confocal microscope with 








3.3.10 Differentiation of THP-1 derived foam cells in the 3D collagen hydrogel 
Following successfully demonstrating the ability to differentiate THP-1 cells into M1 
macrophages within the collagen hydrogels, the next experiments assessed whether 
subsequent treatment of the M1 macrophage-containing 3D cultures with 50 µg/mL oxLDL 
was able to elicit the formation of THP-1-derived foam cells within the collagen hydrogels. 
After the culture of the M1 macrophages, fresh RPMI media containing 50 µg/ml of oxLDL 
was added to the cells for 72 hours. After this, the cell viability of THP-1 cells was assessed 
using live/dead staining. Cells were found to be 95% ± 1.5 % viable (Figure 3.15).  
Experiments were next performed to confirm the presence of foam cells within the 3D 
culture.  This was achieved using nile red, a fluorescent stain that labels intracellular neutral 
lipids and has previously been used to characterise lipid uptake in the cultured macrophages 
(Greenspan et al., 1985). As shown in Figure 3.16, the droplets of the intracellular, neutral 
lipids appear as red dots surrounding the Hoechst-stained nuclei of the THP-1 derived foam 
cells (pseudocoloured blue). These data therefore indicated that oxLDL treatment was able 
to elicit the production of THP-1-derived foam cell production within the collagen hydrogels.  
To assess the specificity of the Nile Red staining, THP-1-derived M1 macrophages were 
produced and treated with 50 µg/mL oxLDL, 50 µg/mL of non-oxidised LDL, or RPMI media 
with an equivalent amount of PBS. The collagen hydrogels were re-incubated for another 72 
hours. The cells were then fixed and stained with Nile Red and Hoechst-33342.  Nile Red 
fluorescence in THP-1-derived M1 macrophages that were treated with oxLDL, was found to 
be significantly higher than those treated either with non-oxidised LDL or PBS (Both P < 0.05). 
These data indicate that the Nile Red fluorescence was specifically labelling THP-1-derived 




neointimal model that could be incorporated within the previously developed tissue-
engineered blood vessel construct. 
     
 
 
Figure 3.17 Nile Red staining indicates oxLDL loading of THP-derived macrophages can 
induce foam cell formation in 3D culture. THP-1 cell suspensions were seeded at 6x105 
cells/collagen hydrogel in RPMI media with 50 nM PMA concentration RPMI media.  Collagen 
hydrogels were then incubated at 5% CO2, 37°C for 48 h. Cells were rested by incubation in a 
PMA-free media for 24 h, and then cells were treated with LPS and IFN-γ for 72 h. Then 
collagen hydrogels were treated with 50 µg/mL oxLDL at 5% CO2, 37°C for 72 h. On the tenth 
day of the experiment, the collagen hydrogels were fixed with10% formalin overnight and 
then were stained with Nile Red and Hoechst-33342 to assess the intracellular accumulation 
of neutral lipid. (A) Brightfield image (B) Hoechst-33342 fluorescence (C) Overlay of the 
Hoechst-33343 and Nile Red fluorescence (D) A -stack imaging using a confocal 
microscope,n=6. 






Figure 3.18. Nile Red specifically labels intracellular neutral lipid accumulation with THP-1-
derived foam cells, but not M1 macrophages. THP-1 cell suspensions was seeded at 6x105 
cells/collagen hydrogel in RPMI media with 50 nM PMA.  Collagen hydrogels were then 
incubated at 5% CO2, 37°C for 48 h. Cells were rested by incubation in a PMA-free media for 
24 h, and then cells were treated with LPS and IFN-γ for 72 h. Then the cells were treated 
with and either 50 µg/mL OxLDL (A), 50 µg/mL LDL (B) or an equal volume of their vehicle, 
PBS (C) at 5% CO2, 37°C for 72 h. After this period, cells were fixed and stained with Nile-
Red/Hoechst stain to assess intracellular accumulations of neutral lipids.  Image J analysis of 
the Nile Red fluorescence present within the entire hydrogel. Values shown are Mean ± SEM 
of 5 experiments. (* = P < 0.05 between indicated conditions using a one-way ANOVA with 
post hoc Tukey test). 
3.3.11 Plastic compression experiment 
Whilst the neointimal culture model developed in a simple collagen hydrogel could be used 
to introduce an atherosclerotic plaque into the tissue-engineered arterial construct, the 





density of the THP-1-derived foam cells within these constructs is relatively low compared to 
that observed in a fatty streak or more advanced lesions.  Additionally, the collagen construct 
is relatively mechanically weak, which could be a disadvantage when trying to incorporate 
this into the tissue-engineered arterial construct. Plastic compression can be used to improve 
the mechanical properties by increasing the collagen content, through squeezing excess 
aqueous fluid out of the gel, leaving the cells and collagen present at a higher density 
increasing the stiffness of the construct (Braziulis et al., 2012). Plastic compression is 
performed by placing a sterile weight on top of the hydrogel for a short period of time, with 
filter paper underneath to absorb any extracted fluid. As previous studies have shown that 
reduced substrate stiffness reduces the phenotypic properties of M1 macrophages (Okamoto 
et al., 2018), experiments were therefore performed to assess whether viable THP-1-derived 
foam cells could be successfully developed within a collagen hydrogel after plastic 
compression. In these studies, the THP-1 cells were seeded into collagen hydrogels and set in 
a mould.  The samples were than subject to plastic compression, and then placed back into 
RRPMI media where it was then treated with PMA, LPS, IFN-γ and oxLDL as described 
previously. Initial live/dead cell staining images demonstrated that the process of plastic 
compression did not significantly reduce cell viability, with viability found in the compressed 
hydrogels to be 89.3% ± 0.7% (Figure 3.18A, B) 
To assess foam cell production within the compressed collagen hydrogels, THP-1-derved M1 
macrophages were prepared in compressed collagen hydrogels using the same cultured 
method which was used for the non-compressed method. The samples were then treated 
wither either complete RPMI media containing either 50 µg/mL oxLDL or 50 µg/mL of non-




with Nile-Red/Hoechst stain using the same protocol which was used for the non-compressed 
hydrogels previously. As shown in Figure 3.19, intracellular neutral lipid droplets (red dots) 
could be observed in most of the cells in samples treated with oxLDL, but not in those treated 
with non-oxidised LDL. Image J assessment of the fluorescent intensity through the hydrogels 
was found to be significantly higher in the oxLDL-treated samples than those treated with 
non-oxidised LDL (P < 0.05; Figure 3.20)  
 
3.3.12 TNF-α and IL-6 secretion is upregulated in THP-1-derived foam cells generated within 
the compressed 3D collagen hydrogel 
M1 macrophages are characterised by the secretion of a variety of pro-inflammatory 
cytokines such as TNF-α, IL-6 and IL-1β (Biswas and Mantovani, 2010). The expression of these 
pro-inflammatory cytokines has previously been shown to be upregulated by treatment of 
THP-1-derived macrophages with oxLDL (Wang et al., 2015; Zhong et al., 2020; Liu et al., 
2014).   Therefore, experiments were conducted to assess whether the foam cells within the 
compressed collagen hydrogel were able to replicate these effects, by assessing cytokine 





Figure 3.19. Live/dead stain of the THP-1 derived foam cells in compressed collagen 
hydrogels. THP-1 cell suspensions were seeded into compressed collagen hydrogels, and then 
incubated in RPMI media with 50 nM PMA at 5% CO2, 37°C for 48 h. Cells were rested by 
incubation in a PMA-free media for 24 h, and then cells were treated with LPS and IFN-γ for 
72 h. The samples were then treated with 50 µg/mL OxLDL at 5% CO2, 37°C for 72 h. After this 
period, cells were stained with Live/Dead Cell staining kit stain to assess cell viability.  Images 
were taken using confocal microscopy.  (A) a single slice through the gel (B) A projection of 






                                                   
 
Figure 3.20 THP-1-derived foam cells could be produced within compressed collagen 
hydrogels. THP-1 cell suspensions were seeded into compressed collagen hydrogels, and then 
incubated in RPMI media with 50 nM PMA at 5% CO2, 37°C for 48 h. Cells were rested by 
incubation in a PMA-free media for 24 h, and then cells were treated with LPS and IFN-γ for 
72 h. The samples were then treated with either 50 µg/mL OxLDL (A) or 50 µg/mL LDL (B) at 
5% CO2, 37°C for 72 h. After this period, cells were fixed and stained with Nile-Red/Hoechst 









Figure 3.21. THP-1-derived foam cells are produced in compressed collagen hydrogels 
treated with oxLDL, but not non-oxidised LDL. THP-1 cell suspensions were seeded into 
compressed collagen hydrogels, and then incubated in RPMI media with 50 nM PMA at 5% 
CO2, 37°C for 48 h. Cells were rested by incubation in a PMA-free media for 24 h, and then 
cells were treated with LPS and IFN-γ for 72 h. The samples were then treated with either 50 
µg/mL OxLDL (A) or 50 µg/mL LDL (B) at 5% CO2, 37°C for 72 h. After this period, cells were 
fixed and stained with Nile-Red/Hoechst stain to assess intracellular accumulations of neutral 
lipids.  Bar chart shows Image J analysis of the Nile Red fluorescence present within the entire 
hydrogel. Values shown are Mean ± SEM of 5 experiments. (* = P < 0.05 between indicated 





containing either THP-1-derived-foam cells or M1 macrophages. Conditioned media samples 
exposed for the same time frame to an acellular collagen hydrogel was used to control for 
basal presence of these cytokines in the FBS-supplemented media. In addition to the 3 
proinflammatory cytokines assays were also assessed for the presence of PDGF-BB, a cytokine 
not widely known to be secreted by M1 macrophages but has been demonstrated to play a 
role in triggering vascular smooth muscle cell migration to the atherosclerotic plaque (Cheng 
et al., 2020). Therefore, we examined whether oxLDL stimulation of the M1 macrophages 
could trigger synthesis of this cytokine.  
As shown in Figure 3.21, conditioned media samples taken from THP-1-derived foam cells 
could be observed to secrete significantly increased amounts of IL-6 and TNF-α into the 
conditioned media compared to the acellular collagen hydrogel.  The M1 macrophages were 
found to secrete IL-6 and TNF-α into the conditioned media, but only IL-6 was found to be 
significantly greater than that observed from the conditioned media from the conditioned 
collagen hydrogel.  The oxLDL loading of the THP-1-derived foam cells was seen to enhance 
the secretion of both pro-inflammatory cytokines compared to M1 macrophages consistent 
with previous research, but this was only found to be significantly higher for IL-6. 
Unexpectedly, it was not possible to detect any IL-1β secretion from the conditioned media 
of any of the samples (Figure 3.22A).  Absorbance readings taken from the zero-concentration 
standard were found to be consistently and significantly higher than that obtained from any 
of the samples. These data therefore indicate the possibility that the complete RPMI media 
may contain chemicals that interfere with the ELISA plate. Similarly, test for PDGF-BB within 
the conditioned culture media found no evidence of secretion of this cytokine, consistent with 





Figure 3.22. TNF-α and IL-6 secretion is upregulated in foam cells generated within the 
compressed 3D collagen hydrogel THP-1 cell suspensions were seeded into compressed 
collagen hydrogels, and then incubated in RPMI media with 50 nM PMA at 5% CO2, 37°C for 
48 h. Cells were rested by incubation in a PMA-free media for 24 h, and then cells were treated 
with LPS and IFN-γ for 72 h. The samples were then treated with either 50 µg/mL OxLDL (Foam 
cells) or an equivalent volume (M1 cells) at 5% CO2, 37°C for 72 h. Acellular collagen gels were 
also placed in culture alongside these constructs as a control sample.  Conditioned media 
samples were then extracted and subjected to ELISA analysis of either TNF-α (A) or IL-6 (B) 
contained within the samples. * Indicates P<0.05 relative to the acellular gel control † = 






Figure 3.23. IL-1β and PDGF-BB could not be detected within the conditioned media 
extracted from compressed 3D collagen hydrogels containing THP-1-derived cells. THP-1 cell 
suspensions were seeded into compressed collagen hydrogels, and then incubated in RPMI 
media with 50 nM PMA at 5% CO2, 37°C for 48 h. Cells were rested by incubation in a PMA-
free media for 24 h, and then cells were treated with LPS and IFN-γ for 72 h. The samples 
were then treated with either 50 µg/mL OxLDL (Foam cells) or an equivalent volume (M1 cells) 
at 5% CO2, 37°C for 72 h. Acellular collagen gels were also placed in culture alongside these 
constructs as a control sample.  Conditioned media samples were then extracted and 
subjected to ELISA analysis of either IL-1β (A) or PDGF-BB (B) contained within the samples.  
* Indicates P<0.05 relative to the zero concentration (blank) standard using a one-way ANOVA 





Overall, these data indicated that the foam cells are not just viable but maintain their 
significant pro-inflammatory phenotype when cultured with the compressed collagen 
hydrogels. 
 
3.3.13 Development of 2D cultures of human coronary artery smooth muscle cell-derived 
foam cells. 
Previous studies have demonstrated that that smooth muscle cell-derived foam cells 
contribute around about 50% of all the foam cells present in atherosclerotic plaques found in 
human arteries (Allahverdian et al., 2014). Therefore, an accurate model of the neointima 
would also incorporate this cell type.  Therefore, initial experiments assessed the possibility 
of culturing human coronary artery smooth muscle-derived foam cells (HCASMC-DFCs) in 2D 
culture. Human coronary artery smooth muscle cells (HCASMCs) were seeded in 24-well 
plates in complete Medium 231 and incubated for 48-72 h to provide time for cell 
proliferation and maturation. At the end of this period, the samples were seen to become 
elongated and spindle-shaped, consistent with the morphology expected of these cells (Figure 
3.22).  The media was then changed to a fresh sample containing 50 µg/mL oxLDL and 
incubated for a further 72 h. After this period cells were fixed and stained with Nile Red and 
Hoechst-33342 to assess intracellular accumulations of neutral lipids.  As Figure 3.23 shows, 
Nile-Red stain labelled intracellular neutral lipid droplets inside smooth muscle cells (red 









Figure 3.24. 2D culture of HCASMCs. HCASMCs were cultured according to the 
manufacturer instructions. The cells were seeded at a cell density of 1x105 cells/well in 24-
well plates in completed Medium 231 and incubated at 5% CO2 at 37°C for 48 h-72 hours. 




                                                                                       
Figure 3.25. Culturing of HCASMC-DFC in 2D cultures. HCASMCs were seeded in 24-well 
plates in completed 231 media at a density of 1x105 cells/well for 48 hours. The cells were 
then treated with 50 µg/mL oxLDL at 5% CO2, 37°C for 72h. After this period, cells were fixed 
and stained with Nile-Red and Hoechst-33342 to assess the intracellular lipid droplets. 
Smooth muscle cells stained with Hoechst-33342 dye, (Right panel) Overlay of Nile-Red and 
Hoechst fluorescence.  Samples were assessed at high (A-C) and low (D-F) magnification. (A, 
D) Brightfield images (B,E) Hoechst-33342 fluorescence (C,F) An overlay or Nile Red and 













A                                                                                         B 
Figure 3.26. HCASMC-DFC can be cultured successfully within 3D collagen hydrogels. 
HCASMCs were seeded at 1x105 cells/collagen hydrogel and set with 1x1cm filter paper 
frames.  The collagen hydrogels were then treated with fresh RPMI media contain 50 µg/mL 
ox LDL in 5% CO2, 37°C for 72h.  Following this the collagen hydrogels were stained with Nile-
Red and Hoechst stains to assess intracellular accumulations of the lipids. Z-stack imaging was 
conducted using a confocal microscope. (A) Z-stack image (B) single slice image, n=6. 
 
3.3.14 Preparation of SMC derived foam cells in collagen hydrogels 
HCASMCs were seeded within collagen hydrogels and then incubated with fresh media 
containing 50 µg/mL oxLDL for 72 hours. HCASMCs within the samples were shown to stain 
positively for Nile Red (Figure 3.24D-F).  Higher magnification imaging demonstrated that the 
HCASMC could be observed to have accumulated granules that stained positively for Nile Red, 
indicating the presence of the intracellular lipid deposits characteristic of foam cells. 
 
3.3.15 Cell viability assessment of HCASMC-DFC 
To ensure that the viability of the HCASMC-DFCs was not impacted by culturing within 3D 




staining of the samples.  As shown in Figure 3.25, the HCASMCs remained a high level of 
viability after culture with 50 µg/mL oxLDL within a 3D collagen hydrogel with 92.4% ± 0.9 of 
cells found to be viable.  
 
3.3.16 HCAMSC-DFCs accumulate greater lipid deposits when cultured with oxLDL than 
with non-oxidised LDL.  
Macrophage-derived foam cells take up oxLDL with a higher affinity than the native, non-
oxidised LDL particles (Chistiakov et al., 2017).  Experiments were performed to assess 
whether oxidation of the LDL particles impacts on the rate of foam cell formation in our 3D 
collagen hydrogels.  After seeding of HCASMCs within a collagen hydrogel, the cells were 
incubated with complete Medium 231 supplemented with either 50 µg/mL oxLDL or 50 µg/mL 
of non-oxidised LDL and incubated for 72 hours. The cells were fixed and stained with Nile red 
and Hoechst-33342. The samples were then subject to z-stack imaging and the mean Nile red 
fluorescence for all slices was compared for cells treated with oxLDL and non-oxidised LDL.  
As shown in Figure 3.27A, B, nile red staining of lipid deposits was seen more frequently in 
HCASMCs treated with oxLDL than non-oxidised LDL. This was confirmed by an ImageJ 
analysis of the mean Nile red fluorescence observed through the hydrogels that showed that 
this was significantly greater oxLDL-treated samples (P < 0.05; Figure 3.27C).  These data 
suggest that oxidation of the LDL particles facilitates the formation of HCASMC-DFCs, in a 







                                                                                        
Figure 3.27 HCASMCs maintain a high level of viability when cultured with 3D collagen 
hydrogels.  HCASMCs were seeded at 1x105 cells/collagen hydrogel and set with 1x1cm filter 
paper frames. The collagen hydrogels were then treated with fresh RPMI media contain 50 
µg/mL ox LDL in 5% CO2, 37°C for 72h.  Following this the collagen hydrogels were stained 
with a lead/dead cell stain. Single slice image (A) and Z-stack (B) imaging were conducted 











Figure 3.28 Nile Red staining was significant greater in samples loaded with oxLDL than non-
oxidised LDL. HCASMCs were seeded at 1x105 cells/collagen hydrogel and set with 1x1cm 
filter paper frames.  The collagen hydrogels were then treated with fresh RPMI media contain 
either 50 µg/mL ox LDL (Top, left) or 50 µg/mL non-oxidised LDL (Top, right), and incubated 
at 5% CO2, 37°C for 72h.  Following this the collagen hydrogels were stained with Nile-Red 
and Hoechst stains to assess intracellular accumulations of the lipids. Z-stack imaging was 
conducted using a confocal microscope. (Lower panel) The mean fluorescence through the 
sample was measured using Image J. * P < 0.05 using a student’s T-test. Values shown are 









In this chapter it has been demonstrated that it is possible to successfully create a 3D 
neointimal culture model through the differentiation of THP-1 cells into foam cells within a 
compressed collagen hydrogel.  Through assessing the ability to develop THP-derived foam 
cells within both 2D and 3D cultures, it was found that it was optimal to trigger the 
differentiation of the THP-1 foam cells within the collagen hydrogel, rather than prior to 
seeding into the gel. Importantly cell viability of the THP-1-derived foam cells remained high 
through all stages of the process and retained their ability to produce and secrete 
proinflammatory cytokines such as IL-6 and TNF-α into the surrounding medium.  
By carefully assessing the effectiveness of each stage in this multi-step culture system, it has 
been possible to develop a reliable and reproducible culture method that can be used to 
produce an ex vivo humanised model of atherosclerotic plaque formation.  Whilst this was an 
original process at the time this was completed in the model, another group has recently 
reported achieving the same feat (Garcia-Sabate et al., 2020).  Although this group has also 
demonstrated the ability to culture THP-1 cells into foam cells within a collagen hydrogel, this 
chapter still represent the first demonstration of producing foam cells within a compressed 
collagen hydrogel.  As macrophage proinflammatory responses improve as stiffness of the 
extracellular matrix increases (Zhuang et al., 2020), it is likely that the stiffer compressed 
collagen hydrogel will provide an optimal environment for culturing foam cells.   
The neointimal culture model detailed in this chapter represents a different strategy to 
previous attempts to create a tissue-engineered model of human atherosclerosis, that have 
revolved around triggering monocyte recruitment and transendothelial migration into the 




et al., 2020). In contrast our strategy is to develop the neointimal environment outside of the 
blood vessel and then adapt our layer-by-layer fabrication strategy to introduce the tissue-
engineered artery once this has been fully developed.  This process allows us to artificially 
introduce a high density of foam cells directly into the model system without having to recruit 
and differentiate these from perfused blood samples. Of the previous attempts, only Zhang 
et al., (2020) have demonstrated that monocytes recruited into the subendothelial space 
were able to undergo transformation into foam cells.   Whilst this is an important step in 
recreating atherosclerosis in tissue-engineered human arteries, it is important to note that 
both our model and that of Zhang et al., (2020) only provide a replica of the fatty streak, an 
early, clinically silent stage of atherosclerotic plaque development.  Therefore, further 
development of the model will be required to create more advanced lesions with the 
construct to ensure that it is able to trigger the later stages that undergo the clinically relevant 
events of plaque rupture and erosion. With this in mind, the demonstration that it is possible 
to effectively develop HCASMC-DFCs within the collagen hydrogels should allow us in future 
to develop more advanced models encompassing this key cell in the atherosclerotic plaque 
(Allahverdian et al. 2014).   Through incorporating the HCASMC-DFC alongside in the 
hydrogels alongside the THP-1-derived foam cells, it is likely that it will be possible to develop 
models that better replicate the cellular environment of the advance atherosclerotic plaque. 
However additional efforts will be needed to replicate both the necrotic core of the plaque 
and the fibrous cap, both of which are characteristic of advanced fibroatheroma stages of 
plaque development.  Modifications of the methods to trigger targeted cellular apoptosis or 
necrosis within the neointimal would provide a basis for developing a necrotic core, however 
further engineering will be required to ensure this does not adversely affect surrounding cells.  




construct with HCASMCs or via the ability of the model to trigger endogenous vascular 
smooth muscle cell migration with cultured within the construct.   The latter of these options 
is explored further in chapter 5. Therefore, it should be possible to utilise this initial prototype 
to develop more advanced stage neointimal models.   
One of the major disadvantages of the neointimal culturing system developed here is the 
prolonged culture period required, with this culture system requiring the THP-1 cells to be 
cultured for 10 days to produce THP-1-derived foam cells.  This extended period creates both 
cost implications as well as practical difficulties in that it slows down the rate at which this in 
vitro model can be made.  Future research will be required to assess whether the 
development of THP-1-derived foam cells can be speed up within the compressed collagen 
hydrogels. During the development of the model, we principally optimised the concentration 
of cytokines and LDL particles used during the culture, but it is likely that similar effects can 
be observed at much shorter durations.  For example, there has traditionally been no 
standardised protocol to differentiate THP-1 cells to macrophages, with the concentration of 
the PMA used and duration of treatment differing widely between labs (Park et al., 2007) 
(Starr et al., 2018; Chanput et al., 2014; Spano et al., 2007; Lund et al., 2016; Feng et al., 2004; 
Daigneault et al., 2010).  For example, investigators have used between 3-72 h of PMA 
stimulation to initiate M0 macrophage differentiation. In this study we utilised 48 h , this has 
previously been shown to be the optimal period for THP-1 differentiation in specialist studies 
(Daigneault et al., 2010); Aldo et al., 2013), however ; future studies should investigate 
whether it is possible to develop effective THP-1-derived foam cell cultures after 24 h or less.  
Similarly, whilst we have used 72 h incubation to induce both M1 polarisation and foam cell 




al., 1997; Genin et al., 2015).  This could therefore reduce the culture length from 10 days 
down to as little as 4 days, which could significantly reduce the culture costs and enhance the 
rate at which these constructs could be made.   
 
3.5 Conclusion 
This chapter details an effective and reproducible system for developing a 3D culture model 
of the neointimal lining of the atherosclerotic human artery.  The foam cells contained within 
can be shown to be highly viable and maintain their proinflammatory properties such that 
they have the potential to influence the cellular behaviour of endothelial and smooth muscle 
cells when cultured together within a tissue-engineered arterial model. Although this model 
currently represents an early stage of atherosclerotic plaque development, through 
development of a protocol for the development of HCASMC-DFC within 3D collagen hydrogels 















Chapter 4: Assessing the prothrombotic potential of the 3D neointimal constructs 
 
4.1 Introduction 
Disruption of the atherosclerotic plaque triggers the onset of acute cardiovascular events 
such as myocardial infarction and ischemic stroke.  Through disruption of the anti-thrombotic 
endothelial barrier, plaque rupture and erosion expose the complex biochemical and cellular 
environment contained within the atherosclerotic plaque to the bloodstream. This triggers 
both the activation of circulating platelets as well as the blood coagulation system (Khandkar 
et al., 2021; Libby et al., 2019).  The resultant thrombi formed can occlude the affected blood 
vessel, causing ischemic damage to the downstream tissue. However, the mechanisms 
underlying these thrombotic events are variable depending on the mechanisms of plaque 
disruption. Post-mortem imaging has demonstrated that plaque rupture is the pathological 
event responsible for most of all fatal myocardial infarctions, whilst plaque erosion (in which 
the plaque is not ruptured) is responsible for fatal coronary thrombi in around a third of all 
patients (Khandkar et al., 2021; White et al., 2016). However, the thrombotic response was 
seen to be distinct in these different pathological events, with ruptured plaques causing the 
formation of thrombi which were more fibrin-rich, whilst plaque erosion lead to thrombi 
which were more platelet-rich (Sato et al., 2005). Importantly, studies have demonstrated 
that patients presenting with plaque rupture tend to have a larger infarct area and reduced 
left ventricular function (Higuma et al., 2015).   Additionally, the prognosis of patients who 
had experienced plaque rupture was found to be worse than those whose acute 
cardiovascular event had been triggered by plaque erosion (Yonetsu and Jang, 2018). These 
results indicate that the method of plaque breakdown plays a key role in determining the type 




of these patients. Through better understanding the mechanisms of atherothrombosis we 
may be able to improve the functional outcomes for patients undergoing myocardial 
infarction. 
In plaque rupture, the mechanical breakdown of the atherosclerotic plaque brought about 
through the weakening of the fibrous cap leads to direct exposure of components of the 
neointima to the bloodstream.  Contained within this layer are a number of components that 
can trigger the activation of platelets. Assessment of lipid-rich atheromatous plaques taken 
from patients with carotid stenosis found the presence of significant quantities of type I and 
III fibrillar collagen (Reininger et al., 2010; Penz et al., 2005). Antibody blockade of 
Glycoprotein VI (GPVI) in human platelets, or genetic knockdown of GPVI in murine platelets, 
prevented platelet activation when exposed to plaque samples. Similarly, collagenase 
treatment of plaque material or exposure to antibodies to type I and III collagen inhibited 
platelet activation in response to the excised atherosclerotic plaques, providing clear 
evidence that collagen plays a role in triggering platelet activation. This effect of collagen is 
likely supported by the presence of other adhesive ligands present in atherosclerotic plaques, 
such as von Willebrand Factor (vWF) and fibronectin (Gencer et al., 2021; Matter et al., 2004). 
Fibronectin has been suggested to trigger platelet activation at plaques through activation of  
GPVI in in vitro studies, however the significance of these findings is unclear as there has been 
limited study of the role of this protein in in vivo studies (Cho and Mosher, 2006). Von 
Willebrand Factor is known to play a key role in mediating platelet activation to collagen 
under conditions of high shear stress, consistent with a role for this protein in assisting in 
platelet adhesion to a ruptured plaque (Mastenbroek et al., 2015; Savage et al., 2021).   




ex vivo platelet activation on material taken from human atherosclerotic plaques obtained by 
surgical endarterectomy (Reininger et al., 2007; Reininger et al., 2010). Interestingly, high 
levels of plasma vWF have been found to be a risk factor for patients in developing recurrent 
myocardial infarction, indicating that this protein facilitates the progression of 
atherothrombosis (Badimon and Vilahur, 2014; Sakai et al., 1999). 
Alongside these adhesive ligands, the soluble chemical constituents of atherosclerotic 
plaques may also sensitize human platelets through the presence of oxidized low-density 
lipoproteins (oxLDLs).  This may also be enhanced further by the presence of additional oxLDL 
within the bloodstream of individuals suffering from dyslipidemia. Previous studies have 
demonstrated that increased oxLDL content of plaques from patients with symptomatic 
carotid disease was associated with symptomatic disease (Nezu et al., 2016) due to the 
enhanced thrombogenic properties of these plaques upon rupturing.  Previous studies have 
demonstrated that the CD36 scavenger receptors are responsible for sensitizing human 
platelets exposed to oxLDL, and therefore responsible for the prothrombotic platelet 
phenotype connected to atherothrombosis (Asada et al., 2020; Podrez et al., 2007). oxLDL 
activation of CD36 triggers a tyrosine kinase- and protein kinase C-dependent signalling 
pathway which activates phosphodiesterases to cleave cAMP, as well as triggering the 
formation of reactive oxygen species which inhibit Protein Kinase G (Wraith et al., 2013; 
Berger et al., 2020). This therefore removes the dampening effects of platelet inhibiting 
compounds such as prostacyclin and nitric oxide produced by endothelial cells, enhancing the 
activity of human platelets. Additionally, the core of atherosclerotic plaques have been 
demonstrated to be rich in lysophosphatidic acid, which has also been demonstrated to 




Although some evidence has demonstrated that prostaglandin E2 (PGE2) is produced within 
human atherosclerotic plaques and could trigger arterial thrombosis (Gross et al., 2007; Gross 
et al., 2014), studies performed on ex vivo human plaques have indicated that blockade of 
this receptor has limited impact on plaque-induced thrombosis (Yang and Chen, 2016).  
However, this discrepancy has been suggested to be due to the limited timeframe in which 
the reactive PGE2 remains active after plaque dissection (Mastenbroek et al., 2015). Overall, 
these studies demonstrate that release of atherogenic lipids from the interior of the plaque 
into the bloodstream can facilitate platelet activation during atherothrombosis. Beyond 
platelet activation, atherothrombosis has also been demonstrated to involve activation of the 
blood coagulation system (Mastenbroek, 2015). Tissue factor is the key extracellular activator 
of the extrinsic pathway through its ability to activate Factor VII.  This enzyme is known to be 
abundantly expressed in atherosclerotic plaques, with this enzyme associated both with foam 
cells and vascular smooth muscle cells, as well as microparticles created by apoptosis of foam 
cells (Grover and Mackman, 2020; Marmur et al., 1996). The degree of expression of tissue 
factor within the plaque had been shown to be a key determinant of the thrombogenicity of 
this structure (Grover and Mackman, 2020;  Toschi et al., 1997). Blocking tissue factor activity 
by incubation with tissue factor pathway inhibitor or an anti-tissue factor antibody was shown 
to significantly reduce the thrombogenic potential of human atherosclerotic plaque samples 
(Badimon and Vilahur, 2014; Badimon et al., 1999), supporting the idea that activation of the 
extrinsic pathway of coagulation plays a significant role in determining the occlusive potential 
of a disrupted plaque.  However activation of the intrinsic pathway of coagulation also 
supports the growth of thrombi formed upon plaque rupture, as genetic knock-out of factor 
XII have also been shown to reduce the longer-term stability of the thrombus triggered by 




the activation of the blood coagulation system and human platelets by disrupted plaques are 
not independent, with evidence suggesting interplay between these two events. For example, 
platelets can be seen to be observed to colocalize with fibrin and tissue factor in 
atherosclerotic plaques, suggesting that tissue factor-dependent activation of coagulation 
helps recruit platelets, facilitating the growth of the thrombus (Hoshiba et al., 2006).  
Similarly, platelet recruitment on plaque-coated surfaces has been shown to trigger a second 
wave of fibrin formation in ex vivo studies, suggesting that the exposure of phosphatidylserine 
on the activated platelet surface plays a key role in progression of the clotting response by 
acting as a catalytic surface for clotting factors (Reininger et al., 2010). Therefore, this self-
propagating interplay between primary and secondary haemostatic responses is responsible 
for the uncontrolled clotting response which is the hallmark of ischemic heart disease and 
stroke.  Any 3D culture model of the neointima must be capable of triggering these 
atherothrombotic properties to be considered a valid model of the human atherosclerotic 
plaque. Previous studies of tissue-engineered blood vessel constructs have demonstrated 
that they can replica the inflammation of endothelial cells and begin to accumulate foam cells 
when exposed to oxidized LDL and pro-inflammatory mediators. However, none of these 
previous studies have assessed the pro-thrombotic potential of these model system, 
therefore making it uncertain if they can be used as valid replacements of current animal 
models of atherothrombosis.  Atorvastatin is currently recommended by the National 
Institute for Clinical Excellence (NICE) as both for primary prevention of cardiovascular events 
in people at high risk of experiencing an acute cardiovascular event, as well as secondary 
prevention to prevent further cardiovascular events (NICE, 2016).  Although statins are 
primarily used to reduce the dyslipidemia found in patients at risk of acute cardiovascular 




cardiovascular function (Davignon, 2004). Atorvastatin has been shown to impact on the 
functional properties of platelets, endothelial progenitor cells, endothelial cells, monocytes 
and foam cells (Hilgendorf et al., 2003; Tekten et al., 2004; Gorabi et al., 2019; Sandhu et al., 
2017; Sanguini et al., 2005).  Due to the complex interactions between platelets, the 
coagulation cascade, and cells of the plaque and blood vessel wall, it is difficult for clinical and 
in vivo studies to dissect the importance of each of the various effects of statins on each of 
these cells in eliciting the thrombotic response to a ruptured or eroded plaque. The layer-by-
layer fabrication model utilized in these experiments provides us with the ability to assess the 
impact of this drug on the interaction between human platelets and macrophage-derived 
foam cells within the atherosclerotic plaque. In this chapter, experiments were performed to 
assess whether the 3D neointimal culture model can function as an effective ex vivo replica 
for a ruptured atherosclerotic plaque by triggering activation of human platelets and tissue 
factor dependent coagulation upon exposure to human blood samples. We also examined 




4.2.1 The 3D neointimal cell culture model containing THP-1-derived foam cells can trigger 
coagulation of human platelet poor plasma 
Ruptured atherosclerotic plaques are able to trigger activation of the blood coagulation 
cascade through the presence of tissue factor present within the neointimal layer(Owens and 
MacKman, 2012). Tissue factor has been shown to be localised within foam cells present 




cultures of THP-1 cells have demonstrated that tissue factor activity of these cultures can be 
upregulated by treatment with either lipopolysaccharide (Guha et al., 2001) or oxidised low 
density lipoprotein (Owens et al., 2012).  However there does not appear to have been similar 
studies conducted in THP-1 cells cultured within a 3D cell culture model – therefore it is 
uncertain whether the 3D neointimal model developed in chapter 3 will be able to trigger 
blood coagulation, and thus be a valid model of the human atherosclerotic plaque. Previously 
Musa et al., (2016) developed a testing platform to assess the ability of tissue engineered 
arterial constructs to activate human platelets. This was achieved through using a custom-
made sodium acetate frame to hold the luminal surface of the construct on top of a washed 
human platelet suspension (Musa et al.,2016).  This method was adapted to assess whether 
the 3D neointimal construct could initiate the activation of the blood coagulation cascade by 
performing a prothrombin time measurement on human platelet-poor plasma samples 
exposed to the luminal surface of neointimal constructs containing either THP-1-derived foam 
cells or M1 cells. As previous experiments have demonstrated an ability for fibrillar collagen 
to activate Factor XII (van der Meijden et al., 2009), it is possible that the compressed collagen 
could trigger activation directly. Therefore, the cellular constructs were also compared 
against an acellular compressed collagen hydrogel as a control. As shown in Figure 4.1, the 
foam cell-containing construct had the shortest prothrombin time (87 ± 5s). This was 
significantly quicker than both the M1 cell-containing gel (158 ± 3s; n = 6; P <0.05) and the 
acellular collagen hydrogel (376 ± 6s; n = 6; P <0.05). These data indicate that foam cells are 
able to effectively trigger the blood coagulation system, consistent with previous studies in 
2D cultures that showed the atherogenic transformation of foam cells (Owens et al., 2012).  




acellular collagen hydrogel (p <0.05) indicating that the LPS-stimulated M1 cells have also 
developed tissue factor activity.  
4.2.2 Plastic compression of the 3D neointimal culture model does not affect its 
procoagulant properties    
Plastic compression increases the stiffness and the collagen concentration of the collagen 
hydrogels (Ahearne, 2014).  Previous studies have demonstrated that THP-1 cells take on a 
more pro-inflammatory phenotype when cultured upon stiffer collagen gels (Sridharan et al., 
2019) suggesting that compression could enhance the pro-coagulant expression of the THP-
1-derived foam cells.  To assess this possibility, experiments were performed to compare the 
procoagulant properties of compressed or non-compressed collagen hydrogels. These were 
compared against a control in which a PPP (platelet poor plasma) sample alone was 
recalcified. As shown in Figure 4.2, compression of the collagen hydrogel did not significantly 
alter the prothrombin time (116 ± 12s vs 90 ± 5s for compressed and non-compressed gels 
respectively; both n = 5; P >0.05). These are both significantly longer than the prothrombin 
time measured from the control samples (735 ± 12s; n = 3; both P<0.05 compared to 
compressed and non-compressed hydrogels). These data indicate that the stiffness or 
collagen concentration of the hydrogel does not alter the procoagulant properties of the 3D 







4.2.3 The 3D neointimal culture model possesses measurable tissue factor activity that is 
enhanced by incubation with oxLDL. 
It has been established that macrophages and foam cells within atherosclerotic lesions 
possess significant tissue factor activity and this activity is a key determinant of the 
thrombotic potential of these structures (Mastenbroek, 2015). As the prothrombin time 
measurements on the M1- and foam cell-containing neointimal constructs demonstrate a 
 
Figure 4.1: The 3D neointimal culture model with THP-1-derived foam cells induces the 
fastest coagulation of PPP. 3D neointimal culture models were produced in which THP-
derived foam cells or M1 cells were cultured, as well as a cell-free collagen hydrogel.  Samples 
were then placed onto sodium acetate frames and placed into contact with the surface of 
prewarmed, recalcified human platelet-poor plasma (PPP). The sample is kept warm in a 37°C 
water bath.  The time taken for fibrin formation after addition of the 3D neointimal cultures 
models was recorded for each sample. Values shown are Mean ± SEM of 6 independent 
experiments.  * Indicates P < 0.05 vs the control sample.  † Indicates P < 0.05 relative to the 






Figure 4.2: Compression of the 3D neointimal culture model does not affect its procoagulant 
properties. THP-1-derived foam cells were cultured within either a compressed or a non-
compressed collagen hydrogel.  Samples were then placed onto sodium acetate frames and 
placed into contact with the surface of prewarmed, recalcified human platelet-poor plasma 
(PPP). The sample is kept warm in a 37°C water bath.  The time taken for fibrin formation after 
addition of the 3D neointimal cultures models was recorded for each sample. Values shown 
are Mean ± SEM of 5 independent experiments.  * Indicates P < 0.05 vs the control sample 






significant capacity for triggering the activation of blood coagulation, experiments were next 
performed to assess the tissue factor activity of the neointimal constructs. A novel microplate 
assay of tissue factor activity developed by our lab to assess tissue factor activity in 3D cell 
culture models was used on the 3D neointimal culture model. This assay involves incubating 
the constructs with a solution containing the target of tissue factor, inactive Factor VII, and a 
fluorescent indicator of activated factor VII (FVIIa) activity, SN-17a.   
When digested by FVIIa, SN-17a becomes more fluorescent, and so the rate of fluorescence 
increase can be used to assess the tissue factor activity contained within each construct 
(Figure 4.3A). Previous experiments have demonstrated that this fluorescence increase is 
dependent upon both the presence of a tissue factor-bearing construct and the presence of 
inactive Factor VII, thus demonstrating it is the presence of tissue factor that is principally 
responsible for this fluorescence increase (Ranjbar & Harper, Personal communication).  As 
can be seen in Figure 4.3B, when both the M1- and foam cell-containing neointimal models 
were incubated with Factor VII and SN-17a, they both elicited a significantly enhanced 
fluorescence increase during the incubation period compared to the acellular collagen gel.  
These data confirm that a tissue factor bearing construct is required to trigger the cleavage 
of SN-17a.  Interestingly, the fluorescent increase was found to be significantly enhanced for 
neointimal constructs containing foam cells (29524 ± 2974 arbitrary units) then those 
containing M1-macrophages (21960 ± 1823 arbitrary units; n =12; P < 0.05). These results are 
consistent with previous studies have demonstrated that oxLDL treatment of THP-1 cells 
significantly enhanced their tissue factor activity (Owens and Mackman, 2012).  They are also 
consistent with the prothrombin time measurements made on these constructs, with the 




tissue factor activity, whilst the avascular collagen hydrogel samples have got the lowest 
values.  
4.2.4 Human Coronary Artery Smooth Muscle Cell-derived foam cells have greater tissue 
factor activity than untreated smooth muscle cells 
In chapter 3, the possibility of developing 3D models incorporating HCASMC-derived foam 
cells into the neointimal culture was demonstrated. Vascular smooth muscle cells in the 
tunica media are known to be a significant source of tissue factor (Mackman et al., 2007). As 
vascular smooth muscle derived foam cells comprise around half of the cells in the human 
atherosclerotic plaque, experiments were performed to investigate if these cells could also 
contribute a significant source of 
tissue factor to a neointimal culture model.  As shown in Figure 4.4, both the 3D HCASMC- or 
HCASMC-derived foam cell-containing cell culture construct were found to trigger coagulation 
of platelet-poor plasma significantly faster than the acellular collagen gel.  However, the 
HCASMC-derived foam cells were found to have a significantly shorter prothrombin time (100 
± 10s) compared to those containing untreated HCASMCs (199 ± 24s; n = 6; P < 0.05).   
To confirm whether this related to changes in tissue factor activity in these constructs, 
experiments were performed using the SN17a-based tissue factor activity. These experiments 
demonstrated that both the neointimal constructs containing both untreated HCASMCs and 
HCASMC-derived foam cells (Figure 4.5). These data suggest that incorporating smooth 





Figure 4.3: The 3D neointimal culture model possesses measurable tissue factor activity, 
which is enhanced by incubation with oxLDL. (A) Tissue factor assay methodology.  A solution 
of inactive factor VII, CaCl2 and the fluorescent Factor VIIa indicator, SN-17a, was added onto 
foam cell and M1-containg neointimal culture models, or an acellular collagen set within 48-
well plates immediately before the start of the recording.  Tissue factor in the sample 
activates Factor VII to Factor VIIa, which in turn can cleave SN-17a, releasing the fluorescent 
moiety ANSN (6 amino-1-naphthalenesulphonamide) moiety which can be measured by the 
microplate reader. (B) Culture media was removed and an HBS solution containing 25 nM 
inactive Factor VII, 1mM CaCl2, and 2.5 µM SN-17a was added to acellular collagen gels, or 
M1- or THP-1-containing 3D neointimal culture models. The well plate was then read 
fluorometrically for 10 minutes. The mean change in SN-17a fluorescence observed between 




SEM of 12 independent experiments.  * Indicates P < 0.05 vs the control sample, † Indicates 
P < 0.05 relative to the indicated sample using one-way ANOVA with post hoc Tukey test. 
 
produce a model more consistent with a fibroatheroma, could further enhance the 
prothrombotic potential of the 3D neointimal constructs, consistent with the higher 
thrombogenicity of this plaque stage (Fernández-Ortiz et al., 1994). 
 
4.2.5 THP-1-derived foam cells can trigger a slow platelet activation and aggregation 
Ruptured atherosclerotic plaques expose the bloodstream to several adhesive and soluble 
ligands that can trigger platelet aggregation, as described in the introduction. For the 3D 
neointimal culture model to be an effective model of the human atherosclerotic plaque, the 
model needs to be capable of triggering human platelet activation and aggregation. Due to 
the complex cellular and biochemical environment present in the plaque it has not been 
possible to identify if foam cells play a role in providing this pro-aggregatory response of the 
atherosclerotic plaque. Due to the ability to engineer the cellular composition of the 
neointimal culture model, it has been possible to assess whether THP-derived M1- and foam 
cells are able to increase the pro-aggregatory potential of the neointimal construct.  This was 
assessed using a cuvette-based system to expose our 3D neointimal culture models to washed 
human platelet suspensions (Figure 2.7).  Washed platelets were utilised to remove the 
potential for platelet activation caused by thrombin generation elicited by the extrinsic 






Figure 4.4: A neointimal culture containing human coronary artery smooth muscle-derived 
foam cells. 3D neointimal culture models were produced in which HCASMC-derived foam cells 
or untreated HCASMCs were cultured. Additionally, a cell-free collagen hydrogel was used as 
a control sample.  Samples were loaded onto sodium acetate frames and placed into contact 
with the surface of prewarmed, recalcified human platelet-poor plasma (PPP). The sample is 
kept warm in a 37°C water bath.  The time taken for fibrin formation after addition of the 3D 
neointimal cultures models was recorded for each sample. Values shown are Mean ± SEM of 
6 independent experiments.  * Indicates P < 0.05 vs the control sample, † Indicates P < 0.05 






Figure 4.5: A neointimal culture model containing HCASMC-derived foam cells possesses 
measurable tissue factor activity, which is enhanced by incubation with oxLDL. Culture 
media was removed and an HBS solution containing 25 nM inactive Factor VII, 1mM CaCl2, 
and 2.5 µM SN-17a was added to acellular collagen gels, or M1- or THP-1-containing 3D 
neointimal culture models. The well plate was then read fluorometrically for 10 minutes. The 
mean change in SN-17a fluorescence observed between the initial reading and that observed 
after 10 minutes for TEML. Values shown are Mean ± SEM of 9 independent experiments. * = 






Figure 4.6: The 3D neointimal constructs trigger slow, weak platelet activation. (A) Washed 
human platelet suspensions resuspended in supplemented HBS containing 1 mM CaCl2, were 
exposed to either an acellular compressed collagen hydrogel, or a 3D neointimal culture 
model containing either THP1-derived M1 or foam cells.  The constructs were incubated for 
10 minutes at 37°C under constant magnetic stirring. The gel was then removed, and the 
samples was transferred for monitoring on a light transmission aggregometer at 37°C under 
constant magnetic stirring for up to 16 minutes. (B, C) Bar charts summarising the mean 
maximum % aggregation observed during the recording period (B) and the mean time taken 




*= P<0.05 relative to the acellular collagen hydrogel using a one-way ANOVA with post hoc 
Tukey test for (B) and a student’s T-test for the indicated samples for (C). 
  
the luminal surface of the construct for 10 minutes at 37°C under constant magnetic stirring.  
The sample was then transferred from the cuvette into a Chronolog aggregometer for further 
monitoring by light transmission aggregometry.  As can be seen in Figure 4.6A, the acellular 
collagen hydrogel was not observed to elicit any significant platelet aggregation in any of the 
experiments (0.6 ± 0.4%), consistent with previous observations by Musa et al., (2016). In 
contrast, preincubation with either the M1- or foam cell-containing constructs was able to 
elicit platelet aggregation – however it was found to be slow in onset, with the time taken to 
transition from shape change into aggregatory responses occurring slowly after onset of 
monitoring on the aggregometer. On average this transition occurred earlier for foam cell-
containing gels (437 ± 157s) compared to M1-cell containing constructs (610 ± 320s), although 
this effect was not significant (n = 7; P = 0.11; Figure 4.6B). Similarly, the maximum % 
aggregation measured over the 15-minute recording period was found to be greater in the 
foam cell-containing constructs (59.9 ± 10.3%), this was not found to be statistically greater 
than that elicited by the M1-containing constructs (41.0 ± 14.6%; n = 7; P > 0.05; Figure 4.6C). 
These data therefore indicate that whilst both foam cell- and M1 macrophage-containing gels 
can consistently elicit aggregation, but these responses are generally slow and variable in 
their time of onset – suggesting that these gels are only able to weakly activate human 
platelets in the absence of thrombin generation. A luciferin-luciferase dense granule secretion 
assay was performed on samples of the washed human platelet suspensions exposed to the 
3D neointimal culture models to further assess the degree of platelet activation. As activated 
human platelets secrete ATP-containing dense granules into the extracellular medium, the 




indicate the extent of platelet activation.  As shown in Figure 4.7, foam cell-containing gels 
elicited a significant increase in luciferase luminescence 
 
Figure 4.7:   THP-1-derived foam cell containing hydrogels induces significant platelet dense 
granule secretion.   Washed human platelet suspensions resuspended in supplemented HBS 
containing 1 mM CaCl2, were exposed to either an acellular compressed collagen hydrogel, or 
a 3D neointimal culture model containing either THP1-derived M1 or foam cells.  The 
constructs were incubated for 10 minutes at 37°C under constant magnetic stirring. The gel 
was then removed, and samples taken for aggregometry.  The remaining platelet solution was 
transferred back to the water batch and incubated for a further 10 minutes.  After this a 
sample was pipetted into a 96-well platelet and mixed with 20% [v/v] luciferin-luciferase, and 
luminescence read for 1 minute on a BioTek2 synergy microplate reader.  n = 7, * = P<0.05 
relative to the acellular collagen hydrogel using one-way ANOVA with post hoc Tuckey test. 





in washed human platelet suspensions (3740 ± 1169 arbitrary units) compared to samples 
exposed to acellular collagen gels (476 ± 121 arbitrary units; n = 7; P <0.05). M1-containing 
gels also elicited an intermediate increase in luciferase light production (3000 ± 1380 arbitrary 
units) compared to the foam cell-containing and acellular collagen hydrogels respectively, 
however this difference was insignificant compared to both other samples (P > 0.05 for both).  
These results are consistent with the aggregation data, with the greatest increase in luciferin 
luminescence elicited by foam cell containing gels correlating with the most rapid platelet 
aggregation.  
 
4.2.6 Atorvastatin reduces the pro-aggregatory properties of the 3D neointimal constructs 
Atorvastatin is widely used in the primary and secondary prevention of acute cardiovascular 
events in patients at risk of suffering thrombotic events.  Previous studies have demonstrated 
that atorvastatin and other statins can inhibit tissue factor expression in monocytes and 
vascular cells (Hilgendorff et al., 2003; Owens and MacKman, 2012; Zheng et al., 2021; Eto et 
al., 2002; Bruni et al., 2003).  Additionally, atorvastatin has been shown to reduce human 
platelet function (Tekten et al.,2003; Sanguigni et al., 2005).  Therefore, 3D neointimal cell 
culture constructs were treated during the oxLDL loading period either with 20 µM 
atorvastatin or an equal volume of its vehicle, methanol (MeOH). As shown in Figure 4.8C, 
prior treatment with atorvastatin tended to reduce the extent of the maximum platelet 
aggregation observed (35.0 ± 2.0%) compared to the methanol control sample (72.0 ± 17.6%; 
n = 6), although this effect was not statistically significant (P = 0.07).  Atorvastatin was found 
to significantly increase the latency of the onset of platelet aggregation (681 ± 140s vs 434 ± 





Figure 4.8 Treatment with atorvastatin reduces the pro-aggregatory properties of the 3D 
neointimal constructs. Washed human platelet suspensions resuspended in supplemented 
HBS containing 1 mM CaCl2, were exposed to either an atorvastatin- or methanol (MeOH)-
treated neointimal construct containing foam cells. The constructs were incubated for 10 
minutes at 37°C under constant magnetic stirring. The gel was then removed, and the samples 
was transferred for monitoring on a light transmission aggregometer at 37°C under constant 
magnetic stirring for up to 16 minutes. Prior treatment of the 3D neointima with Atorvastatin 
has decreased the percentage of the maximum platelet aggregation in comparison with that 
of Methanol (35.0 ± 2.0% vs 72.0 ± 17.6%), although this was statistically insignificant (A &C). 
In addition, Atorvastatin has increased the latency of the platelet aggregation in comparison 
with that of Methanol (681 ± 140s vs 434 ± 129s), (A&D), * indicates p value< 0.05 using a 





In some experiments, the neointimal constructs that were exposed to the washed human 
platelet suspensions were fixed immediately after extraction to allow for assessment of 
platelet adhesion and aggregation upon the surface of the construct exposed to the washed 
human platelet suspension. To do this the samples were stained with Hoechst-33342 and a 
FITC-conjugated CD41a antibody that should specifically bind to human platelets and imaged 
using confocal microscopy to isolate the surface layer of the construct. Despite blocking with 
normal goat serum prior to the exposure to the antibodies, the primary antibody was found 
to bind non-specifically to the foam cells within the gel.  Due to this limitation, platelet 
populations upon the surface of the construct were identified through counting cellular 
material stained with the CD41a antibody (Pseudocoloured red in Figure 4.9), but not Hoechst 
33342 (pseudocoloured blue) as platelets are anucleate.  Using this methodology, it was 
possible to identify platelet populations closely associated either above or adjacent to the 
nucleate foam cells on the surface of the construct. The density of these CD41+, Hoechst-
populations on the surface of the construct were found to be significantly greater for 
methanol-treated samples (23.4 ± 4.6 populations/image) compared to atorvastatin-treated 
samples (9.0 ± 1.4 populations/image, n = 4; P < 0.05). As we have previously shown that the 
acellular collagen hydrogel alone does not support platelet activation (Musa et al., 2016), 
these data indicate that foam cells can trigger platelet a small upregulation of platelet binding 
to the neointimal construct in a manner that can be inhibited by atorvastatin pre-treatment.  
Further work will be required to confirm these findings in samples in which platelets have 





Figure 4.9 Treatment with atorvastatin reduces the interaction of human platelets with the 
3D neointimal constructs. (A, B) Washed human platelet suspensions resuspended in 
supplemented HBS containing 1 mM CaCl2, were exposed to either an atorvastatin- or 
methanol (MeOH)-treated neointimal construct containing foam cells. The constructs were 
incubated for 10 minutes at 37°C under constant magnetic stirring. The gel was then removed 
and fixed with paraformaldehyde. Samples were then stained with a FITC-labelled anti-CD41a 
antibody (red) and Hoechst 33342 (blue).  The surface of the construct exposed to the washed 




Luciferin-luciferase measurements also showed that atorvastatin treatment tended to reduce 
the dense granule secretion elicited by the foam cell construct, however this was currently 
insignificant due to the variability of the measurements (2385 ± 600 vs 1068 ± 398; Figure 
4.10) for MeOH- and Atorvastatin-treated constructs respectively; n = 6; P = 0.14). These data 
indicate that atorvastatin treatment can reduce the pro-aggregatory potential of the 3D 
neointimal constructs, although further experimental repeats will be needed to confirm these 
initial data. 
 
4.2.7 Atorvastatin reduces the pro-coagulant properties of the 3D neointimal constructs 
Experiments also assessed the procoagulant properties of the foam cell-containing constructs 
after being treated with either atorvastatin or its vehicle, methanol.  As shown in Figure 4.11, 
treatment with atorvastatin significantly increased the measured prothrombin time of the 
constructs compared to methanol-treated control samples 567 ± 93s vs 109 ± 34s for 
atorvastatin- and MeOH-treated constructs respectively; n = 3; P < 0.05; Figure 4.11). Control 
samples in which the platelet poor plasma was treated with calcium alone failed to induce 
visible fibrin formation after 30 minutes in two of the three samples tested, whilst the other 
sample took 1267s (1622 ± 177 s) – demonstrating that the faster fibrin formation is due to 
exposure to the constructs.  Further repeats will be required to ensure the repeatability of 
the results. However, these initial studies indicate the likelihood that the develop 3D 
neointimal construct is able to replicate previous findings that show that atorvastatin 






Figure 4.10 Treatment with atorvastatin did not significantly inhibit platelet dense granule 
secretion elicited by exposure to the 3D neointimal construct. Washed human platelet 
suspensions resuspended in supplemented HBS containing 1 mM CaCl2, were exposed to 
either to either an atorvastatin (20 µM)- or methanol (MeOH)-treated neointimal construct 
containing foam cells. The constructs were incubated for 10 minutes at 37°C under constant 
magnetic stirring. The gel was then removed, and samples taken for aggregometry.  The 
remaining platelet solution was transferred back to the water bath and incubated for a further 
10 minutes.  After this a sample was pipetted into a 96-well platelet and mixed with 20% [v/v] 
luciferin-luciferase, and luminescence read for 1 minute on a BioTek2 synergy microplate 






Figure 4.11 Treatment with atorvastatin reduces the procoagulant properties of the THP-
derived foam cell constructs. 3D neointimal culture models were produced with THP-derived 
foam cells which were either treated with methanol (MeOH) or 20 µM atorvastatin at the 
same time as the oxLDL. At the end of the culture period, samples were placed onto sodium 
acetate frames and placed into contact with the surface of prewarmed, recalcified human 
platelet-poor plasma (PPP).  A negative control was also conducted in which acellular collagen 
hydrogels were also monitored for procoagulant activity (data shown only in caption). The 
sample is kept warm in a 37°C water bath.  The time taken for fibrin formation after addition 
of the 3D neointimal cultures models was recorded for each sample. Values shown are Mean 







To further investigate the procoagulant properties of the atorvastatin-treated constructs, 
conditioned media samples were collected after the end of the final incubation with oxLDL 
and either atorvastatin or methanol and assessed for tissue factor activity using the SN-17a 
assay.  As can be seen in Figure 4.12, conditioned media from both methanol- and atorvastatin 
constructs possessed observable tissue factor activity.  No such activity was observed in 
samples in which Factor VII and SN-17a was added to HBS alone (∆SN-17a fluorescence = -
834  ± 246 ; n = 3).  The tissue factor activity was found to be consistently greater in samples 
taken from Methanol-treated constructs (∆SN-17a fluorescence = 46844 ± 3653) compared 
to atorvastatin-treated constructs (42258 ± 3821 increase; n = 6; P <0.05) indicating that 
atorvastatin treatment reduces the expression of tissue factor expression in these THP-1-
derived foam cell cultures. 
 
4.2.8 Treatment with atorvastatin reduced the accumulation of lipids into THP-1-derived 
foam cells 
Previous studies have demonstrated that statins are able to inhibit the uptake of oxidised 
LDLs by foam cells. This potentially occurs due to a number of differing effects including 
regulation of foam cell scavenging receptor expression, a tendency for lipids with lower 
oxidation potential to be loaded into LDLs, and the direct antioxidant properties of statins 
reducing the oxidative state of the LDLs (Hofnagel et al., 2009). To examine whether 
atorvastatin-mediated inhibition of oxLDL uptake could be replicated in our model, and if it 
could be responsible for the impact of this statin on inhibiting the activation of human 





Figure 4.12 Atorvastatin decreases the tissue factor content of conditioned media extracted 
from the 3D neointimal constructs.  3D neointimal culture models were produced with THP-
derived foam cells which were either treated with methanol (MeOH) or 20 µM atorvastatin 
at the same time as the oxLDL. At the end of the culture period, conditioned media was 
collected, and mixed with a CaCl2-containing HBS, inactive Factor VII and SN-17a.  (A) 
Fluorescence increases were then recorded for 15 minutes in a BioTek 2 Synergy microplate 
reader.  (B) A bar chart summarising the mean increase in SN-17a fluorescence observed in 
methanol- and atorvastatin-treated constructs. * = P < 0.05 when compared to methanol 






assess both the uptake of lipids into the foam cells, as well as the concentration of oxLDL 
remaining in the conditioned media after the incubation period with atorvastatin or 
methanol.  As shown in Figure 4.13A, measurements of residual oxLDL remaining within the 
culture media at the end of the 72h culture period. An ELISA analysis of oxLDL within the 
culture media was then conducted and compared to the initial loading concentration to allow 
for a calculation of the residual oxLDL present. Although the proportion of the originally added 
oxLDL remaining in the sample was higher in atorvastatin-treated samples (5.6 ± 1.0%) than 
in methanol-treated samples (4.6 ± 0.4%; n = 6; P = 0.23) there was no significant difference 
in the residual oxLDL remaining within the sample. This may indicate that either there is no 
impact on cellular uptake of the oxLDL between atorvastatin-treated and control samples, or 
that there are other metabolic processes that may mask this difference through reduction or 
breakdown of the oxLDL during the prolonged loading period. To further clarify this, 
experiments were performed to directly assess the uptake of lipids into atorvastatin- and 
methanol-treated THP-1-derived foam cells.  As can be seen in Figure 4.13B, an Oil Red O 
staining assay indicated that there is more lipid stored within the foam cells generated in 
methanol-treated conditions, than those neointimal cultures treated with atorvastatin.   This 
data therefore is consistent with previous observations that statins block oxLDL uptake into 
macrophages and foam cells and indicates that oxLDL may be subject to other metabolic 
processes in the neointimal culture models other than scavenger receptor mediated uptake 





Figure 4.13. Atorvastatin treatment reduces lipid accumulation within THP-1-derived foam 
cells within the 3D neointimal co-culture model.  (A) 3D neointimal culture models were 
produced with THP-derived foam cells which were either treated with methanol (MeOH) or 
20 µM atorvastatin at the same time as the oxLDL. At the end of the culture period, 
conditioned media was collected and assayed for residual oxLDL using an ELISA assay kit 
performed according to the manufacturer’s instructions.  % Of residual was calculated against 
the initial concentration (33 µg/mL) added at the start of the experiment.  (B) Washed human 
platelet suspensions resuspended in supplemented HBS containing 1 mM CaCl2, were exposed 
to either an atorvastatin- or methanol (MeOH)-treated neointimal construct containing foam 
cells. The constructs were incubated for 10 minutes at 37°C under constant magnetic stirring. 
The gel was then removed and fixed with paraformaldehyde. The gels were then labelled with 
Oil Red O and washed three times to remove dye that remained unbound to intracellular 
lipids.  After washing the remaining dye bound to intracellular lipids was leached out of the 
sample by incubation with isopropanol.  The concentration of Oil Red O dye in the isopropanol 
sample was then measured by loading into a 96-well plate and using a BioTek 2 synergy 
microplate reader to assess sample absorbance at 570 nm.  Values shown are Mean ± SEM of 





4.2.9 Atorvastatin does not reduce IL-6 secretion from THP-1-derived foam cells cultured 
within the 3D neointimal culture model  
In chapter 3 it was demonstrated that incubation with oxLDL induces an increased secretion 
of IL-6 into the culture media.  Previous studies have demonstrated that atorvastatin can 
reduce the secretion of IL-6 from peripheral blood mononuclear cells (de Oliviera et al., 2020), 
and human platelets can be activated by IL-6 (Oleksowicz et al., 1994).  Therefore, we 
hypothesised that the inhibitory effect of atorvastatin on platelet activation elicited by 
exposure to the 3D neointimal cultures may be due to reduced secretion of IL-6 from the 3D 
neointimal culture.  However, no significant difference in IL-6 secretion could be observed in 
an assessment of IL-6 secretion into the conditioned media extracted from atorvastatin- and 
methanol-treated 3D neointimal cultures containing THP-1-derived foam cells (Figure 4.13). 
Therefore, atorvastatin does not function to reduce the prothrombotic effects of the 








Figure 4.14. Atorvastatin 
does not reduce the IL-6 
secretion of the THP-1-
derved foam cell 
containing constructs. 3D 
neointimal culture models 
were produced with THP-
derived foam cells which 
were either treated with 
methanol (MeOH) or 20 
µM atorvastatin at the 
same time as the oxLDL. At 
the end of the culture 
period, conditioned media 
was collected and assayed 
using an IL-6 ELISA assay 
kit. (A) Calibration curve 
for the ELISA assay kit with 
using a student’s T-test 










In this chapter, we have evaluated the potential prothrombotic effects of the 3D tissue 
engineered neointima containing THP-1-derived foam cells. The results demonstrate that the 
THP-1-derived foam cells within the gel provide a strong procoagulant activity as well as a 
weaker pro-aggregatory response to the construct. These data represent the first 
experimental evidence that a tissue-engineered model of a human atherosclerotic plaque can 
replicate the ability of an in vivo plaque to trigger the activation of the haemostatic system, 
and as such represents a viable method to study the atherothrombotic responses underlying  
myocardial infarction and stroke in an ex vivo environment. 
 
4.3.1 THP-1-derived foam cells provide significant tissue factor activity to the 3D neointimal 
constructs 
Many studies have reported the presence of significant tissue factor activity in in vivo 
atherosclerotic plaques (Wilcox et al., 1988; Annex et al., 1995; Marmur et al., 1996; Ardissino 
et al., 1997; Hatakeyama et al., 1997). This tissue factor activity has been shown to be 
associated both with foam cells and vascular smooth muscle cells, as well as microparticles 
created by apoptosis of foam cells within the plaque (Marmur et al., 1996; Kaikita et al., 1997; 
Landers and Gupta, 1994). Wilcox et al., (1989) have reported that necrotic core of the 
atherosclerotic plaque is particularly rich with TF, which is the principal location of foam cells 
within the plaque.  These data therefore suggest that a valid tissue-engineered model of the 
atherosclerotic plaque should possess significant tissue factor activity.  As shown in Figure 




provides a significant source of tissue factor activity within the construct, and this can trigger 
rapid activation of the coagulation cascade in PPP (Figure 4.1).  These data therefore 
demonstrate that the model can effectively replicate the procoagulant properties of the 
atherosclerotic plaque.  The data is consistent with previous findings that showed treatment 
with oxLDL is able to upregulate tissue factor activity of both THP-1 derived and SMCs-derived 
foam cells (Colli et al., 1999; Lesnik et al., 1992; Schwartz et al., 1981; Meisel, et al., 2011). 
This have been shown to occur through oxLDL-mediated activation of the NF-κβ tissue factor 
(nuclear factor -kappa B tissue factor) (Mackman et al., 1991; Sanguigni et al., 2005). Through 
augmenting this signalling pathway, it may be possible to further enhance the expression of 
tissue factor activity in these constructs. For example, previous studies have demonstrated 
that tissue factor activity can be augmented in THP-1 cell cultures through inclusion of 
Monocyte chemoattractant peptide-1 (Schechter et al., 1998). Thus, further optimisation of 
the culturing conditions may be able to further improve the thrombogenic properties of these 
constructs. 
 
4.3.2 THP-1-derived foam cells activate human platelets exposed to the 3D neointimal 
constructs  
As shown in Figures 4.5-4.9, the 3D tissue engineered can induce slow platelet activation and 
aggregation. This effect is mediated by the presence of M1- and THP-1 cells within the 
constructs, as the acellular collagen hydrogel was found not to possess this same activity.  This 
is consistent with previous studies that have demonstrated that the soluble collagen hydrogel 
does not possess the requisite tertiary structure of collagen required to activate human 




cells can elicit platelet activation. This work demonstrates one of the potential advantages of 
this layer-by-layer fabrication method as it allows us to identify novel intercellular interactions 
such as this, through allowing us to selectively alter the composition of the neointimal layer 
and examine how this modifies the responses of blood cells and cells of the vascular wall. The 
mechanism by which the THP-1 activity is elicited is unclear – this could be due to the release 
of a soluble platelet activator, the synthesis of an adhesive ligand on the surface of the 3D 
neointimal construct or directly providing a platelet-binding surface on the cell surface. The 
ability of M1 cells to inconsistently evoke this response, indicates that this stimulus is likely to 
be present in M1 cells but is upregulated by oxLDL treatment. Due to the slow and variable 
speed of the activation of the response it is unlikely that this is a strong platelet activator such 
as collagen or thrombin. The ELISA data presented here suggests that this is unlikely to be 
related to the release of IL-6, which is the cytokine that was observed to be released at 
greatest concentration from the neointimal cultures in chapter 3, as atorvastatin treatment 
does not impact on the release of this cytokine.   However, other cytokines might also be 
involved.  TNF-α production has also been shown to be enhanced by oxLDL production in our 
cultures, and therefore this might also represent another potential low-level activator of 
human platelets. Pignatelli and colleagues have documented a correlation between platelet 
activation and the plasma level of TNF- α among patients with heart failure in comparison 
with control group.  In this In vitro study they have documented an upregulation for the 
platelets TNF-receptors expression. Furthermore, they have reported a statistically significant 
decrease in the platelet activation after they treated the plasma of the study group with TNF- 
antagonist and inhibitors of arachidonic acid. This indicates that the TNF- α may play an 
essential role in platelet activation in this situation through stimulation of arachidonic acid 




that TNF- α stimulate platelet activation through upregulation of the platelet CD40L (which is 
a protein that has proinflammatory and procoagulant effects) among patients with heart 
failure in comparison with healthy control group. In this in vitro study they have documented 
that plasma TNF-α upregulated CD40L.  Interestingly CD40 has been shown to be expressed 
in macrophages in atherosclerotic plaques (Häkkinen et al., 2000) – suggesting the possibility 
that TNF- α produced in the construct could initiate an expression of this cell surface ligand 
on the surface foam cells, which in turn could trigger platelet adhesion and activation on the 
surface of the construct.  This would be consistent with the observation of binding of CD41+, 
Hoechst- populations on the surface of the construct in close proximity to foam cells (Figure 
4.9). Alternatively, the production of adhesive extracellular matrix molecules may play a key 
role in recruiting platelets to the surface of the construct.  Generally, macrophages are 
considered principally to degrade the extracellular matrix through the production of matrix 
metalloproteinases, however, studies have demonstrated that they are able to synthesise 
collagen VI (Schnoor et al., 2008), which has been demonstrated to be able to trigger human 
platelet activation (Ross et al., 1995). However, it is unclear whether oxLDL application can 
upregulate collagen VI production in foam cells. Therefore, further experiments will be 
required to further assess this activating interaction between human platelets and THP-1-
derived foam cells within the neointimal culture model. 
  
4.3.3 Treatment with atorvastatin reduces the pro-aggregatory and pro-coagulant 
properties of the 3D neointimal constructs 
Statins are known to decrease the morbidity and mortality of CVD (Davi and Patrono, 2007; 




(Cheng et al.,2009), decreasing platelets activation (Pignatelli et al.,2012), as well as their anti-
inflammatory effects (Mobarrez et al., 2011).  In this chapter, experiments have 
demonstrated that pre-treatment with atorvastatin significantly impacts on the 
thrombogenic properties of the 3D neointimal constructs through both reducing the 
proaggregatory and procoagulant properties of the construct.  From the initial data seen here 
this does not appear to be a specific impact on IL-6 secretion as the rate of production of this 
cytokine appears not to be affected by atorvastatin treatment.  However, we can see a 
significant reduction in the accumulation of lipids within the foam cells of our 3D neointimal 
constructs.  This is consistent with previous studies that have reported that statin can 
decrease the intracellular lipid contents by stimulating the cholesterol efflux from foam cells 
(Chong et al., 2020; Yu et al., 2019.,Zheng et al.,2021). Pre-treatment with atorvastatin also 
induced a slight reduction in the % of residual oxLDL left over in the conditioned culture media 
at the end of the incubation period, however this was found not to be statistically significant.  
The lack of significant effect may be due to the prolonged incubation period masking a slowing 
of the loading of oxLDL into these samples, by allowing both samples to load to saturation. 
Alternatively, this experiment assumes that no other factors are involved either in modifying 
the oxidation state of the LDL or triggering their breakdown with the 3D culture environment 
during the course of the experiment – if other methods exist to remove oxLDL from the 
culture media these may also impact on our ability to detect a reduced lipid loading in this 
manner.  Therefore, direct measurement of lipid loading within the foam cell is likely to 
represent a more accurate method for assessing the impact of statins here.  As uptake of 
oxLDL has been shown to induce a number of changes in the cellular phenotype of foam cells 
(Bekkering et al., 2014), further assessment of the impact of atorvastatin on these genetic 




function. However, through replicating the anti-thrombotic properties elicited by atorvastatin 
treatment, these studies have demonstrated the potential of using the 3D neointimal culture 
model as a humanised model of atherosclerosis. This model could be used to screen the 
effects of drugs and drug combinations on preventing atherothrombotic events prior to 
clinical trials.  This would provide a potential replacement to at least some of the in vivo 




In this chapter it has been demonstrated that the 3D neointimal model possesses the 
prothrombotic properties of the native plaque, through their ability to induce the activation 
of the blood coagulation cascade and weakly activate human platelet aggregation. This 
represents the first demonstration that a tissue-engineered atherosclerosis model can trigger 
significant thrombotic effects. Interestingly these pro-thrombotic effects were inhibited by 
pre-treatment of the 3D neointimal constructs with atorvastatin, consistent with the known 
ability of this statin to reduce the incidence of acute cardiovascular events in patients at risk 
of myocardial infarction.  These studies therefore demonstrate the potential capability of the 
developed neointimal model as an in vitro humanised drug testing platform to assess the 






Chapter 5: Assessing the impact of the 3D neointimal cell culture model on the cellular 
phenotype of cocultured smooth muscle and endothelial cells 
 
5.1 Introduction 
Atherosclerosis is a complex pathology, with Its development and progression dependent 
upon two predominant factors - inflammation and lipid accumulation within the arterial wall. 
Several metabolic and genetic factors are involved in the pathogenesis of this disease (Libby 
et al., 2019). The formation of an atherosclerotic plaque starts at a dysfunctional endothelial 
segment (Costa et al., 2016). Under normal conditions, endothelial cells create a tightly-
meshed monolayer that covers the entire internal surface of the blood vessels (Qiu et al., 
2020; Qiu et al.,2021). Endothelial cells synthesize a range of molecules such as prostacyclin 
(PGI2), NO, tissue factor pathway inhibitor and anti-thrombin III, to prevent platelet 
aggregation and activation of the blood coagulation cascade.  Additionally, the healthy 
endothelial surface provides an anti-inflammatory lining to prevents leukocytes adherence 
and migration out of the blood vessel (Mitchell et al., 2008), and is characterized by high 
expression of CD31 (an endothelial cell marker) and minimal expression for ICAM1 (Granger 
and Senchenkova, 2010). When endothelial cells are exposed to toxic or inflammatory 
molecules, such as a high level of LDL molecules, this will lead to endothelial cell dysfunction 
(Qiu et al., 2020). Endothelial cells will start to produce adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), 
ICAM2 and platelet endothelial cell adhesion molecule-1 (PECAM-1) as a response to the 
inflammation (Golia et al., 2014). These cell surface receptors will facilitate adhesion of 




they differentiate to macrophages. Additionally, inflammation will increase the permeability 
in the intercellular junctions, allowing plasma molecule such as LDL to enter the 
subendothelial space (Varghese et al., 2017). Here the LDL particles are subject to chemical 
modifications such as oxidation, acetylation, and desialylation, that facilitates their uptake by 
macrophages (Bobryshev et al., 2016). The engulfment of the thrombogenic oxLDL triggers 
the formation of foam cells (Lillis et al., 2015). Further accumulation of foam cells will create 
fatty streaks, which is one of the earliest stages in atherosclerotic plaque development. After 
phagocytosis of oxLDL, the resultant foam cells increase their synthesis and secretion of 
cytokines and matrix metalloproteinase, that help to propagate the local inflammatory 
responses.  These chemical signals include cytokines such as IL-1ß, IL-6, TNF-α, and platelet 
derived growth factor  (PDGF; Biros, et al., 2021) 
The inflammation in the affected vascular segment triggers the upregulation of pro-oxidative 
enzymes in macrophages, endothelial cells, and smooth muscle cells to trigger production of 
more oxLDL. These include enzymes such as myeloperoxidase, nitric oxide synthase, and 15-
lipoxygenase (Bobryshev et al., 2016) . Through reinforcing the inflammatory phenotype of 
the endothelial cells, the foam cell-produced cytokines trigger further recruitment of 
leukocytes, as well as increasing the endothelium’s contribution to the oxidative modification 
of LDL in the subendothelial space (Westthorpe et al., 2012), thus favouring the expansion of 
the atherosclerotic plaque. Additionally, the pro-inflammatory cytokines and matrix 
metalloproteinases released by foam cells also contribute to alterations in the cellular 
phenotype and tissue remodelling that are required for the development of the 




In the healthy blood vessel, the tunica media predominantly contains smooth muscle cells 
adopting a contractile phenotype that enables its effective participation in vasomotor 
responses of the artery. Contractile smooth muscle cells possess specific markers like smooth 
muscle cell actin, smooth muscle cell myosin heavy chain, and smoothelin (Bennett et al., 
2016). Due to the inflammatory environment, smooth muscle cells within the tunica media 
switch from their normal contractile phenotype to a proliferative phenotype and begin to 
migrate to the intima.  Once here they proliferate, assisting in the thickening of the neointima 
and the formation of the fibrous cap of the fibroatheroma. Additionally, proliferative smooth 
muscle cells also increase their deposition of extracellular matrix components, such as Type I 
collagen. This can play a significant role in mechanically strengthening the developing plaque 
and can help prevent against plaque rupture. The switch in smooth muscle cell phenotype 
occurs both through the loss of inhibitory signals (such as NO) from the dysfunctional 
endothelium and due to the localized release of cytokines such as IL-1β and platelet-derived 
growth factor (PDGF) from endothelial cells and macrophages (Sheikine and Hansson, 2006). 
Previously it has been suggested that it is difficult to assess vascular smooth muscle cell 
(VSMC) migration in human atherosclerotic plaque because the migrated cells do not have 
specific markers (Bennett et al., 2016). Therefore, a methodology which allows us to better 
assess VSMC migration could improve our ability to assess ways to slow the development of 
atherosclerotic plaque. Bennett et al., (2016) have also reported that matrix 
metalloproteinase, an enzyme secreted from neointimal macrophages and foam cells, 
promotes VSMCs phenotypic switching and enhances their proliferation and migration 
(Bennett et al.,2016). These phenotypically switched VSMCs play an essential role in the 
progression of the atherosclerotic plaque, as they will be the principal constituent of the 




cap as a protective step against plaque rupture (Xue et al., 2020). Furthermore, it has been 
reported that most of these phenotypically switched VSMCs lack the expression of the 
common cell markers of the contractile VSMCs and instead start to express macrophage cell 
markers, like CD11b and CD68 (Feil et al., 2014). One study has documented that about 20% 
of CD68 cells in the advanced atherosclerotic plaque were VSMCs in origin (Gomez et al., 
2013). Similarly, epigenetic research has reported that 38% of foam cells within late coronary 
atherosclerotic plaque were of VSMCs origin (Shankman et al., 2015). Allahverdian and 
colleagues have reported that SMCs can take up lipids in a similar manner to macrophages, 
and demonstrated that 50% of all foam cells in human atherosclerotic plaques are of smooth 
muscle origin(Wang et al., 2019; Allahverdian et al., 2014), suggesting that these play a key 
role in maintaining the local inflammatory state and deciding the fate of the developed 
plaque. 
Once SMC invades the neointimal space, they will begin to produce and release a range of 
extracellular matrix molecules such as collagen and proteoglycans, leading to creating a 
fibrous cap that lies between the endothelium and the collected foam cells. C-X-C motif 
chemokine 12 (CXCL12) is a protein responsible for regulating several biological processes. 
Overexpression of this protein was associated with a high rate of VSMCs proliferation and 
their transformation to foam cells. Antagonizing the effect of this chemokine may decrease 
the rate of VSMs derived foam cells formation, which could suppress the progression of 
atherosclerosis (Li et al., 2020).   
In addition to the cellular components, extracellular matrix proteins play a role in the 
pathogenesis of atherosclerosis. The essential interstitial substances in arteries are collagen 




atherosclerotic plaque (Bentzon et al., 2014), as well as providing mechanical strength to the 
wall, these collagens also contribute to the thrombogenic properties of the subendothelial 
matrix, playing a key role in atherothrombosis after plaque rupture (Clemetson and 
Clemetson, 2001). Matrix metalloproteinases released by macrophages also breakdown 
collagen and other extracellular matrix proteins, with the resultant products of this 
proteolysis enhancing VSMCs proliferation and migration (Fukumoto et al., 2004).  
 
5.2 Aims and objectives 
A valid in vitro model of the atherosclerotic plaque should be able to induce similar 
inflammatory changes in the phenotype of the blood vessel wall to that seen in vivo in the 
native plaque. In this chapter, the experiments aimed to establish coculture models 
incorporating the neointimal model and assess the impact of the 3D neointimal cell culture 
model on the phenotype of the cocultured smooth muscle and endothelial cells.  
Objective 1:  Establish the optimal parameters for creating neointimal co-cultures with 
endothelial and smooth muscle cells to facilitate the development of a full tissue-engineered 
atherosclerotic vessel that can undergo plaque rupture. 
Objective 2: Investigate whether coculture of the neointimal model with human coronary 
artery smooth muscle cells (HCASMCs) can induce phenotype switching away from a 
contractile phenotype and towards a migratory, proliferative phenotype 
Objective 3: Assessing the impact of co-culture of the neointimal model with human umbilical 






5.3.1 Optimizing media composition to allow optimal foam cell viability when cocultured 
with endothelial and smooth muscle cells  
Previous work by Musa et al., (2016) and Njoroge et al., (2021) have utilized a layer-by-layer 
fabrication method to create tissue-engineered blood vessel constructs in which tissue-
engineered intimal and medial layers were cultured separately prior to attachment using a 
collagen hydrogel adhesive, followed by a further period of coculture to allow full 
proliferation and maturation of cells. The intimal layer was created by culturing HUVECs on 
top of fibronectin-coated aligned PLA (Poly-L, D-lactic acid (96% l/4% d) nanofibers, whilst the 
medial layer was created by culturing HCASMCs within a non-compressed collagen hydrogel 
(Musa et al., 2016). 
 In this project we aim to create a tissue-engineered blood vessel incorporating a neointimal 
layer between these constructs. To effectively coculture the foam cell constructs within 
HUVEC and HCASMCs, it is important to optimize a culture media that facilitates foam cell 
viability whilst allowing optimal development and proliferation of the cocultured cell. 
Experiments were conducted to assess the viability of foam cells when cultured in both 
Medium 200 and Medium 231. After culturing of THP-1-derived foam cells within the 
neointimal model for 10 days, the samples were transferred to either fresh RPMI (foam cell 
culture media), or complete Media 200 (endothelial cell culture media) or Media 231 (smooth 
muscle cell culture media).  The cells were then incubated for a further 4 days and then cell 
viability of the THP-1-derived foam cells was assessed.  As shown in Figure 5.1, foam cell 
viability was found to be largely unaffected by culturing within either the endothelial or 




Media 200 (86.7 ± 1.6% of cells viable), Medium 231 (87.5 ± 0.9% of cells viable) and the base 
media for foam cells, RPMI (88.5 ± 1.6% of cells viable, n =18).  These data therefore indicate 
that foam cells remain sufficiently viable when cultured within both the endothelial and 
smooth muscle cell culture media. Therefore, it was deemed viable to utilize the optimal 
conditions for endothelial and smooth muscle culture for the future coculture experiments. 
 
                                                                                                                      
Figure 5.1 Cell viability of the compressed THP-1-derived foam cells within the neointimal 
model when cultured in different culture media. On the tenth day of the neointima 
experiment, the neointimal construct was placed into either (A) complete RPMI media (B) 
Complete Medium 200 or (C) Complete Media 231. The collagen hydrogels of the foam cells 
were then cultured for a further 4 days at 37°C, 5% CO2 . After the culture period, the sample 










5.3.2 Creating a fibrin gel-based adhesive to create a reversible attachment of the 
neointimal culture to the tissue-engineered medial layer  
The key clinical event in atherosclerotic plaque development is the process of plaque rupture 
or erosion that allows for the exposure of the thrombogenic contents of the neointimal layer 
to the flowing blood.  To ensure that the developed tissue-engineered atherosclerotic arterial 
model can replicate this key event, a method will be required to facilitate reversible 
detachment of the tissue engineered neointimal layer from the underlying medial construct. 
Previously Musa et al., (2016) developed the use of freshly made collagen hydrogel to create 
effective attachment of the intima layer to the medial layer. Whilst this provide strong 
attachment of the constructs together it would be difficult to effectively detach these 
structures without disrupting the underlying tissue-engineered medial layers.  Fibrin gels are 
widely used as a natural biodegradable scaffold for the construction in vascular tissue 
engineering (Shaikh et al., 2008; Li et al., 2015).  They are made by mixing thrombin together 
with a calcified fibrinogen solution. The kinetics of fibrin formation and the density of fibrin 
fibres are dependent upon the concentration of calcium, thrombin, and fibrinogen, and so 
can be modified to provide different hydrogel properties dependent upon the use.  A fibrin 
polymerization assay was performed to determine the thrombin required to initiate effective 
and reproducible fibrin gel formation.  An ideal concentration would provide a high fibrin fibre 
density (high absorbance) but not start to polymerize for around 5 minutes after thrombin 
addition to provide time to pipette onto the construct and allow for appropriate alignment of 
the attached neointimal and medial constructs.  As shown in Figure 5.2, a final concentration 
of 0.5 U/mL thrombin was found to reproducibly produce a dense fibrin gel, whilst not 




prematurely.   This dose of thrombin was therefore used going forward in further 
experiments.  
 
5.3.3 The use of fibrin gel followed by plasmin treatment permits reversible detachment 
of the tissue engineered constructs 
Using the fibrin gel production method, we successfully attached together a compressed and 
non-compressed hydrogel to examine if we could attach the respective scaffolds of the 3D 
neointimal layer and the tissue-engineered medial layer using this fibrin adhesive solution. As 
can be seen in Figure 5.3A, B this permitted strong attachment of the constructs. 
The breakdown of the fibrin scaffold holding together blood clots is mediated by plasmin in 
vivo (Chapin and Hajjar, 2015), as such this protease could be used to help selectively target 
the fibrin gel holding together the constructs and permit reversible detachment of the 
constructs.  As shown in Figure 5.3C, these layers could be easily separated manually after 
treatment of the conjugated hydrogels using a PBS solution containing 30nM plasmin for one 
hour at room temperature. Following this treatment compressed collagen hydrogels were 







Figure 5.2. Fibrin gel polymerization assay. A 3 mg/mL fibrinogen solution made in HBS 
containing 5 mM CaCl2 was mixed with a range of concentrations of thrombin, and the rate 
of absorbance was recorded at 350 nm by a microplate reader every minute for 1 hour.  The 





























A                                                        B                                                    C 
Figure 5.3 Plasmin-induced detachment of the neointimal-medial co-constructs produced 
using a fibrin attachment solution. The collagen hydrogels of the compressed neointima and 
the non-compressed medial layer were prepared using the same method. The two layers 
were attached together using a fibrin gel made by mixing a 3 mg/mL fibrinogen solution 
containing 5 mM CaCl2 with 0.5 U/mL thrombin. Immediately after mixing, 20 -30 μL of the 
fibrinogen solution were distributed over the corners of the media layer then the collagen 
hydrogel of the neointima layer was put over it. The gel was left to set for 1 hour at room 
temperature prior to experiments.  (A) A picture of the attached hydrogels. Note the two sets 
of filter paper frames that allow for independent handling of each construct. (B) A 
demonstration of the attachment, as the filter paper frame of one construct is held 
independently of the other gel. (C) The hydrogel conjugate was then treated for 1 h at room 
temperature with a 300 μL PBS solution containing 30nM Plasmin. Following this treatment, 
the gels were picked up by one of the filter paper frames of the conjugate to assess whether 






coronary artery smooth muscle cells using the fibrin attachment solution, and then detached 
using a plasmin detachment solution using the same methodology indicated above. Using this 
methodology, it was possible to successfully separate the cellular and acellular constructs. To 
assess whether the plasmin or the manual handling during this detachment impacted on cell 
viability, the detached TEML was subjected to live/dead cell staining.  As shown in Figure 5.4, 
the tissue-engineered medial layer did not appear to be significantly impacted by the 
detachment process, with cell viability having been assessed as 91% ± 0.8% in the samples 
examined.   These experiments demonstrate that using a fibrin-based attachment solution 
could provide a method to allow us to artificially trigger the rupture of the tissue-engineered 
neointimal model to assess the resultant thrombotic response.  
 
5.3.4 Flow-mediated detachment of the fibrin-attached collagen hydrogel model 
Plaque rupture is mediated by the mechanical weakening caused by thinning of the fibrous 
cap, in conjunction with the shear forces elicited by the flow of blood over the affected arterial 
segment.  These shear forces can be particularly high in an artery subjected to significant 
stenosis by the thickening of the neointima, with previous studies suggesting shear stresses 
of between 500-3000 dynes/cm2 (Strony et al., 1993).  These are significantly above the 
common ranges found in healthy large conduit arteries in which values range from 5-40 
dynes/cm2 (Cunningham and Gottlieb, 2005).  These shear forces therefore play a significant 
role in dissociating the plaque from the surrounding vessel wall.  Therefore, we investigated 
whether our plasmin-detached hydrogels could be dislodged from one another by laminar 






A                                                                                  B 
Figure 5.4 Plasmin-induced detachment does not impact on the viability of human coronary 
artery smooth muscle cells within the tissue engineered medial layer.  A compressed 
acellular collagen hydrogel was attached to a tissue-engineered medial layer containing 
human coronary artery using a fibrin attachment solution.   Following setting the combined 
construct was incubated in a plasmin-containing PBS solution for 1h at room temperature.  
The TEML was then detached and stained using a live/dead cell staining kit II and imaged 
under a confocal microscope.  (A) a slice showing the elongated morphology of HCASMCs 
within the hydrogel. (B) a 3D projection of the z-stack taken through the gel demonstrating 






hydrogel conjugates and tissue-engineered construct for use within commercially available 
flow chambers (Njoroge et al., 2021), the difficult in creating a limited flow space would 
significantly impede the development of any physiologically relevant shear stresses.  
Therefore, a custom-designed 3D-printed flow chamber was designed and produced in which 
to incorporate a smaller version of the hydrogel conjugates, as described in Section 2.2.2.6 
These flow chambers provide a close fit with the hydrogels and permits greater control over 
the height and width of the flow chamber to ensure a better seal and to provide greater 
flexibility over the height of the flow channel over the construct.    
A pilot experiment using the fibrin-attached hydrogel conjugates was performed to see 
whether it was possible to utilize shear forces initiated by fluid flow to initiate the detachment 
of Plasmin-treated hydrogels. To ensure maximal visibility of the construct during the 
experiment and to ensure steady pressure throughout, we performed the samples with HBS.  
Human plasma or whole blood was not used as any blood clotting would change flow 
resistance and could cause changes in the flow variables during the experiments.  The flow 
elicited through the chamber at maximum pumping rate was 0.07 cm3/s, corresponding to a 
shear stress of 4.7 dynes/cm2 slightly below the range of shear stresses found in large conduit 
arteries.  Following perfusion for 10 minutes, a notable deformation of the neointimal 
construct could be observed (Arrow; Figure 5.5B).  These pilot experiments therefore 
demonstrate that use of the fibrin-plasmin attachment-detachment system provides a basis 
for creating an atherosclerotic plaque model that can be triggered to rupture upon plasmin 
treatment and exposure to physiologically relevant shear stresses.  Further work using human 




higher shear rates that should facilitate better separation of the hydrogel-based constructs 
and assess the thrombotic responses to this plaque rupture model. 
 
Figure 5.5 Perfusion of the Plasmin-detached hydrogel conjugate triggers hydrogel 
displacement. The compressed and non-compressed collagen hydrogel scaffold models of 
the neointimal and medial layers were attached using the fibrin-attachment solution as 
previously described.   After setting the hydrogel conjugate was placed in a custom-made flow 
chamber (See Section 2.2.2.6 for full details; Huang et al., 2020) and perfused with HBS at the 
maximal pumping rate of a Watson-Marlow 505 series peristaltic pump. This generated a 
shear stress of 4.7 dynes/cm2. (A) The sample at the onset of perfusion. (B) The sample after 
10 minutes of perfusion. The arrow indicates the separation of the neointimal and medial 





5.3.5 The neointimal-medial layer co-construct containing THP-1-derived foam cells 
secretes higher levels of IL-6 and TNF-α 
The macrophage-derived foam cells within the neointimal layer play a significant role in 
creating and maintaining the proinflammatory environment within the atherosclerotic 
plaque.  They do this by synthesizing and secreting a range of cytokines, chemokines and 
matrix metalloproteinases into the local environment (Newby, 2016; Bekkering et al., 2014). 
To assess the pro-inflammatory environment that the THP-1-derived foam cells and HCASMCs 
are exposed, samples of conditioned culture media were collected at the end of the 14-day 
coculture and assayed for pro-inflammatory cytokines that have been shown to initiate 
changes in endothelial and vascular smooth muscle cell phenotypes. TNF-α, IL-1β and IL-6 
have all been reported to be upregulated by oxLDL uptake by foam cells (Bekkering et al., 
2014;  Wang et al., 2015; Liu et al., 2014), whilst oxLDL has been reported to upregulate PDGF 
production by smooth muscle cells (Stiko-Rahm et al., 1992). 
TNF-α has been shown to alter vascular smooth muscle cell behaviour by increasing 
proliferation, cell migration and extracellular matrix production, regulating apoptosis, and 
inducing phenotype switching towards a synthetic phenotype (Ali et al., 2013; O’Blenes et al., 
2001; Tang and Fang, 2017; Rastogi et al., 2012; Goetze et al., 1999). An ELISA assay 
demonstrated that significant TNF-α was produced by the neointimal-medial co-constructs 
produced with THP-1-derived foam cells, but not the M1 macrophage-containing or acellular 
constructs (Figure 5.6).  These data are consistent with the results previously seen by others 
(Bekkering et al., 2014), as well as our previous studies in the neointimal constructs in 
isolation (Figure 3.21).  






Figure 5.6. Inclusion of foam cells in the neointimal-medial co-construct enhances TNF-α 
secretion into the cell culture media.  Neointimal constructs containing either no cells, M1 
cells or foam cells were cultured until day 10, and a tissue engineered medial layer was 
cultured until day 6.  On these days the neointimal model was attached on top of the medial 
layer construct using a fibrin attachment solution. After setting of the fibrin gels, the samples 
were cultured for a further 4 days at 37°C, 5% CO2 in complete Medium 231.   The cell culture 
media was then collected and assayed for TNF-α using an ELISA kit. * Indicates P < 0.05 relative 
to the acellular collagen gel. † Indicates P < 0.05 to the two indicates samples , one-way 
























migration in the vascular wall, increases cellular proliferation and MMP production, and 
induces phenotype switching towards the synthetic phenotype (Morimoto et al., 1991; Wang 
and Newman, 2003; Zhu et al., 2000; Ohkawa et al., 1994).  As shown in Figure 5.7, IL-6 can 
be found to be significantly raised above control levels in neointimal-media co-constructs 
containing THP-1-derived foam cells, but not M1 cells.  These data are again consistent with 
the results obtained when the neointimal layer was cultured in isolation (Figure 3.21). 
PDGF-BB has previously been shown to play a key role in endothelial cell control over vascular 
smooth muscle cell proliferation and phenotype, with endothelial-produced PDGF-BB 
favouring smooth muscle cells adopting a synthetic phenotype (Millette et al.,2004; Qi et al., 
2011). Unlike our previous finding with the neointimal culture in isolation where we will  
unable to detect any PDGF-BB in any of the samples, we did detect low levels of PDGF-BB in 
the conditioned media taken from macrophage-containing samples (2/5 of the M1-containing 
cultures and 3/5 of the foam cell-containing cultures; Figure 5.8). However, the inconsistent 
findings meant that these were not statistically significant.  These data therefore suggest that 
there might be low-level secretion of PDGF-BB from these cultures is around the threshold 
sensitivity limit for this ELISA assay (2.1 pg/mL).  
IL-1β has also been reported to induce changes in the smooth muscle cell phenotype, increase 
cellular proliferation and elicit smooth muscle cell migration (Eun et al., 2015; Alexander et 
al., 2012).  The ELISA assay used to assess IL-1β secretion into the conditioned media sample 
provided absorbance readings in all samples that were consistently below the absorbance 
values provided by samples from the 0 mg/mL standard consisting solely of the sample diluent 
reagent (Figure 5.9). This was consistent with the previous findings in conditioned media 





Figure 5.7. Inclusion of foam cells in the neointimal-medial co-construct enhances IL-6 
secretion into the cell culture media.  Neointimal constructs containing either no cells, M1 
cells or foam cells were cultured until day 10, and a tissue engineered medial layer was 
cultured until day 6.  On these days the neointimal model was attached on top of the medial 
layer construct using a fibrin attachment solution. After setting of the fibrin gels, the samples 
were cultured for a further 4 days at 37°C, 5% CO2 in complete Medium 231.   The cell culture 
media was then collected and assayed for IL-6 using an ELISA kit. * Indicates P < 0.05 relative 

























Figure 5.8. Inclusion of foam cells in the neointimal-medial co-construct inconsistently 
triggers detectable PDGF-BB secretion into the conditioned media.  Neointimal constructs 
containing either no cells, M1 cells or foam cells were cultured until day 10, and a tissue 
engineered medial layer was cultured until day 6.  On these days the neointimal model was 
attached on top of the medial layer construct using a fibrin attachment solution. After setting 
of the fibrin gels, the samples were cultured for a further 4 days at 37°C, 5% CO2 in complete 
Medium 231.   The cell culture media was then collected and assayed for PDGF-BB using an 
ELISA kit. * Indicates P < 0.05 relative to the acellular collagen gel using one way ANOVA with 

























Figure 5.9. No IL-1β could be detected in the conditioned culture media of the neointimal-
medial constructs.  Neointimal constructs containing either no cells, M1 cells or foam cells 
were cultured until day 10, and a tissue engineered medial layer was cultured until day 6.  On 
these days the neointimal model was attached on top of the medial layer construct using a 
fibrin attachment solution. After setting of the fibrin gels, the samples were cultured for a 
further 4 days at 37°C, 5% CO2 in complete Medium 231.   The cell culture media was then 
collected and assayed for IL-1β using an ELISA kit.  The absorbance of the samples was 
recorded at 450 nm on a microplate reader and compared against a standard in which no IL-
1β had been included in the sample dilution sample.  * Indicates P < 0.05 relative to the blank 
standard using one way ANOVA with post hoc Tukey test which was used in the statistical 




















is in insufficient IL-1β to be detected in this manner.   
The ELISA assay demonstrates that the neointimal culture can replicate some, but not, all of 
the pro-inflammatory stimuli that are present within the atherosclerotic plaque.  As TNF-α 
and IL-6 are both able to trigger vascular smooth muscle cell proliferation, migration and 
phenotype switching, it is possible they can replicate the changes in smooth muscle cell 
function that underlie the formation of the fibrous cap of the atherosclerotic plaque. 
 
5.3.6 Assessment of smooth muscle cell localization within cryosections of the neointimal-
medial co-constructs by light microscopy 
Upon the establishment of the fatty streak, the inflammatory changes elicited by the foam 
cells elicit smooth muscle cell migration and proliferation from the medial layer of the artery. 
Here they lay down collagen and other extracellular matrix molecules creating the fibrous cap 
that helps strengthen the wall of the plaque and prevent contact with the blood of the 
prothrombotic contents of the neointima (Huang et al., 2020).   To assess whether similar 
changes can be elicited by the presence of foam cells within the neointimal-medial cocultures, 
samples from a coculture created with either no cells (acellular), M1 cells or foam cells within 
the neointimal constructs were produced and fixed with formaldehyde at the end of the 14-
day coculture. Following this the samples were embedded within OCT (optimal cutting 
temperature) and cryosectioned to create 10 µm slices of the constructs to allow examination 
of the morphology and cellular properties at the end of the coculture period.  As shown in 
Figure 5.10, the sectioning procedure caused dissociation of the compressed neointimal 
scaffold, and the non-compressed collagen hydrogel of the tissue engineered medial layer.  




visibility, and presence of a striated internal structure of the compressed neointimal construct 
(Figure 5.10A). This allowed analysis of the structures within each of these constructs 
independently in M1- and foam cell-containing samples.  In samples prepared with a 
compressed acellular collagen hydrogel, the compressed gel was consistently lost across all 
samples after dissolution of the OCT with PBS. This was likely due to the lack of cellular to 
bind to the poly-L-lysine surface such that the thin collagen hydrogel was unable to offer 
significant attachment to the slide and was lost through the washing process.  Therefore, 
these were considered to contain negligible cellular content, and therefore have been subject 
to limited change during the culture period.  
Initially, the cryosections were subject to haematoxylin and eosin staining, and examined by 
light microscopy (Figure 5.10).  The eosin was seen to more effectively stain the compressed 
neointimal layer, indicating the higher collagen content of this hydrogel (Figure 5.10A).  
Additionally, whilst nuclear material could be identified in the medial layer through the dark 
staining of the haematoxylin, this was patchy in these non-compressed hydrogels, indicating 
a lower cell density in these layers (Figure 5.10B, C). Closer examination of the cellular 
morphology present within the individual gels found that the cells in the medial layer hydrogel 
showed an elongated shape that was consistent with the presence of smooth muscle cells in 
the layer in which they were introduced into the coculture (Figure 5.10B). Interestingly these 
elongated, spindle shaped could also be observed alongside smaller, irregularly shape cells in 
the neointimal layer of both the M1- and foam cell-containing sections. A small number of 
larger cells which were rounder and thicker were also observed at lower density, that may be 
indicative of either larger THP-1-derived macrophages or may be smooth muscle cells 





Figure 5.10. Smooth muscle cells could be detected within the compressed collagen 
hydrogel in cryosections of the neointimal-medial culture constructs.   Neointimal constructs 
containing either no cells, M1 cells or foam cells were cultured until day 10, and a tissue 
engineered medial layer was cultured until day 6.  On these days the neointimal model was 
attached on top of the medial layer construct using a fibrin attachment solution. After setting 
of the fibrin gels, the samples were cultured for a further 4 days at 37°C, 5% CO2 in complete 
Medium 231.   The samples were then cryosectioned and stained with H&E.  (A) Picture taken 
with 10x objective showing both the compressed neointimal hydrogel model and non-
compressed tissue engineered medial layer. (B, C) 20x objective pictures focussing on the 
tissue-engineered medial layer (B) and neointimal model (C). The bottom panel shows a 




indicated that contractile human coronary artery smooth muscle cells could be found in the 
neointimal layers of these samples and indicated the possibility that human coronary artery 
smooth muscle cells were migrating from the medial layer constructs into the neointimal 
models containing M1 macrophages and THP-1-derived foam cells. Further cellular 
characterization is needed to positively identify the smooth muscle cells within the neointimal 
layer and suggest their potential phenotype. 
 
5.3.7 Immunofluorescent assessment of smooth muscle cell migration within cryosections 
of the neointimal-medial co-constructs 
5.3.7.1 Nile Red staining 
Initial studies attempted to validate the presence of foam cells within the construct by using 
the florescent lipid stain, Nile Red.  This dye has no fluorescence in aqueous media but 
becomes fluorescent in hydrophobic environments.  The spectral properties of the dye also 
change dependent upon the types of lipids present with the phospholipids of cellular 
membranes presenting with optimal excitation and emission at longer wavelengths 
compared to neutral lipids such as triacylglycerides and cholesterol esters, that cause a blue 
shift in the spectral properties of the dye (Greenspan and Fowler, 1985).  The ability to 
specifically detect neutral lipid droplets within lipid-loaded macrophages was found to 
require excitation and of <570 nm, whilst Nile red loses its selectivity when fluorescence 
emissions are monitored at >590 nm (Greenspan et al., 1985). Therefore, the cryosections 
were stained with Nile Red and fluorescence emissions were examined using excitation 




755nm respectively to image fluorescence from intracellular neutral lipid droplet 
(pseudocoloured red in figures) and cellular membranes (pseudocoloured green). 
Smooth muscle cells within the acellular constructs were found to stain with Nile red in both 
fluorescent excitations, demonstrating the lack of any significant presence of intracellular 
lipid droplets in these constructs (Figure 5.11). This is consistent with the lack of oxLDL used 
in these neointimal-medial cocultures.  Similarly, in M1-cell containing cocultures the cells in 
the compressed neointimal layer predominantly showed weak staining of most of the cells, 
with a small minority of cells staining strongly for intracellular lipids, suggesting some limited 
droplets present within the M1 macrophages here (red).  Similar findings were also observed 
for smooth muscle cells present within the medial layer.  In contrast, in foam cell containing 
cultures, the cells within the compressed neointimal layers stained more strongly for 
intracellular lipid (as shown by orange-red staining cells in Figure 5.11C) indicating that foam 
cells can be detected in this layer.  Interestingly this was observed for both irregularly shaped 
smaller cells as well as elongated contractile smooth muscle cells, indicating the possibility 
that the THP-1-derived foam cells release lipid during the coculture period which can be taken 
up by the nearby human coronary artery smooth muscle cells, as has previously been shown 
recently by other investigators (He et al., 2020). Smooth muscle cells present within the 
medial layer constructs were found to stain weakly with Nile red indicating that they did not 
form foam cells (Figure 5.12). These data verify the differential lipid-loading present in these 
different constructs and indicate the possibility that vascular smooth muscle foam cells may 






Figure 5.11. Nile red staining identifies intracellular lipid deposits in the compressed neointimal 
model of only the foam cell-containing cultures. Neointimal constructs containing either no cells, M1 
cells or foam cells were cultured until day 10, and a tissue engineered medial layer was cultured until 
day 6.  On these days the neointimal model was attached on top of the medial layer construct using a 
fibrin attachment solution. After setting of the fibrin gels, the samples were cultured for a further 4 
days at 37°C, 5% CO2 in complete Medium 231. The samples were then cryosectioned and stained with 
DAPI and Nile Red.  A) Brightfield images of the remaining non-compressed medial layer of the 
acellular model, and compressed neointimal layer of the M1- and foam cell-containing models. Note 
the non-compressed hydrogel of the medial layer present in the upper half of the section containing 
M1 cells. (B, C) Overlay of emission recording using 473 nm (Red) and 635 nm (green) excitation 
wavelengths to differentiate between intracellular lipids (Red predominant) and cell membrane-based 
lipids (green predominant). (D) overlay of DAPI and Nile red fluorescence staining. Images taken at 




During observations of the Nile red-stained cryosections containing THP-1-derived foam cells, 
one of the sections could be observed to contain a gel of a different density lying between 
the compressed neointimal model and the non-compressed medial layer (Figure 5.12).  This 
layer is likely to be remnants of the fibrin gel used to attach the two samples together. These 
indicate that the fibrin hydrogel does not provide sufficient support to mechanical hold the 
two layers together under sectioning.  Future studies may benefit from the use of a dense 
fibrin hydrogel made by increasing the basal fibrinogen concentration within the solution to 
help allow for cleaner sectioning.  
Interestingly this layer could also be observed to contain a number of elongated, spindle 
shaped HCASMCs that were found on the surface adjacent to the neointimal layer (Figure 
5.12). These cells were DAPI-stained but were weakly stained with Nile Red in both excitation 
wavelengths, consistent with other smooth muscle cells within the medial layer construct.  
These data therefore directly demonstrate an intermediate stage of the migration of smooth 
muscle cells out of the medial layer into the fibrin hydrogel, where they could then migrate 
into the neointimal model.  
 
5.3.7.2 α-smooth muscle actin immunostaining 
As the previous experiments had indicated the possibility of the migration of the HCASMCs 
from the medial layer into the neointimal model of co-constructs containing THP-1-derived 
cells, the cryosections were next stained for the key smooth muscle cell marker, α-smooth 
muscle actin (α-SMA;Owens, Kumar and Wamhoff, 2004).   This marker is strongly expressed 








Figure 5.12 Smooth muscle cells appear 
to accumulate within fibrin hydrogel 
linking the neointimal model and the 
medial layer construct. Neointimal 
constructs containing either no cells, M1 
cells or foam cells were cultured until day 
10, and a tissue engineered medial layer 
was cultured until day 6.  On these days 
the neointimal model was attached on top 
of the medial layer construct using a fibrin 
attachment solution. After setting of the 
fibrin gels, the samples were cultured for 
a further 4 days at 37°C, 5% CO2 in 
complete Medium 231. The samples were 
then cryosectioned and stained with DAPI 
and Nile Red. (A) Brightfield image 
showing the fibrin gel linking the 
constructs (Black arrows) (B) Brightfield 
image showing close up of the fibrin gel. 
(C) Overlay with DAPI and Nile Red 
fluorescence (473 and 635nm).  Note the 
DAPI-stained spindle-shaped HCASMCs 
present on the layer of the fibrin gel that 
would have been adjacent to the 





adopting a synthetic phenotype (Rensen et al., 2007) .  As shown in Figure 5.13, cells staining 
strongly with α-SMA could be observed in the non-compressed medial layers from intimal-
medial cocultures made using M1 macrophages, foam cells or no additional cells in the 
neointima (A, B1 and C1, Figure 5.13). This is consistent with the presence of contractile 
HCASMCs being present in these layers. Additionally, some smooth muscle cells could also be 
observed in the compressed neointimal layers of the M1- and foam cell-containing cocultures, 
however cells generally showing weaker staining than in the medial layer construct from that 
sample (B2 and C2, Figure 5.13). There did appear to be variance between cells with 
elongated, spindle-shaped cells generally showing brighter fluorescence than smaller more 
irregularly shaped cells, indicative of some cells switching phenotype towards a synthetic 
smooth muscle cell phenotype. To rule out non-specific binding, a primary-free antibody 
control was conducted on a section taken from a foam cell-containing coculture.  As shown 
in Figure 5.14, no significant staining could be observed in any of the cells in this sample 
indicating that the fluorescence seen was not due to either non-specific binding of the 
secondary antibody to the sample nor due to autofluorescence of the sample at the 
fluorescent wavelengths used to identify the Alexa fluor488-labelled secondary antibody. 
These data provide further evidence that HCASMCs migrate during the coculture period, 







Figure 5.13. α-smooth muscle actin is present within both the medial and neointimal construct 
contain α-smooth muscle actin. Neointimal constructs containing either no cells, M1 cells or foam 
cells were cultured until day 10, and a tissue engineered medial layer was cultured until day 6.  On 
these days the neointimal model was attached on top of the medial layer construct using a fibrin 
attachment solution. After setting of the fibrin gels, the samples were cultured for a further 4 days at 
37°C, 5% CO2 in complete Medium 231. The samples were then cryosectioned and labelled with a 
Mouse anti-α-smooth muscle actin antibody, followed by detection with an Alexa Fluor conjugated 




C1 are reprasanting the non-compressed medial layers of the acellular, M1 and foam cells 
neointima-medial construct. B2 and C2 are reprasanting the compressed neointima of the M1 
and foam cells of the neointima-medial constructs,n=5. 
 
 
Figure 5.14 Primary-free control for α-smooth muscle actin staining. A neointimal construct 
containing foam cells was cultured until day 10, and a tissue engineered medial layer was 
cultured until day 6.  On these days the neointimal model was attached on top of the medial 
layer construct using a fibrin attachment solution. After setting of the fibrin gels, the samples 
were cultured for a further 4 days at 37°C, 5% CO2 in complete Medium 231. The samples 
were then cryosectioned blocked and labelled overnight with a staining solution containing 
no primary antibody. This was followed by detection with an Alexa Fluor conjugated goat-anti 
rabbit secondary antibody.  Samples were imaged using a confocal microscope, n=3. 
 
5.3.7.3 Human type I collagen immunostaining 
The reduction in α-SMA observed in some of the cells within the compressed neointimal 
construct indicated the potential presence of a subpopulation of the HCASMCs adopting a 
synthetic phenotype.  Type I Collagen synthesis by synthetic human coronary artery smooth 
muscle cells has been used as a marker for detection of the presence of cells switching to this 
phenotype (Rensen et al., 2007).  Previously Musa et al., (2016) have used an antibody specific 
to human type I collagen to specifically detect the production of neo-collagen within type I 
collagen hydrogels made using rat tail collagen (Musa et al., 2016). Cryosections from 
neointimal-medial construct containing either M1 macrophages, foam cells or an acellular 




shown in Figure 5.15, a low-level of type I collagen staining was observed in the non-
compressed medial layers in acellular neointimal models, as well as those containing M1 
macrophages and foam cells.  In contrast, the compressed neointimal models containing both 
M1 macrophages and foam cells were seen to exhibit much greater immunofluorescent 
staining.  Samples stained without the use of primary antibodies demonstrated minimal 
fluorescence in both the medial and neointimal layers of the coculture. A quantitative analysis 
found that fluorescent levels obtained in both the medial and neointimal layers of the 
primary-labelled samples were consistently higher than those from the equivalent primary-
free control (Figure 5.16). This indicates that most of the fluorescent signal seen in the fully 
labelled samples was not due to either non-specific binding of the antibody or sample 
autofluorescence and was instead caused by specific binding of the antibody to type I human 
collagen within these constructs. As foam cells are not known to synthesis type I collagen 
(Schnoor et al., 2021), these data indicate that synthetic smooth muscle cell subpopulations 
exist within both the medial and neointimal layers of the constructs imaged. 
The quantitative analysis of the samples also demonstrated that the density of type I collagen 
present within the neointimal layer of the construct was found to be higher in cocultures in 
which foam cells were included.  This is consistent with the finding that greater TNF-α and IL-
6 is present within the culture media of these samples (Figures 5.6 and 5.7), as both of these 
cytokines have been demonstrated to initiate phenotype switching in vascular smooth muscle 
cells (Ali et al., 2013; Ohkawa et al., 1994; Owens et al., 2004). These data therefore indicate 
that smooth muscle cells migrate from the medial layer to the neointima of the coculture 
during the culture period. In the foam cell-containing cocultures the higher rate of secretion 








Figure 5.15 Human Type I collagen expression in the neointimal models. Neointimal 
constructs containing either no cells, M1 cells or foam cells were cultured until day 10, and a 
tissue engineered medial layer was cultured until day 6.  On these days the neointimal model 
was attached on top of the medial layer construct using a fibrin attachment solution. After 




complete Medium 231.  The samples were then cryosectioned and labelled with a mouse anti-
type I collagen antibody specific for human collagen, followed by detection with an Alexa 
Fluor conjugated goat-anti mouse secondary antibody.  Samples were imaged using a 
confocal microscope, n=6. 
 
 
Figure 5.16: Initial quantification of the type I collagen immunofluorescence elicited from 
cryosections of the medial-neointimal cocultures. Image J was used to delineate the area 
occupied by the neointimal construct (compressed) and the medial layer construct (non-
compressed) in the cryosection, or samples in which no primary antibody was included during 
the immunolabelling process. The mean pixel fluorescence from Type I Collagen 
immunostaining was measured for 2-3 slices of each gel type from a single neointimal-medial 
layer coculture. Data are shown as mean ± SEM of 6 experiments. * Indicates P < 0.05 with 

































5.3.7.4 Tissue Factor Immunostaining 
In chapter 4, the neointimal constructs were demonstrated to possess measurable tissue 
factor activity that was able to elicit coagulation of platelet-poor plasma samples (Figures 4.2 
and 4.3).  Therefore, immunofluorescent staining for tissue factor was performed on sections 
from the neointimal-medial coculture to assess the presence of this key activator of the 
extrinsic coagulation pathway within the constructs.  As shown in Figure 5.17, tissue factor 
activity was found associated with the cells in each of the constructs.   This activity was found 
to be greatest in the compressed neointimal constructs due to their higher cell density than 
the non-compressed medial layer and the higher fluorescence coming from the small 
irregularly shaped foams cells in this culture. This is consistent with our previous findings in 
chapter 4, the neointimal layer containing foam cells was found to have a higher expression 
of tissue factor than those incorporating M1 cells or no cells within this structure. Crucially, 
minimal fluorescence was observed in medial and neo-intimal layers in which the sample was 
not treated with a primary antibody, thus demonstrating this effect is not due to non-specific 
binding of the antibody or autofluorescence of the sample.  Therefore, these data would 
suggest that the medial-neointimal co-construct would also be able to trigger blood 
coagulation as we saw previously for the neointimal model in isolation.   
 
5.8 Intimal-neointimal co-constructs show a variable aggregatory and secretory response  
To create an intimal-neointimal construct, the neointimal model was cultured for 10 days and 
the uppermost surface was coated with fibronectin to enhance HUVEC cell attachment on the 






Figure 5.17 Tissue Factor expression in the neointimal-medial cocultures. Neointimal 
constructs containing either no cells, M1 cells or foam cells were cultured until day 10, and a 
tissue engineered medial layer was cultured until day 6.  On these days the neointimal model 
was attached on top of the medial layer construct using a fibrin attachment solution. After 
setting of the fibrin gels, the samples were cultured for a further 4 days at 37°C, 5% CO2 in 
complete Medium 231.   The samples were then cryosectioned and labelled with a Rabbit 
anti-tissue factor antibody, followed by detection with an Alexa Fluor conjugated goat-anti 






Figure 5.18: Initial quantification of the tissue factor immunofluorescence elicited from 
cryosections of the medial-neointimal co-cultures. Image J was used to delineate the area 
occupied by the neointimal construct (compressed) and the medial layer construct (non-
compressed) in the cryosection, or samples in which no primary antibody was included during 
the immunolabelling process. The mean pixel fluorescence from tissue factor immunostaining 
was measured for 2-3 slices of each gel type from a single neointimal-medial layer coculture. 
Data are shown as mean ± SEM of 6 experiments. * Indicates P < 0.05 using one way ANOVA 






































allowed time to attach, and then placed in complete medium 200 and incubated at 37°C, 5% 
CO2 for 4 days to allow time for the cells to proliferate across the surface of the construct.  
As HUVECs synthesis and release a range of endogenous platelet inhibitors such as 
prostacyclin and NO, experiments were conducted to assess if this coating could inhibit the 
pro-aggregatory properties of the neointimal model. Samples were used intact or after 
treatment with ferric chloride (FeCl3), which is widely used in in vivo thrombosis models to 
trigger thrombotic responses through redox-induced endothelial cell injury (Li et al., 2016), 
and thus allow us to identify if this endothelial response could be inhibited. FeCl3 injury was 
applied through applying a thin 2 mm strip of FeCl3-soaked filter paper to the centre of the 
neointimal surface of the 1 x 1 cm intimal-neointimal cocultures.    
To assess endothelial-dependent inhibition of platelet responses, the intimal surface of the 
uninjured intimal-neointimal cocultures was held in contact with a human platelet suspension 
using sodium acetate frames in a spectrophotometer cuvette. A control sample in which the 
washed human platelet suspension was incubated without any hydrogel was used as a 
standard reference point for all platelet responses. The samples were then incubated for 10 
minutes at 37°C under constant magnetic stirring.  At the end of this period, the construct 
was removed and some of the platelet suspension was transferred to an aggregometer to 
read for 15 minutes, after this the suspension was activated with 0.05 U/mL thrombin to 
exogenously trigger platelet activation.  At 10 minutes into the aggregometer recording, 
platelet suspension was also subject to a luciferin-luciferase-based assay of platelet dense 
granule secretion.   
The dense granule secretion assay demonstrated that both the uninjured intimal-neointimal 




compared to the control sample not treated with a hydrogel-based construct (585 ± 310, 553 
± 274, arbitrary units for uninjured constructs, FeCl3-treated constructs, and the platelet 
suspension respectively; n = 5; P > 0.05; Figure 5.19A). However, this was not found to be 
statistically significant despite consistently showing higher values than the control sample due 
to the significant variation in response observed in both the hydrogel construct.  These data 
were consistent with the basal aggregometry readings taken from the samples which showed 
no significant change in the baseline reading (Figure 5.19B).  These data therefore indicated 
that the degree of platelet activation triggered by either construct was weak or was 
insufficient to trigger platelet aggregation.  
Following this and prior to thrombin addition, the aggregometer recordings were seen to 
demonstrate variable responses, with 1/5 of each of the platelet samples exposed to no gel, 
or the injured and uninjured constructs underwent full aggregation during this period. 
Additionally, 3/5 of the platelet samples exposed to the FeCl3-injured cocultures underwent 
notable shape change, in contrast to 1/5 of the samples not exposed to a construct, and 1/5 
of the platelet samples from the uninjured intimal-neointimal constructs. Thus 1/5 of the 
platelet samples exposed to the FeCl3-treated cocultures remained quiescent through this 
incubation period, compared to 4/5 of the samples exposed to uninjured constructs, and 3/5 
of the untreated platelet suspensions. These highly variable aggregatory and secretory 
responses contrast with the results observed in samples exposed to the neointimal construct 
in isolation which showed a consistent but slow pro-aggregatory and secretory response 







show a variable 
aggregatory and secretory 
response. HUVECs were 
seeded on top of 
Neointimal constructs for 
4 days at 37°C.  After the 
culturing period, samples 
were either subject to 
FeCl3 injury or left intact, 
and then washed three 
times with HBS prior to 
use.  The gels were then 
held in contact with a 
washed human platelet 
suspension for 10 minutes 
at 37°C under constant 
magnetic stirring. A gel-
free platelet sample was 
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sample. The construct was 
then removed, and the 
sample read on a light 
transmission 
aggregometer for 15 
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            One-way ANOVA with post hoc Tukey test. Values shown are Mean ±SEM, n=12. 
                                                                                                                       




After the recording period, the platelet suspensions were then stimulated with 0.05 U/mL 
thrombin to assess if exposure to the constructs had sensitized or inhibited their 
responsiveness to platelet agonists.  As shown in Figure 5.19C, the latency between the onset 
of thrombin addition and the onset of aggregatory responses (the time when the 
aggregometry trace transitions from shape change to aggregation at 0% on the calibrated 
traces), was shown to be consistently longer for platelet samples exposed to both uninjured 
and FeCl3-treated intimal-neointimal constructs.  However again, the highly variable 
responses observed meant that these effects were not statistically significant. These data 
therefore indicate that the HUVEC lining is functional and able to inhibit platelet 
responsiveness to both the neointimal lining as well as exogenous thrombin, consistent with 
its role in vivo. The inability of the FeCl3-treated constructs to trigger platelet activation or 
sensitize platelets to exogenous agonists may be due to the FeCl3 injury only affecting a small 
central section of the construct.  
 
5.9 Immunofluorescent staining of cryosections of intimal-neointimal co-constructs 
demonstrates inconsistent coverage of the intimal surface of the construct  
The aggregometry and dense granule secretion assays demonstrate that the HUVEC lining is 
functional, but the variability of this effect suggest that the degree of coverage of the sample 
may not be optimal.  To assess this further, a set of intimal-neointimal co-cultures were made 
in which the compressed neointimal gel contained either M1 macrophage, THP-1-derived 
foam cells or no cells (acellular). These were then cultured for 10 days, followed by fibronectin 
coating and seeding with HUVECs. These samples were then cultured for 4 days to match the 




in formaldehyde, embedded in OCT and then 10 µm cryosections were made. These 
cryosections were labelled using antibodies targeted to the endothelial cell surface marker, 
CD31, and imaged using Alexa Fluor-labelled secondary antibodies.  
As shown in Figure 5.20, CD31 staining was found to be specific for the surface of the 
construct in the acellular neointimal constructs, consistent with the seeding location of the 
endothelial cells.  These data therefore indicate that endothelial cells remain on the surface 
of the constructs. The CD31+ endothelial cells could be observed at low density on the surface 
of the acellular constructs leaving significant intercellular gaps and large sections of the 
construct surface uncoated. The HUVECs seen were relatively short and did not extend 
significantly over the surface of the construct.  These data therefore suggest that the 
endothelial cells may have limited ability to adhere to the surface of the acellular neointimal 
constructs.  This may provide an explanation as to why the constructs do not elongate over 
the surface of the construct and why there is limited surface coverage.   
Cryosections on samples containing either M1 macrophages or THP-1-derived foam cells were 
found to show staining both of endothelial cells on the surface of the construct (yellow 
arrows) and the THP-1-derived cells seeded within the construct.  As there was minimal 
fluorescence observed in primary-free control samples, this staining was unlikely to be due to 
non-specific binding of the secondary antibody to the THP-1-derived cells or autofluorescence 
of the samples.  Instead, these data indicate that the CD31 antibody binds either specifically 
or non-specifically to the THP-1-derived cells.  A literature search revealed that CD31 has 
previously been found to be expressed in macrophages and THP-1 cells (Virnon-Wilson, 2006; 




Therefore, future experiments will require the use of endothelial-specific markers not present 
in macrophages.  However, examination of these samples indicated that the endothelial cells 
  
 
Figure 5.20 Endothelial cells only partially cover the surface of the intimal-neointimal 
constructs. HUVECs were seeded on top of neointimal constructs containing either M1 
macrophage, foam cells or no additional cells (acellular) for 4 days at 37°C.  Following this the 
samples were fixed with formaldehyde, embedded in OCT and subject to cryosectioning.  The 
samples were then immunostained with a mouse anti-CD31 antibody and a goat anti-mouse 




also incubated without primary antibody to produce primary-free control samples.  After 
labelling the samples were imaged using a confocal microscope. n=6 
 
 
present on the surface of both the THP-1-derived cell-containing constructs appeared to be 
thinner and more elongated than those observed in the acellular constructs.  This indicates 
the possibility that either cytokines secreted by these cells or the ability of these cells to 
produce extracellular matrix molecules within the coculture.  Interestingly previous studies 
have demonstrated that human macrophages are able to produce fibronectin (Tsukamoto et 
al., 1981), suggesting that THP-1-cells might facilitate endothelial cell growth by facilitating 
greater endothelial cell attachment to allow their extension upon the surface.  
Despite the improved phenotype surface coverage with endothelial cells was still poor with 
significant gaps between endothelial cells.  This patchy growth upon the surface of the 
intimal-neointimal cocultures may explain the variable response of the washed platelet 
suspensions when exposed to these constructs, with different HUVEC cell densities on the 
surface of the construct altering the balance between the anti-platelet effects of the HUVECs 
and the pro-aggregatory properties of the neointimal model. This would also explain the lack 
of difference observed between intimal-neointimal cocultures that were untreated and those 
that had been subject to FeCl3 injury.  Due to the limited coverage the FeCl3 injury does not 
significantly increase the surface area of the exposed construct and thus there is limited 
physical barrier to the interaction of the platelet suspension with the neointimal surface.  
Thus, triggering similar raised levels of basal platelet dense granule secretion.  Interestingly, 
this data also indicates that low HUVEC coverage of the constructs can overcome the pro-




work will be required to enhance the confluency of HUVECs grown on top of the intimal-
neointimal constructs.  
5.4 Discussion  
In this chapter, the aim was to establish coculture models incorporating our neointimal layer 
alongside endothelial and smooth muscle cells and examine whether it was possible for the 
neointimal model to trigger appropriate changes in the behaviour of these cells. This aim was 
partially met with initial data demonstrating that HCASMCs within the medial layer are 
triggered to migrate into the neointimal layer, mimicking the events that elicit the start of the 
transition of an initial fatty streak into a fibroatheroma – thus providing proof-of-concept that 
it is possible to develop advanced stages of atherosclerotic plaques within the context of an 
artificial vascular wall developed using tissue engineering techniques. In contrast, the attempt 
to establish a HUVEC monolayer on top of the neointimal model required modification, with 
the imaging studies demonstrating a low confluency of the HUVECs seeded on these 
constructs.  
 
5.4.1 Development of a plaque rupture model through reversible attachment of the 
neointimal model to the medial layer 
Before establishing our co-culture model, experiments were performed to assess whether it 
was possible to create a neointimal layer that can be artificially triggered to detach from the 
underlying medial layer to artificially replicate the process of atherosclerotic plaque rupture. 
Here we utilized a fibrin hydrogel coupled with subsequent plasmin treatment to selectively 




construct in a plasmin-containing solution or inject a concentrated plasmin solution into the 
construct to trigger the breakdown of the construct. The initial studies have demonstrated 
that this has no adverse effect on the viability of HCASMCs within the construct, but further 
work will be required to ensure that the presence of this enzyme within the construct does 
not alter foam cells viability, or the thrombotic responses observed upon plaque detachment.  
The exposure of remnant fibrin on the exposed medial surface would provide a replica of the 
local activation of the blood coagulation system, and thus is unlikely to significantly alter the 
validity of the model.  However, the potential presence of plasmin or fibrin-degradation 
products entering the blood flow over the surface of the construct could artificially slow 
platelet aggregation or the rate of fibrin formation by any formed thrombi (Larrieu et al., 
1975; Hoover-Plow, 2010) – thus future work will need to monitor exogenous plasmin or 
fibrin-degradation product entry from the rupture construct into the blood circulation and 
assess its impact on the thrombotic response seen. The presence of plasmin could be 
controlled through either washing of the constructs prior to incorporation in the flow 
chamber and/or the use of natural or artificial plasmin inhibitors following the incubation 
period. Alternatively a smart hydrogel could be used in place of the fibrin gel used here whose 
gelation can be triggered to reverse by a variety of external stimuli, such as in response to 
exposure to light, or changes in pH, temperature or ionic strength (Huang et al., 2019; Kasiński 
et al., 2020; Raman et al., 2020).  These would provide a more controlled dissociation of the 
gels but would need to be investigated for their biocompatibility with both the tissues within 
the gel and their effect on the haemostatic system prior to use.  
The ability of shear stresses initiated by perfusion to trigger the separation of these layers in 




stress elicited in the flow chamber was marginally below the lowest end of the range found 
in arteries (Cunningham and Gotlieb, 2005).  Modification of the methodology to use a syringe 
pump to increase the flow rate, and the use of whole human blood with its higher viscosity 
would increase the shear stresses and trigger greater separation of these layers. However 
further testing will be required to investigate whether this effect still occurs within a 
neointimal model that has been seeded with cells.  As can be seen in Figure 5.15, these 
constructs will be stiffer due to the production of neo-collagen by HCASMCs, and so are likely 
to be harder to deform than the acellular compressed hydrogels used in these pilot studies. 
Therefore, whilst these pilot studies demonstrate the viability of this methodology, further 
studies will be required to demonstrate the validity of the flow-based system in mediating 
this dissociation.   
Beyond the use in detachment of the neointimal-medial layer, the custom-made 3D printed 
flow chamber provides a prototype for the creation of a testing chamber for real-time imaging 
of the thrombotic response elicited upon exposure of the complete tissue-engineered 
atherosclerotic artery to platelet-rich plasma or whole human blood.  This could create a 
humanized ex vivo plaque rupture model that could offer a viable alternative to current 
animal models.  This would be beneficial in both improving the biological relevance of the 
model as well as reduce the costs of research due to the expensive nature of animal 
husbandry. The ability to independently culture each of the layers within the model also 
provides a route to selective alteration of specific proteins within the system to provide a 






5.4.2 Properties of the neointimal-medial co-cultures 
The co-culture of a medial layer alongside the neointimal model did not significantly impact 
upon the inflammatory conditions present within the culture, with the relative amounts of IL-
1β, IL-6, TNF-α and PDGF-BB release into the conditioned media of the coculture.  The one 
difference found was the presence of threshold concentrations of PDGF-BB in the THP-1-
derived cultures that were not observed in the neointimal construct alone. However, as this 
difference was not consistently observed in all samples this was not found to be statistically 
significant at this stage. These data therefore suggest that the use of complete Medium 231 
or the presence of the smooth muscle cells in the coculture does not significantly alter the 
inflammatory responses of the THP-1-derived macrophages, and such they remain viable and 
functional within the coculture.    
The co-culture imaging studies demonstrate the presence of human coronary artery smooth 
muscle within the neointimal construct at the end of the culture period.  This is consistent 
with the behaviour of smooth muscle cells in the native artery when exposed to the pro-
inflammatory conditions within the neointima (Biros et al., 2021). These data therefore 
indicate that the cells can migrate through the fibrin and collagen hydrogels to the 
compressed neointimal culture.  The finding of smooth muscle cells within the linking fibrin 
hydrogels in the Nile red staining experiments (Figure 5.12) provides a demonstration of this 
intermediate step in the migration of the cells as well as the presence of elongated, spindle-
shaped cells that are consistent with the presence of contractile smooth muscle cells within 
the neointimal layers. It is also possible to see significant presence of α-SMA positive cells and 
the deposition of type I collagen, which has previously been shown to be synthesized and 




provide confidence that the medial-neointimal cocultures possess similar biological 
properties to the native artery. Importantly, this also provides us with a first demonstration 
that a tissue-engineered neointimal model can progress beyond a fatty streak and start to 
recruit the smooth muscle cells required to form the fibrous cap of the fibroatheroma. As can 
be seen in the immunostaining studies, it is already possible to observe uniform deposition of 
type I collagen across the construct, however further development will be required to attempt 
to direct this to coat the intimal surface of the construct to mimic the structure found in vivo. 
 To fully validate this work, several additional experiments will have to be performed.  Firstly, 
a major limitation in the cryosectioning studies are they are based off of samples all taken 
from a single culture of the neointimal-medial constructs.  To confirm that these initial 
findings are reproducible further work will be required to validate these in other samples.  
Secondly, the loss of the compressed collagen hydrogels from acellular samples limiting the 
ability to definitively conclude if this migration occurs in the absence of THP-1-derived cells, 
although given the limited ability of the construct to adhere to the slide it would seem unlikely 
that significant numbers of cells are moving.   Approaches to solve this might be to enhance 
the attachment of the samples to the slide by producing paraformaldehyde-fixed samples and 
the use of egg whites to hold the samples more firmly in place.  Further work will also be 
required to identify the stimulus triggering this migration.  Previous studies have 
demonstrated that both TNF-α and IL-6 are both able to trigger smooth muscle cell migration 
(Goetze et al. 1999; Wang and Newman, 2003).  Additionally, studies have also demonstrated 
that extracellular vesicles from macrophage-derived foam cells are also able to trigger this 
movement (Niu et al., 2016).  Therefore, many different macrophage-dependent stimuli could 




THP-1 cells and triggered by non-cellular cues such as the gradient of hydrogel stiffness 
elicited by the compressed and non-compressed gels (Hartman et al., 2016; Isenberg et al., 
2015; Wong et al., 2003), or the presence of  fibrin within the constructs (Naito et al., 1990). 
Therefore, additional studies will be required to assess the individual contribution of these 
such that we can maximize the smooth muscle migration to the neointimal layer.   
5.4.3 Properties of the intimal-neointimal co-cultures  
The intimal-neointimal co-cultures represented the initial attempt to develop an endothelial 
lining for the tissue-engineered atherosclerotic arterial model. The data shown in this chapter 
suggests that further modification of the scaffold supporting the attachment and proliferation 
of the endothelial cells will be required to create a confluent layer atop the neointimal model, 
as all constructs showed limited HUVEC coverage on the seeded surface.  The morphology of 
HUVECs seeded upon acellular neointimal models indicated that there is insufficient density 
of matrix molecules to attach to as the HUVEC cells appear not to spread over the surface to 
the same extent seen in those containing either M1 macrophages or THP-1-derived foam 
cells.  Previous work by Musa et al., (2016) found that HUVEC alter the adhesive properties of 
the rat tail collagen hydrogel through the production of type I and III human collagen during 
the culture period.  Although macrophages are generally considered to principally remodel 
tissues through the release of matrix metalloproteinases, they have also been shown to 
synthesis their own extracellular matrix molecules such as fibronectin and type IV collagen 
(Tsukamoto et al., 1981; Schnoor et al., 2021).  Further work will be required to investigate if 
the THP-1-derived M1 macrophages and foam cells could be used to create a surface 
chemistry that would better support HUVEC attachment and proliferation across it. 




fibronectin-coated nanofibers to create an effective scaffold for the attachment and 
development of the intimal lining.   This scaffold has previously been demonstrated to offer 
optimal properties for HUVEC attachment and development, with the aligned nanofibers 
helping to create an aligned endothelial cell monolayer through contact guidance (Musa et 
al., 2016).  Future development of the intimal-neointimal model will utilize this methodology 
to produce an enhanced intimal layer for the coculture.   
Despite the limited coverage of the neointima with HUVECs, this partial endothelial layer was 
still shown to possess significant anti-platelet activity inhibiting aggregation of washed 
platelet samples exposed to the intimal-neointimal constructs and slowing aggregatory 
responses to exogenous thrombin stimulation.  These data therefore indicate that whilst a 
confluent monolayer was not produced in this study, the HUVECs were still functional within 
the system.  Unexpectedly, the use of FeCl3 injury was not sufficient to significantly inhibit this 
effect.  This is likely due to the narrow region of the construct exposed to the FeCl3-soaked 
filter paper.   Use of a wider filter paper strip and prolonging the time for exposure to allow 















In this chapter, a method has been developed for co-culturing the neointimal culture model 
with the previously devised tissue engineered medial layer.  This co-culture still possessed the 
same pro-inflammatory properties of the neointimal model in isolation, as could be seen 
through the continued presence of TNF-α and IL-6 within the conditioned media. Through 
immunofluorescent and histological staining of cryosections of these co-cultures it was 
possible to demonstrate that smooth muscle cells from the medial layer could migrate 
through to the neointimal construct.  This is the first demonstration of medial smooth muscle 
cell migration in any in vitro tissue engineered atherosclerosis model. This therefore 
demonstrates that this construct can be the earliest event in fibroatheroma formation.  
Through development of the construct, as well as utilising the prototype plaque rupture 
protocol and 3D printed flow chamber, this construct has the potential to be able to form a 




Chapter 6:  Discussion  
This study aimed to develop and validate a simple 3D neointimal model that can be inserted 
into the previously developed human tissue-engineered arterial construct. This would provide 
the basis for creating a human in vitro tissue-engineered atherosclerotic plaque model for use 
as an alternative to current in vivo animal atherosclerosis studies and ex vivo studies on 
endarterectomy samples.  
This thesis documents the successful development of a protocol for a novel neointimal culture 
model that, for the first time, demonstrates the effective culture of THP-1-derived foam cells 
within a compressed collagen hydrogel.  The foam cells produced were found to retain good 
viability as well as an enhanced inflammatory phenotype initiated by oxidised LDL uptake, 
indicating that there is no significant loss of cell function from this culturing process. When 
exposed to other cells and blood plasma the construct could also be demonstrated to initiate 
appropriate changes in biological responses.  This includes the activation of the blood 
coagulation cascade, as well as human coronary artery smooth muscle cell migration 
consistent with the known effects of these cells in elicit atherosclerotic plaque development 
and subsequent atherothrombotic responses upon its rupture.  These data therefore provide 
an early confirmation that the neointimal model can replicate at least some of the biological 
properties of the native atherosclerotic plaque. However, a final validation will require direct 
comparison of the functional properties of the neointimal model when successfully integrated 
into the tissue-engineered arterial model, against endarterectomy samples taken from 
patients. Currently the neointimal model developed here is not an accurate replica of clinically 
relevant atherosclerotic plaques as the isolated model currently only replicates fatty streak 




muscle cells, the neointimal model demonstrates the initial stages of progression to the more 
advance fibroatheroma stage as medial smooth cells migrate into the neointima thus 
providing the potential for this model to develop into later stages of atherosclerosis.   
 
6.1 Comparison to pre-existing tissue-engineered atherosclerosis models 
Other groups have previously attempted to generate tissue-engineered models of human 
atherosclerosis.  Prior to the beginning of this project, only two previous studies had been 
published by Robert et al., (2013) and Liu et al., (2017), with five other studies having been 
published subsequently (Figure 6.1).  These studies utilised a range of different cells sources 
(e.g., induced pluripotent stem cells (iPSCs), primary cells extracted from umbilical tissues, 
cell lines) and scaffolds (e.g., collagen hydrogels, PGA (polyglycolic acid) meshes and cell-free 
cell culturing) for the development of their respective models. Whilst the use of THP-1 cells is 
a practical choice for model development, other groups have demonstrated it is feasible to 
use monocytes extracted from human blood (Robert et al., 2013; Zhang et al., 2020).  
Additionally, the recent pre-print report of using iPSCs provides a method to reduce the 
variability elicited by using primary cells from different donors or batches, however these cells 
still retain the foetal phenotype of this cell type that may impact upon their biological 
functionality (Mallone et al., 2020). These different reports demonstrate that there are likely 
to be multiple different methods to successfully develop models of atherosclerosis, with 
different groups employing different strategies (Figure 6.1). These can be evaluated by 
considering the biological relevance of the cells and scaffold used, the ability to effectively 
replicate the chemical and physical environment the cells develop in, as well as potential 




The most used strategy is to utilise a replica of a model tissue engineered artery and use THP-





Figure 6.1. A table comparing the methods used in published atherosclerosis models to the 
model developed in this study. AF = arterial fibroblasts, EC = Endothelial Cells, SMC = Smooth 
Muscle Cells, THP1 = THP-1 cells, 
 
  
First Author (Year) Cells Scaffold Strategy
Robert (2013) SMC, EC, Monocytes
Artificial (PGA 
meshes)
Induce atherosclerosis in healthy 
tissue engineered artery using 
atherogenic stimuli
Liu (2017) SMC, EC, THP1 Collagen 
Induce atherosclerosis in healthy 
tissue engineered artery using 
atherogenic stimuli
Mallone (2018)




Coating a spheroid model of cytokine-
treated myeloid cells coated with 
myofibrasts.  Independent of artery.
Gu (2019) SMC, EC, THP1 Collagen
Induce atherosclerosis in healthy 
tissue engineered artery using 
atherogenic stimuli
Zhang (2020) SMC, EC, Monocytes
Collagen 
(compressed)
Induce atherosclerosis in healthy 
tissue engineered artery using 
atherogenic stimuli
Garcia-Sabaté (2020) THP1 Collagen 







Induce atherosclerosis in healthy 
tissue engineered artery using 
atherogenic stimuli
Echrish (2021) SMC, EC, THP1
Collagen 
(compressed)
Insert neointimal layer that is cultured 
independently of the layers of the 




cells within the construct (Robert et al., 2013 ; Liu et al., 2017 ; Gu et al., 2019 ; Zhang et al., 
2020 ; Mallone et al., 2021).  Whilst these mimic the biological events underlying the onset of 
atherosclerosis, no-one of these groups have managed to document events involved in the 
formation of the advanced fibroatheroma stage of plaque development (Figure 6.2). The 
major limitation for this will be the culture length required to allow these models to begin to 
show the extensive cellular recruitment and tissue remodelling needed to induce these 
structures. Thus, whilst an attractive model for studying preventing early stages of 
atherosclerosis it does not look like a practical method for developing later stage 
atherosclerotic models – as this is a clinically-silent stage that naturally occurs in children it is 
unlikely to have an impact on patient treatment. 
Other methods involve the generation of the models of the atherosclerotic plaque outside 
the confines of the artery (Mallone et al., 2018; Garcia-Sabaté et al., 2020).  The spheroid 
fibroatheroma model developed by Mallone in which myeloid cells were encapsulated in a 
fibrous cap made from human umbilical vein myofibroblasts, replicates the most advanced 
stage model created currently.  With the fibrous cap and an ability to recreate all of the major 
cell populations found within the human atherosclerotic plaque, this represents a highly 
impressive model.  However, as it is produced in isolation from the arterial wall, it is not 
possible to use it to study endothelial dysfunction or plaque rupture – limiting its usefulness 
in studies of atherothrombosis.  However, is conceivable that this model could be introduced 
artificially into a blood vessel model – although the spheroid generated by the hanging drop 
culture would make this more difficult than a layered model.  The strategy developed in this 




atherosclerotic lesion outside of the artery, but in a format that is accessible for easy 






















Figure 6.2 A comparison of the stages of atherosclerotic plaque development achieved in 
this study to previously published tissue-engineered atherosclerosis models. N/A = not 






















Robert (2013) Yes Yes Yes Yes No No No No No
Liu (2017) Yes No Yes Yes Yes No No No No





Gu (2019) Yes Microfluidic Yes Yes Yes No No No No
Zhang (2020) Yes Vascular Yes Yes Yes No No No No
Garcia-Sabaté (2020) No No N/A Yes Yes N/A No N/A No













layer fabrication methodology developed previously by Musa et al., (2016), as it provides the 
flexibility to introduce or remove individual biochemical and cellular elements from the 
construct and observe the effect on the biological activity. Through utilising this strategy, it 
should be possible to independently develop the culture of the neointimal layer construct to 
represent more advanced lesions more easily than if contained within the arterial construct. 
However, the demonstration that the neointimal layer can successfully trigger migration of 
HCASMCs from the medial layer does also provide the possibility of using cells within the 
construct to endogenously produce some of the maturation effects, rather than developing 
them exogenously. Therefore, there remains a number of possible routes to develop 
advanced stage atherosclerotic lesions from these constructs and demonstrates the great 
potential of this development strategy to successfully create a valid model of the 
atherosclerotic human artery. 
As can be seen in Figure 6.2, the demonstration that our construct can trigger smooth muscle 
cell migration and trigger key events in thrombus formation, means the neointimal construct 
has demonstrated that it can replicate both fatty streak formation as well as some of the 
earliest events in fibroatheroma formation. These have not been previously demonstrated 
for tissue-engineered atherosclerotic plaques, and therefore represent a key advance in the 
process of replicating atherothrombotic events ex vivo. The finding that THP-1-derived foam 
cells within the neointimal model can generate tissue factor has been previously 
demonstrated (Owens et al., 2012), and thus the finding that the construct can trigger the 
coagulation of PPP is not unexpected.  However, the demonstration that the THP-1-derived 
foam cells can weakly elicit platelet aggregation is a novel and unexpected finding. Future 
studies will examine if conditioned media taken from the foam cell-containing neointimal 




a result of the production of a soluble agonist such as the cytokines that these cells have been 
demonstrated to produce, or because of deposition of an adhesive ligand on the surface of 
the construct. This adhesive surface could be extracellular matrix molecules, or it could be the 
surface of the THP-1-derived foam cells themselves. Interestingly the initial imaging data 
seemed to suggest the presence of an adhesive ligand as platelet could be observed to bind 
on or around the cell (Figure 4.9), indicating that the cell might be either producing a 
pericellular extracellular matrix or acting as binding surface for the platelets.  This possibility 
could be tested by immunostaining the gels for extracellular matrix molecules or through 
blocking common platelet and macrophage surface receptors to see if they prevent this 
accumulation. Whilst the aggregation seen in these experiments is weak in these 
experiments, it will be interesting to also examine if the pro-aggregatory responsiveness is 
upregulated with inclusion of vascular smooth muscle-derived foam cells. Previously Musa et 
al., (2016) demonstrated that HCASMCs within the tissue engineered medial layer construct 
elicited a robust pro-aggregatory effect through the deposition of type I and III neocollagen 
within the collagen hydrogel scaffold.  Therefore, the production of a fibrous cap may 
significantly enhance this pro-aggregatory effect.  These interactions may also provide novel 
leads into identifying potential targets that can specifically inhibit platelet aggregation in 
response to plaque rupture but not vascular injury. 
 
6.2 Comparison to in vivo animal atherosclerosis models 
The ultimate aim of this work is to produce a model of the atherosclerotic human artery to 
use as a replacement for in vivo animal models used for drug testing and basic research.  
Therefore, it is important to also consider how the neointimal model compares to animal 




to the ability to generated advanced atherosclerotic plaques within the artery, and the 
presence of physiological blood flow through the affected arteries.  Our lab has previously 
demonstrated the ability to perfuse the tissue-engineered arterial construct with human 
blood products as a method for bridging the gap between current in vivo and in vitro 
thrombosis models (Njoroge et al., 2021). This expertise led to us developing a prototype 3D 
printed flow chamber to incorporate the neointimal construct.  This was initially used to 
demonstrate the ability to use fluid perfusion to separate the plasmin-treated hydrogel 
conjugates (Figure 5.5).   These pilot experiments demonstrated that the flow chamber is 
function and should permit us to examine the thrombotic responses elicited by the neointimal 
construct when perfusion with whole human blood under arterial shear stresses.  Therefore, 
provided these are successful, it should be possible to bring the neointimal construct one step 
closer to being a novel model system for monitoring atherothrombotic responses ex vivo.  
One of the major disadvantages of most in vivo animal models is that the elicited 
atherosclerotic lesions do not spontaneously rupture, and therefore these models are able 
not to reliably replicate the key clinical event that causes myocardial infarction or stroke. In 
this study, the development of the neointimal-medial constructs considered how to produce 
a model in which the neointimal model can be reversibly detached under flow conditions 
using a simple fibrin-plasmin interaction (Figure 5.5).  Through this model we have been able 
to create a model that can be triggered to rupture after application of plasmin. This novel 
adaptation of our in vitro atherosclerosis model should therefore allow us to generate a 
model that can be triggered to rupture without requiring dietary, mechanical, or genetic 
interventions like some current animal models (Rosenfeld et al., 2002; Hartwig et al., 2015; 
van der Heiden et al., 2016).  However, this approach does risk introducing artefactual 




triggering fibrinolysis or through the presence of the resultant fibrin-degradation products. 
Therefore, whilst these experiments provide an initial proof-of-concept further refinement of 
the model could introduce other methods for eliciting the same effects. One potentially 
attractive model is the use of smart hydrogels that breakdown under light exposure (Ji et al., 
2020) – this would allow the user to trigger a loss of gelation of the linking hydrogel after 
setting up the construct on an imaging platform, thus potential providing specific temporal 
and spatial control of these responses. However, this study still provides a first demonstration 
on how in vitro atherosclerotic models could generate this critical event in plaque 
development. 
 
6.3 Future development of the atherosclerotic plaque model 
As seen in Figure 6.2 and discussed above, whilst the neointimal model developed in this 
thesis is an exciting prototype that can be used to generate an in vitro model of the human 
atherosclerotic artery, there is still a need for further development, optimisation and 
refinement of the techniques showcased here.    
Whilst it has been possible to meet most of the objectives for the project, one of the main 
limitations of the model was the inability to produce a confluent HUVEC lining upon the 
surface of the neointimal construct.  From assessing the cryosections of the intimal-
neointimal constructs, this appeared to be due to the limited ability of the HUVECs to bind to 
the surface of the hydrogel, with the acellular constructs demonstrating limited coverage and 
lacking the elongated morphology expected of these cells (Figure 5.20).  These data therefore 
suggest the need to provide a more appropriate scaffold on which to grow the endothelial 
lining.  Previously Musa et al., (2016) and Njoroge et al., (2021) have utilised aligned, 




represent the intimal lining of the tissue-engineered arterial construct.  This methodology 
should be easily adaptable to the neointimal construct. As a verified method for producing 
the layer this does not appear to be a significant barrier to successfully generating the final 
tissue-engineered atherosclerotic artery.  However, one disadvantage of this approach is the 
difficulty in other groups being able to generate these nanofiber scaffolds, as electrospinning 
is a specialist technique not widely used amongst biologists. Therefore, this technique may 
provide a significant barrier for other groups adopting this method as an alternative to current 
in vivo models of atherosclerosis.   Another alternative would be to investigate the use of 3D 
bioprinting to generate a monolayer on the surface of the neointimal layer.  As the techniques 
become more widely available due to the availability of custom made bioinks and protocols 
for the printing of endothelial cells, this may provide another method that is more easily 
accessible to researchers in future.  
Once the intimal-neointimal layer has been generated and validated another key milestone 
in the development of this in vitro atherosclerosis model would be the development of a 
method to create an intimal-neointimal-medial layer co-construct.  This would involve 
spending time assessing whether this model can remain viable and functional when cultured 
in these conditions.  Previous studies have demonstrated that through using carefully 
optimised blends of the different culture media to maintenance each of the component cell 
type in culture, it is possible to maintain tissue-engineered arteries in culture effectively for a 
prolonged culture period to facilitate the onset of atherosclerotic events (Robert et al., 2013; 
Mallone et al., 2021). Therefore, studies will need to optimise the culture conditions.  Due to 
the presence of the foam cells, the pro-inflammatory environment will likely elicit significant 
changes in the biological properties of both the smooth muscle cells (as seen in this project), 




that any changes are indicative of this co-culture and not artefactual events elicited by the 
inappropriate maintenance of the cells within the culture environment. 
Following the full development and validation of the initial multi-layered atherosclerosis 
model, the next step in improving the current model would be to develop the neointimal 
plaque further to better resemble more advanced stages of atherosclerosis.  In particular, the 
work would need to focus on the production of a necrotic core, creation of the fibrin cap, and 
replication of the biochemical and mechanical changes of plaque rupture.   This will likely 
include the incorporation of other key cells and using bioengineering techniques to selectively 
trigger changes in their phenotype. For instance, in this thesis experiments have 
demonstrated the ability to culture vascular smooth muscle cell-derived foam cells within the 
collagen hydrogels used as a basis for these models. These cells are known to have differences 
in lipid metabolism compared to the macrophage-derived foam cells (Miller & Zhang, 2021).  
Therefore, inclusion of these cell may play a key role in modulating the development of a 
necrotic core due to the differential sequestration of LDL particles in these cell type. 
Therefore, assessing the impact of varying the ratio of macrophage-derived and smooth 
muscle cell-derived foam cells may provide a method for facilitating the development of 
optimal conditions to trigger an increased plaque development in vitro. 
 This progressive development of the neointimal layer has the additional benefit of also 
allowing us to examine how plaque development might impact on the atherothrombotic 
responses, and so may provide new insight into key targets for providing prophylactic 
treatment for patients at high risk of experiencing acute cardiovascular events. The developed 
mode would also provide a platform for pre-clinical testing of novel drugs aimed at targeting 
these responses.  Through the layer-by-layer fabrication strategy it is possible to create both 




of drugs on atherothrombotic and normal haemostatic responses, which in turn may help us 
develop anti-atherothrombotic drugs with less bleeding side effects. 
 
6.4 Conclusion 
This project has utilised a layer-by-layer fabrication method to develop a 3D human 
neointimal model that replicates the formation of the fatty streak, and the earliest events in 
fibroatheroma formation through eliciting smooth muscle cell migration from a co-culture 
medial layer. This ability to replicate both early and more advanced stage events in plaque 
development highlight the potential for this construct to be further developed into an 
effective model of atherosclerotic plaque rupture.  This 3D neointimal culture model was also 
demonstrated to elicit a pro-thrombotic response when exposed to washed human platelets 
and platelet-poor plasma. Through further development of the construct and the prototype 
flow chamber document here, it will be possible to create a viable in vitro drug testing 
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